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Abbreviations and symbols 
  
AA amino acid 
ASP affected sibling pair 
bp base pairs 
BRPF3 bromodomain and PHD finger containing, 3 
CARD15 caspase recruitment domain family, member 15 (synonym: NOD2) 
CCD charge coupled device (camera) 
CD Crohn's disease 
cDNA complementary DNA 
CED chronisch-entzündliche Darmerkrankungen 
CEPH Centre d'Etude du Polymorphisme Humain (cell lines) 
cM centiMorgan 
CU Colitis ulcerosa 
°C degree Celsius 
c2 chi-square, measure of association or independence 
D' D prime (measure of LD) 
dATP 2'-deoxyadenosine-5'-triphosphate 
dCTP 2'-deoxycytidine-5'-triphosphate 
DDW double-distilled water 
dGTP 2'-deoxyguanosine-5'-triphosphate 
DNA deoxyribonucleic acid 
dNTP 2'-deoxynucleoside-5'-triphosphate 
dsDNA double-stranded deoxyribonucleic acid 
dTTP 2'-deoxythymidine 5'-triphosphate 
EDTA ethylenediaminetetraacetic acid 
FAM 6-carbofluorescein 
Fig. figure 
Figs figures 
g gram(s) 
xg relative centrifugal force (RCF) 
h hour(s) 
HFE hemochromatosis gene 
HLA human leukocyte antigen 
HSP heat shock protein (e.g. HSP-70) 
HWE Hardy-Weinberg-Equilibrium 
IBD Inflammatory bowel disease 
ibd identity by descent 
ibs identity by state 
IFN interferon (e.g. IFN-g) 
IkB inhibitor of NF-kB (e.g. IkB-a) 
IL interleucin 
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kb kilobase 
kD kilodalton 
l liter(s) 
LD linkage disequilibrium 
LDU linkage disequilibrium units 
LOD logarithm of odds 
Log10 decadic logarithm 
LTA lymphotoxin-alpha (synonym: tumour necrosis factor beta, TNF-b) 
M molar (mol/l) 
MAPK mitogen-activated protein kinase 
Mb Mega base 
MC Morbus Crohn 
mg milligram(s) 
MHC Major Histocompatibility Complex 
min minute(s) 
MKK mitogen-activated protein kinase kinase 
ml millilitre(s) 
MLE maximum likelihood estimate 
mM millimolar (mmol/l) 
MRC Molecular Research Center 
mRNA messenger RNA 
Mxi2 Max-interacting protein-2 
µg microgram(s) 
µl microlitre(s) 
µM micromolar (µmol/l) 
ng nanogram(s) 
nM nanoMolar (nmol/l) 
NOD2 nucleotide oligomerization domain-2 (synonym: CARD15) 
NPL nonparametric linkage 
OR odds ratio 
p probability 
p. a. pro analysi 
p-ANCA perinuclear antineutrophil cytoplasmic antibody 
PCR polymerase chain reaction 
pH potentia hydrogenii (hydrogen ion concentration) 
pmol picomol 
r.t. room temperature (ca. 20°C) 
rmax maximum radius (centrifuge parameter) 
Rn fluorescent emission of the normalised reporter dye 
RNA ribonucleic acid 
rpm rotations per minute (centrifuge parameter) 
s second(s) 
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SNP single nucleotide polymorphism 
Taq-polymerase Thermophilus aquaticus DNA polymerase 
TAMRA 6-carboxytetramethylrhodamine 
TBE Tris borate EDTA 
TCR T-cell receptor 
TDT Transmission disequilibrium test 
TE Tris EDTA 
TEMED N,N,N',N'-tetramethylethylenediamine 
TET tetrachloro-6-carbofluorescein 
TH T-helper cell (TH1 and TH2: type 1 and 2, respectively) 
Tm melting temperature 
TNFA tumour necrosis factor alpha 
TREM1 triggering receptor expressed on myeloid cells 1 
Tris tris-(hydroxymethyl)-aminomethane 
UC ulcerative colitis 
UV ultraviolet (light) 
VIC trade name for fluorescent dye 
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Amino acid symbols 
A Alanine 
C Cysteine 
D Aspartic acid 
E Glutamic acid 
F Phenylalanine 
G Glycine 
H Histidine 
I Isoleucine 
K Lysine 
L Leucine 
M Methionine 
N Asparagine 
P Proline 
Q Glutamine 
R Arginine 
S Serine 
T Threonine 
V Valine 
W Tryptophan 
Y Tyrosine 
 
DNA base nomenclature 
A Adenine 
G Guanine 
C Cytosine 
T Thymine 
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1. Introduction 
 
1.1. The human peri-MHC region 
 
1.1.1. General features of the human peri-MHC region 
 
The human major histocompatibility complex (MHC) is an about 3.6 Megabases (Mb) large 
genomic region on the short arm of human chromosome 6 (1, 2). The area is subdivided into 
three parts called class I, II and III according to the function and protein structure of the genes 
first located there. While class I is most telomeric on the chromosome 6p and class II most 
centromeric, the class III is centric to the other two. From the 224 gene loci identified in the 
human MHC 128 are predicted to be expressed, and it is estimated that about 40% of these are 
functional in the immune system, while many are still of unknown function (3). The average 
gene density (including pseudogenes) over the entire MHC is one gene per 16 kilobases (kb) 
with distinct regional variations. While the class I and II have a high rate of pseudogenes, the 
class III seems to contain only few pseudogenes (3). Within the class I and II gene cluster the 
most polymorphic human proteins have been found, some of which have over 200 allelic 
variants (3). The classical HLA antigens encoded in each region are HLA-A, -B, and -C in the 
class I region, and HLA-DR, -DQ and -DP in the class II region (Fig 1.1). All class I genes 
are between 3 and 6 kb length, whereas class II genes are 4-11 kb long (4). Analysis of the 
immediate flanking regions revealed that the 'classical' class I and class II regions extend 
further than previously thought (5, 6). The 1998 Nomenclature Committee recognized 
additional HLA genes all of which are in the class I and Ib regions: HLA-E, -F, -G, -H, -J, -K 
and -L (7). Among those, only HLA-E, -F and -G are expressed (8) Besides the classic HLA 
genes the region contains a number of related genes that are not accounted to the classic HLA 
genes (MICA etc.). 
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Fig. 1.1: Complete gene map of the 
human MHC as published by The 
MHC sequencing consortium 
[consortium, 1999 #49].  
Genes are in the order from telomere 
to centromere but not to scale. 
Indicated by filled boxes are gene 
loci that were discovered or located 
to the MHC as a direct result of the 
genomic sequence. The other genes 
had been located in the region 
before. In regions where different 
haplotypes are known they are 
indicated. 
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1.1.2. Function of genes in the human MHC  
 
The products of genes within MHC play a fundamental role in the regulation of immune 
response. The HLA class I and II genes encode for cell surface glycoproteins that are relevant 
in the adaptive immune response to present antigens to T-cells. The antigens, small protein 
fragments (peptides of 7-12 amino acids) of pathogens, are fixed in a binding cleft of the 
HLA glycoproteins and are carried to the cell surface where they can be detected by T-cells. 
The 2 classes of HLA molecules are specialized to present different sources of antigens. HLA 
class I molecules present endogenously synthesised antigens, e.g. viral proteins. HLA class II 
molecules present exogenously derived proteins, e.g. bacterial products or viral capsid 
proteins. Class I molecules can be found on each body cell. Antigens presented through class 
I molecules are recognized by T-cell receptors (TCR) of cytotoxic T-cells that express the 
same HLA antigen, resulting in the destruction of the infested cell. HLA class II surface 
glycoproteins are usually expressed only on activated leucocytes, the expression can be 
activated in certain cells that normally do not express class II molecules by stimulation with 
Interferon-g (IF-g). T-helper cells can recognize antigens presented this way. 
 
 
Class I and II molecules are transmembrane heterodimer from two different polypeptide 
chains (a- and b-chains) that are not covalently bound (Fig. 1.2). For the class I molecules 
only the variable 45 kilodalton (kD) a-chain is encoded in the MHC region, the b-chain is the 
12 kD b2-microglobulin (encoded on the human chromosome 15q). The a-chain is divided in 
Fig. 1.2: Schematic representation 
of HLA class I and II cell surface 
glycoproteins.  
The epitopes in the a-1 and a-2 
domains of the class I and a-1 and b-1 
of the class II molecule are specific for 
each individual and are themselves an 
antigen target in the immune response 
to transplanted tissue. 
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3 extracellular globular domains, the transmembrane region and a cytoplasmatic tail. The 
variable antigen-binding cleft is formed by the highly variable a1 and the a2 domain and can 
contain polypeptide chains with up to 12 amino acids. The b2-microglobulin is attached by 
hydrophobic interaction and has no transmembrane compound. For the class II molecule both 
chains are encoded in the MHC region (A and B), and both contain 2 extracelluar globular 
domains (a1, a2 and b1, b2) a transmembrane region and an intracellular anchor domain. The 
a-chain can vary between 30 and 34 kD, the b-chain between 26 and 29 kD. The antigen-
binding cleft is formed by the highly variable a1 and b1 domains of the two chains and by this 
has no direct limitation to the length of the polypeptide presented. While the b2-microglobulin 
and the a3 domain from HLA class I and the a2 and b2 domains from HLA class II show high 
similarity to immunoglobulins, the other domains do not exhibit any similarity. A highly 
relevant feature of the HLA molecules is their co-dominant expression, both alleles contribute 
equally to the phenotype. Together with the diversity in the HLA molecules, this generates a 
great variety of antigen binding clefts, which means a wider potential immune response to 
pathogens. 
 
In addition to the highly polymorphic HLA class I and II genes, several other immune-
regulatory genes are known to be located in the MHC region (3). The Class III region is not 
actually a part of the MHC complex, but is located within the MHC region, and its 
components are either related to the functions of HLA-antigens or are under similar control 
mechanisms to the HLA genes. Genes of class III region encode structurally and functionally 
diverse molecules such as serum complement proteins (C2, C4A, C4B, BF), which are part of 
the innate immune response (9, 10), tumor necrosis factors (TNFA, LTA) which are cytokines 
essential in the regulation of the immune response, heat shock proteins (HSP) and adrenal 21 
hydroxylase enzyme (CYP21B) which is important in the corticosteroid metabolism (4, 11, 
12). 
 
In the extension of the HLA region centromeric to class II there is a significant number of 
genes involved in the immune regulation pathways such as MAPK14, FKBP5, the binding of 
the HLA molecules (TAPBP) and genes related to apoptosis (DAXX). Furthermore the HFE 
gene, important in hemochromatosis and in structure similar to the HLA class I genes and 
some of the genes encoding for histone proteins are positioned to the telomeric side of the 
HLA class I (6). 
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1.1.3. Polymorphism and genomic organization of the human peri-MHC region 
 
The extreme polymorphism is one of the most prominent features of the MHC. Variation 
levels of 5-17% have been reported at some loci (HLA-DP, DQ; B and C), which are the 
highest levels found in the human genome so far (3, 13-16). While the majority of variation 
results from polymorphisms in the exons, the classical HLA-like genes have nearly identical 
intron/exon structures in all vertebrates and classical MHC molecules can be found 
throughout the vertebrates (17-20). Most affected by the high degree of variation are those 
exons coding for the antigen binding regions providing a means against the large variety of 
pathogens. Important is the selection of T-cells during their thymic development to ensure the 
deletion of variants with a high affinity to "self" peptide complexes. This is a requirement to 
prevent immune response to body innate peptides and MHC molecules. Through this step the 
immune response phenotype of the individual is determined. The ability to present antigens is 
dependent on the variation and therewith the amino acids present in the binding cleft. Some 
alleles might be more efficient, others less, in binding an antigen, which has consequences in 
the ability to trigger the immune response (21).  
 
Despite the enormous number of alleles at each expressed loci, the genes of the MHC region 
are normally inherited unchanged from the parents, so that one set of allelic variants of the 
HLA genes present in the parents is present in the same form in the offspring. This 
phenomenon caused the formation of so called haplotypes where certain alleles of different 
gene loci tend to segregate together rather than randomly. The effect is caused through 
linkage disequilibrium (LD) between gene loci, which is described as decreasing with 
increasing physical distance. The phenomenon of LD will be addressed later in more detail. 
The number of haplotypes observed in populations is much smaller than theoretical 
expectations. The formation of haplotypes can be observed to different degrees between the 
HLA genes, as in other areas of the genome. At HLA class II, this phenomenon is so 
pronounced, that the presence of specific HLA-DR alleles can be used to predict the HLA-DQ 
allele with a high degree of accuracy before testing (22). The assignment of association 
signals of diseases to HLA class I or II genes or adjacent non-HLA genes is therefore difficult 
in the MHC region. Haplotype structures within the MHC region have been characterized 
through classical HLA typing, and high levels of LD have been detected for HLA class I and 
II genes, between certain class I and II genes, and with neighbouring loci in the class III 
region (23, 24). An average distance between adjacent recombination hot-spots of 0.8 Mb has 
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been demonstrated in single sperm analyses, but these data also showed a high degree of 
variation. Between hot-spots, comparatively stable blocks comprising some 100 kb of low 
level recombination occurred, which were separated by less active spots of recombination 
(“warm spots“)(25). It appears likely that the mammalian MHC genes have developed their 
enormous diversity through a combination of frequent recombination and diversifying 
selection (26). This implies that neither the concept of rapid LD decay with increasing 
distance nor that of a stringent organization into well-defined haplotype blocks may be fully 
compatible with the LD pattern pertaining to this region.  
 
1.1.4. MHC and disease 
 
The importance of HLA genes in antigen presentation and regulation of immune response 
results in association of the region with more diseases than any other region of the human 
genome. The MHC region therefore represents a primary target for disease gene discovery 
efforts. Most of these diseases are of chronic inflammatory or autoimmune background. For 
some diseases a linkage with the HLA region has been established as for example rheumatoid 
arthritis (27), psoriasis (28), sarcoidosis (29) and chronic inflammatory bowel disease (IBD) 
(30). In many cases the exact gene is not identified but associations to a number of HLA 
genes have been established. For many more diseases association to the HLA region was 
shown as for example diabetes mellitus (31, 32), and multiple sclerosis (33). A great number 
of studies have analysed potential association with certain HLA gene alleles or haplotypes, 
often with contradictory results. In a few cases a disease gene with causative polymorphisms 
was successfully identified, as in the case of hemochromatosis (HFE) (34). 
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1.2. Methods of disease gene detection 
 
1.2.1. Genome mapping linkage analysis 
 
Once epidemiological evidence shows a genetic background for a disease, the next important 
step is to identify the gene or, for polygenic diseases the genes, that carry the disease causing 
mutation. Considering that 20,000 genes are presently known and the amount of genes that is 
estimated for the human genome, estimations range between 28,000 and 120,000 (35), most 
estimates range between 30,000 to 50,000 genes (36, 37), it is necessary to reduce the area of 
the genome in which such a gene could be situated. One method developed for that purpose is 
the genome-wide linkage analysis. The unknown position of the potential disease gene is 
thereby estimated similar to the establishment of a genetic map on the basis of recombination 
frequency. The method employs polymorphic markers of which the genetic and physical 
positions are known or are estimated as well on the basis of the recombination fraction, which 
can vary from 0 (no recombination, the two markers are completely linked) to 0.5 (no linkage 
between the markers). The disease itself is handled like a polymorphic marker with 2 variants, 
affected and unaffected for a qualitative trait, but of unknown position. For quantitatively 
measurable traits the measured values are used. Recombination between each of the genetic 
markers and the disease "marker" is determined based on the frequency each allele was 
observed. The maximum likelihood that the observed data are caused by a determined 
recombinant fraction is tested. The likelihood for each value of the recombinant fraction 
between pairs of markers is compared and thereby the odds ratio and the logarithm of the 
odds ratio (LOD score) are determined. The LOD score indicates the likelihood of linkage 
(38, 39). This is the logarithm of 10 from the probability that two markers are linked with a 
given recombination value divided by the probability that they are unlinked. The most 
probable position of the disease "marker" is between those 2 genetic markers where the 
smallest recombination frequency is measured, indicating the strongest linkage and the 
shortest genetic distance. The maximum likelihood estimate (MLE) is the value that gives rise 
to the largest value of the likelihood (or LOD score) (40). The MLE is highly efficient, in the 
sense of the precision obtained using a given set of data. With increasing sample size it will 
converge closer to the true value. For small samples, the MLE value might tend to be lower or 
higher than the true value. The steepness of the LOD curve around the MLE reflects the 
precision of the estimate (40). In the analysis of a qualitative trait usually the nonparametric 
linkage (NPL) is measured, where the algorithm is adapted to the bipolarity of the trait. The 
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usual method is the multipoint linkage analysis where several markers at the same time are 
used to map the disease locus. For an initial screening a density of one marker every 10 cM is 
aimed at. The markers employed for this are microsatellites. They are abundant in the human 
genome so that an even spacing can be achieved easily and due to their great number of 
variants they are of high information content. The analysis of the polymorphic markers is 
performed in affected sibling pairs (ASP). They share the disease allele through identity by 
descent (ibd). With the determination of the allele status at the polymorphic marker 
recombination can be detected between the marker and the disease allele. The closer the 
disease allele is linked to the marker, the less recombination can be expected and the higher is 
the resulting LOD score. If one or more regions in the genome scan are marked with high 
LOD scores, a fine mapping of that region can follow. In that situation a density of one 
marker per 1 cM is aimed at. Taking the possibility of false positive results in account, a 
critical value of > 3.6 for the LOD score was suggested (41). However LOD scores depend on 
the density and information content of the marker, the size of the ASP population and 
preciseness of the disease phenotype. 
 
1.2.2. Association mapping analysis 
 
Association analysis is useful to refine the location of major genes prior to positional cloning 
or the candidate gene analysis. A linkage region even after fine mapping might be several Mb 
long and contain several hundred genes. For this analysis the density of markers is increased 
(3 to 50 kb) and usually diallelic single nucleotide polymorphisms (SNPs) are employed as 
markers. Association studies can be family or population based resulting in two different 
analysis methods, the transmission disequilibrium test (TDT) for family based studies (42) 
and the case control analysis for population based studies. 
 
In a population based study with the case control set-up, the Pearson's c2 statistic (or any 
other appropriate c2 statistic) is calculated. Thereby the number of each allele or genotype 
present in each disease category (case and control) is transferred into a contingency table (43). 
The significance at the 95% confidence interval is determined which is depending on the 
degrees of freedom (df) in the contingency table (1 for allele association and 3 for genotype 
association). Additionally the odds ration or the relative risk can be calculated for interesting 
markers. 
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 For the TDT study design the marker analysis involves families with at least one affected 
offspring (monoplex families) but may have more (multiplex families) and the healthy parents 
(44). The transmission of alleles from a heterozygous parent to an affected offspring is tested 
and compared to the untransmitted alleles. Different methods to evaluate the transmission to 
the affected offspring have been developed. Either transmitted alleles are compared direct to 
untransmitted alleles or the difference to the number of alleles expected to be transmitted 
according to HWE is analysed (45-47). TDT association studies are considered to be more 
sensitive (having greater power) than linkage methods to detect genes with small to moderate 
effects on disease (47). Compared to the population based association analysis the TDT is not 
affected by stratification in the population.  
 
1.2.3. Candidate gene analysis 
 
Candidate genes are characterised through their possible functionality within a disease or trait 
phenotype. They might be identified by their structure or their role within a biochemical 
pathway (biological candidates). Genes that have been identified for similar traits in other 
species or animal models for a disease phenotype might help to identify a homologue gene in 
the species of interest (comparative candidates). Once a genomic region has been identified 
through linkage or association analysis the search for candidate genes can focus on that region 
(positional candidates). The procedure of analysis in a candidate gene approach is to perform 
sequence analysis for the detection of mutations, with emphasis on the coding sequence. This 
could be a SNP, an insertion or a deletion. Depending on the location of a mutation this could 
have different impacts on the functionality of the encoded protein. SNPs in exons could lead 
to an exchange in the amino acid (AA) chain, or the truncation of the protein if the new base 
causes a stop codon. Insertion or deletion mutations could result in a shift in the reading frame 
leading to a completely different protein. SNPs in the introns could in some cases change the 
affinity to enhancer or silencer proteins and a mutation in the promotor region could alter the 
level of expression of the protein. Such a variation is then tested in an association study. A 
positive association can either identify the causative mutation itself or is linked to another 
variation on the same haplotype. This should be confirmed through an analysis of the 
biological relevance of the polymorphism. A direct functional impact of an SNP in the coding 
sequence causing a change in the amino acid sequence, with consequent alteration of the 
phenotype is the most probable situation. The proof of functional relevance of polymorphisms 
in the promotor region or in introns is somewhat more complicated. 
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1.2.4. The problem of genome haplotype structure 
 
For the understanding of the genetic determination of human phenotypic characteristics, 
including the predisposition to disease, the characterization of human genetic variability and 
its correct interpretation are important. Therefore, considerable research efforts have been 
undertaken in order to quantify the statistical association between physically linked genetic 
variants in the human genome, and to classify the concomitant haplotype diversity. The 
amount of haplotype diversity in a population is inversely related to the level of linkage 
disequilibrium (LD) between neighbouring loci, i.e. to the excess in co-occurrence in germ 
cells of particular allelic variants of these loci. The usually observed decrease of LD between 
loci of increasing physical and genetic distance broadly reflects their gradually increasing 
likelihood of recombination (48). This inverse relationship between LD and distance should - 
at least in principle - facilitate the positional cloning of disease-associated genetic variants 
through the analysis of surrogate markers located close to the respective susceptibility genes. 
Under a model of nearly neutral evolution, any newly introduced mutation would initially be 
of low population frequency but at the same time would show strong LD with the alleles 
defining the haplotype background on which it first arose. Over time, the population 
frequency of the mutation must increase in order for it to be detectable in a given extant 
population, but LD would decrease during the same process due to recombination (49, 50). 
Recent empirical evidence suggests that the relationship between LD and distance is not 
uniform. Instead, the human genome appears to be organized into regional blocks with high 
LD within, and little or no LD between blocks (51). According to this supposition, 
recombination events are located at so-called “hot-spots" (52) that define intermittent blocks, 
each represented even in different populations by a few common haplotypes. Under such 
conditions the construction of systematic haplotype maps would be possible and useful (53, 
54). Whilst the existence of haplotype blocks and recombination hot-spots has been 
convincingly demonstrated, the criteria for the definition and localization of haplotype blocks 
are still subject to discussion (55, 56). The design and efficiency of association gene mapping 
studies is critically dependent upon a detailed knowledge of the local LD pattern.  
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1.3. Inflammatory bowel diseases (IBD) 
 
1.3.1. Pathogenesis and pathophysiology of IBD 
 
Inflammatory bowel disease (IBD) refers to a complex chronically relapsing autoimmune 
disorder of the gastrointestinal tract of unknown etiology. It has been classified into Crohn’s 
disease (CD) and ulcerative colitis (UC) based on clinical, radiologic, endoscopic and 
pathological criteria (57). Active inflammation is marked by chronic diarrhea, rectal bleeding, 
abdominal pain, fever, joint pain, and weight loss. These symptoms can range from mild to 
severe, and may gradually develop from an initial minor discomfort, or may present 
themselves suddenly with acute intensity. Between periods of active inflammation, the 
disease can be inactive with a low degree or no inflammation (remission) for days up to years. 
During remission, patients suffer few, mild or no symptoms. The disease incidence peaks in 
early adulthood and is rising worldwide, with a current lifetime prevalence of 0.1–0.5% in 
Western countries (58, 59). IBD is a multifactorial disease caused by the interplay of genetic, 
environmental and immunological factors (60). Epidemiological and genetic linkage studies 
in IBD provide a thorough proof for a genetic background (61, 62), and a first disease gene 
(NOD2 or CARD15) has been identified for CD. (63-65). No single genetic variant is 
sufficient to initiate the disease. In addition, complex environmental triggers are required for 
disease expression. The lifestyle of an industrialized society seems to be important for the 
penetrance of the genetic factors (66). 
 
In CD inflammation can arise anywhere in the digestive tract from the mouth to the anus. The 
site of inflammation determines the range of symptoms. In the intestine CD manifests as 
patchy skip lesions (diseased segments of bowel interspersed with normal segments). 
Aggregates of immune cells consisting of T cells, monocytes and macrophages in the bowel 
wall can be observed in half of the cases. The structure of the mucosa is distorted and shows 
progressive atrophy. From aphthous and focal mucosal ulcers in early disease, linear ulcers 
can develop. CD affects all strata of the intestinal wall and other organs in contact with the 
intestine may become involved through transmural inflammation. This leads to the formation 
of fistulae, e.g. between the intestine and bladder or other inner organs. Inflammation, oedema 
or fibrotic scaring in the healing process can cause strictures of the bowel lumen. 
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Inflammation in UC starts in the rectum and extends proximally up the bowel. The damage of 
the mucosa is continuous from the rectum to the proximal colon without evidence of skip 
lesions. The inflammation is located predominantly within the lamina propria of the mucosa. 
Scattered crypt abscesses with ulceration and islands of regenerating mucosa forming 
pseudopolyps are observed. A ‘backwash ileitis’(with a wide open ileocecal valve and dilated 
terminal ileum) may involve the ileum and appendix and can occur in 10% of the cases of 
serious pancolitis. A severe course of UC is the formation of a toxic megacolon, a sudden 
cessation of bowel function leading to toxic dilatation and eventual perforation of the bowel. 
As only the inner lining of the intestine is affected in UC, nearby organs are not affected by 
the formation of fistulae. Both CD and UC can lead to numerous extra-gastrointestinal 
inflammatory manifestations in the liver, eyes, skin and joints (57).  
 
The gut lamina propria is constantly exposed to antigens and pathogens coming along with 
the nutrition. A low level of ‘physiological’ intestinal inflammation is normally maintained by 
the immune system to prevent infection. The enteric flora and food antigens are thought to 
induce and sustain this state. In IBD, this carefully balanced state is altered, which results in a 
destructive and persistent ‘pathological’ inflammation. After a primary inflammatory process 
microbes and microbial products may infiltrate the submucosa or lamina propria, resulting in 
a reinforced inflammation leading to an increased mucosal damage (67). 
 
When the state of inflammation shifts from the physiologic to the pathogenic state the pro- 
and anti-inflammatory cytokines become imbalanced (68, 69). In CD a predominant TH1 
response with elevated levels of IL-2 and IFN-g was observed in studies (70, 71). In UC 
humoral immunity with an increased level of IL-5 and IL-10 seems to predominate, but 
evidence for a classical TH2 situation is scarce (60, 72). In both CD and UC, activated 
macrophages participate in the mucosal immune response, e.g. by producing pro-
inflammatory cytokines such as TNF-a, IL-1b and the chemokine IL-8 (73-75). It has been 
suggested that TNF-a plays a central role in the pathogenesis of CD and is likely to be at the 
apex of the inflammatory cascade (69, 71, 73, 76). 
 
In almost half of UC affected individuals and in a small group of CD cases a perinuclear 
antineutrophil cytoplasmic antibody (p-ANCA) can be detected. It seems to be more prevalent 
in more aggressive UC. P-ANCA reactivity is suggested to derive from the recognition of 
heterogeneous neutrophil-associated antigens (77). A sub group of the antibody, called 
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atypical p-ANCA, recognizes a 50 kD myeloid-specific nuclear envelope protein that can be 
detected in UC affected carriers of the antibodies (78). 
 
1.3.2. Genetic background of IBD 
 
Epidemiological investigations of IBD have consistently shown familial clustering with a 10 
fold increase in the familial risk of UC or CD (79). This and an increased concordance of the 
IBD phenotype in monozygotic twins (80, 81) clearly show a genetic cause of the disease. In 
25% of multiply affected families cases of CD and UC are present (82), indicating that at least 
some of the risk alleles will be common to UC and CD. Genetic linkage studies in IBD 
affected sibling pairs support this with susceptibility loci on the chromosome 1 (83), 
chromosome 5 (84, 85) called IBD5, chromosome 6 (30, 85) named IBD3, chromosome 12 
(86) identified as IBD2, chromosome 14 (87, 88) called IBD4, chromosome 16 (86, 89) 
IBD1, the first IBD locus determined, and chromosome 19 (85), and as well on chromosome 
X (90).  
 
Within the linkage region on chromosome 16 (IBD1) a first disease gene CARD15 (or 
NOD2) has been identified. Variants of the NOD2 gene (C14772T (R702W) in exon 4, 
G25386C (G908R) in exon 8 and 32629insC (1007insC)) are highly associated with CD (63-
65), but cannot account for all cases. NOD2 encodes a protein with homology to disease 
resistance gene products in plants. Among other functions, NOD2 may be involved in NF-kB 
signalling (67). Besides this first gene, the multiple linkage regions and segregation models 
indicate that more than one risk allele is involved in the pathogenesis of IBD (91, 92). 
 
1.3.3. IBD and the human MHC 
 
An IBD susceptibility gene in the MHC region on chromosome 6 (IBD3) has been suggested 
through linkage and association analysis methods. An initial linkage analysis in our group 
employing non-parametric linkage analysis on 353 sibpairs with 17 markers on chromosome 
6 (average spacing 9.4 cM) showed a LOD score of 2.1 for IBD (93). As in other screenings 
the linkage on chromosome 6 did not achieve the proposed significant LOD score of > 3.6 
(86, 94). Supportive evidence for a linkage on chromosome 6p was given by a multiple 
regression analysis in 49 families with CD (95). In order to support or reject the linkage to 
IBD the marker density in the region on chromosome 6p including the MHC (microsatellite 
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markers: D6S309 - D6S257) was increased by 11 microsatellite markers and the study 
population was expanded to 428 ASPs total. Additionally all five known functional single 
nucleotide polymorphisms in the TNFA and LTA genes were tested (30). In this analysis we 
observed a peak LOD score of 4.1 in IBD in the HLA region (microsatellite markers: 
D6S470–D6S271) (30). Linkage was stronger in CD but present for UC as well (Fig. 1.3). 
Evidence for linkage in the MHC region has been repeated in other samples (85, 96). 
 
Fig. 1.3: a) Multipoint MLS curves for 
the complete chromosome 6 and b) for 
the detailed analysis of the peak region,  
as published Hampe et al. [Hampe, 1999 
#28]. Data for the complete chromosome 6 
linkage were received from the analysis of 
353 ASPs. In the detail analysis additional 
markers were introduced and a set of 428 
ASPs were analysed. Genetic distances 
between the markers were estimated from 
the dataset. 
a) 
b) 
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In the past 25 years more than 50 studies evaluating IBD association with polymorphisms in a 
limited number of genes in the MHC have been published. Several studies show positive 
associations with class I allele variants or haplotypes (97-100). A number of studies have 
described association to HLA class II gene variants or haplotypes (101-104). Genes from the 
HLA class III like the immune regulatory important TNF-a have been under investigation as 
well (105, 106). However other publications decline associations to genes in the MHC 
described (30, 107-110). Some studies show that associations of HLA genes with UC (111, 
112) differ from associations with CD (113, 114). A meta-analysis of a great number of 
association studies indicated that DR2, DR9, and DRB1*0103 are positively associated with 
UC, a negative association was found for DR4 and UC. For CD a positive association was 
found with DR7, DRB3*0301, and DQ4 and a negative association with DR2 and DR3 (115). 
 
Within the MHC region, the identification of a causative mutation is complicated through the 
high density of genes and the extent of LD. The polymorphism in the HLA genes and the 
great number of possible haplotypes as well as the variation of more frequent haplotypes 
between different populations reflect the limitations of association studies in the MHC region. 
Despite the ambiguity of the study outcomes, the HLA class I and II genes remain important 
to be studied, due to their antigen presenting function.  
 
TNF-a is a key inflammatory mediator in the pathophysiology of IBD (69, 71, 73, 76). An 
association of an inferred haplotype (TNFa2b1c2d4e1) of microsatellites flanking the TNF 
locus with CD has been described (105), yielding a p-value of 0.01 (odds ration 4.4). In a 
direct investigation of polymorphisms of the TNFA gene promoter the uncommon allele 2 of 
the –308 TNFA promoter polymorphism was found to be decreased in UC (p=0.044) (106). 
Linkage and association analysis of 3 TNFA promotor polymorphisms and 2 LTA 
polymorphism declined a direct connection between TNF and IBD (30). Even though the 
TNF-a by itself might not be the susceptibility gene for IBD in the chromosome 6 linkage 
region, genes coding for proteins involved in the downstream signalling pathway might be 
directly associated and the association observed to alleles of the TNFA gene might be caused 
by linkage to other variants in nearby inflammatory relevant genes. One of these genes might 
be a mitogen activated protein kinase (MAPK14 / MAPK13) that are located centromeric of 
the TNF. The activation of the MAPK14 protein upregulated the expression of TNF in vitro 
(116). The activity of the MAPK14 is upregulated in the inflamed mucosa of patients with 
both CD and UC resulting in a substantial increase of the active form of p38a (117). 
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Activation of MAPK14 and the isoforms results from phosphorylation in response to 
treatment with proinflammatory cytokines or exposure to environmental stress (118).  
 
1.4. Aims of the study 
 
A linkage region for IBD has been established and confirmed for the human chromosome 
6p21. Through fine mapping linkage analysis with additional markers and ASPs the region 
was located between the microsatellite markers D6S461 and D6S271, which covered about 20 
Mb including the peri-MHC region. In order to further confine the region where a potential 
gene with a disease causing mutation might be located and to eventually identify the gene 
carrying the causative mutation the aims of the present work were 
 
(i) to establish a dense map with SNP markers and to analyse association with IBD 
within the region defined. 
 
(ii) to identify functional and positional candidate genes from the association study and 
analyse for coding polymorphisms that could be causative for IBD. 
 
(iii) to reveal underlying structure of linkage disequilibrium between markers that could 
account for association signals distorted from their origin. 
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2. Materials and methods 
 
2.1. Materials 
 
Table 2.1 Materials part 1 
Material Manufacturer / Supplier 
100 bp DNA ladder Invitrogen; Karlsruhe, Germany 
2.2 ML storage plate (96 well) ABgene, Epsom, UK 
384 deep well storage plate ABgene, Epsom, UK 
Agarose Eurogentec; Köln, Germany 
AmpliTaq® DNA Polymerase Applied Biosystems; Weiterstadt, Germany 
AmpliTaq® Gold DNA Polymerase Applied Biosystems; Weiterstadt, Germany 
AmpliTaq® DNA Polymerase Applied Biosystems; Weiterstadt, Germany 
Bacillol® Bode Chemie; Hamburg, Germany 
BigDye Terminator Ready reaction kit Applied Biosystems; Weiterstadt, Germany 
Bromophenol blue Sigma; München, Germany 
Cell culture flasks (250 ml; canted neck) BD Biosciences; Heidelberg, Germany 
Cryotubes (2ml) Greiner Bio-One GmbH; Frickenhausen, 
Germany 
DNAzol® Molecular Research Center, inc. Cincinatti, 
Ohio, USA 
dNTP set (100mM solutions 100µM each ) Amersham Biosciences; Freiburg, Germany 
Easy peel heat seal foil ABgene, Epsom, UK 
EDTA Sigma; München, Germany 
EDTA blood vial 9 ml Sarstedt; Nümbrecht, Germany 
Ethanol p. a. Merck; Darmstadt, Germany  
Ethanol technical Bundesmonopol für Branntwein (BfB); 
Offenbach, Germany 
Ethidium bromide solution (10mg/ml) Invitrogen; Karlsruhe, Germany 
ExoI (Exonuclease I) Amersham Biosciences; Freiburg, Germany 
GeneAmp PCR buffer system (10x buffer 
w/o MgCl2; 25mM MgCl2 solution) 
Applied Biosystems; Weiterstadt, Germany 
Glycerol Sigma; München, Germany 
Invisorb Blood Giga Kit Invitek, Berlin, Germany 
isopropanol  Merck; Darmstadt, Germany 
MgCl2 Merck; Darmstadt, Germany 
MicroAmp® optical 96 well reaction plate Applied Biosystems; Weiterstadt, Germany 
MicroAmp® single strips Applied Biosystems; Weiterstadt, Germany 
MicroAmp® single tubes Applied Biosystems; Weiterstadt, Germany 
Microtiter 384 well plates Sarstedt; Nürnberg, Germany 
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Table 2.1 Materials part 2  
Material Manufacturer / Supplier 
Microtiter 384 well plates Greiner Bio-One GmbH; Frickenhausen, 
Germany 
Microtiter 96 well plates Sarstedt; Nürnberg, Germany 
Microtiter 96 well plates Costar Corning Incorporated; Cambridge, 
MA, USA 
Microtiter plates, 96-well, round bottom, 
with lid 
Sarstedt; Nümbrecht, Germany 
Microtiter strips (Nunc-Immuno 
MaxisorpTM, 8-well, flat bottom) with 96-
well frame 
Nunc; Wiesbaden, Germany 
Multiscreen column loader Amersham Biosciences; Freiburg, Germany 
PEQLAB DNA isolation system PEQLAB Biotechnology GmbH; Erlangen, 
Germany 
PicoGreen Molecular Probes Europe BV, Leiden, The 
Netherlands 
Pipette (serological, sterile with filter 5 / 
10 / 25 ml)  
Sarstedt; Nümbrecht, Germany 
Pipette tips with filter (10 / 200 / 1,000 µl) Sarstedt; Nürnberg, Germany 
protein-kinase K Invitek, Berlin, Germany 
proteinase K Molecular Research Center, inc. Cincinatti, 
Ohio, USA 
saccharose Merck; Darmstadt, Germany 
SAP shrimp alkaline phosphatase Amersham Biosciences; Freiburg, Germany 
Sephadex powder (G50 superfine) Amersham Biosciences; Freiburg, Germany 
Sephadex spin column plates MAHVN 
4550 
Amersham Biosciences; Freiburg, Germany 
SmartLadder DNA marker Eurogentec; Köln, Germany 
TAE Buffer 25x ready pack Amresco; Solon, OH, USA 
TaqMan® Universal PCR Master Mix Applied Biosystems; Weiterstadt, Germany 
TBE buffer 10x ready pack Amresco; Solon, OH, USA 
TEMED Sigma; München, Germany 
Tris Merck; Darmstadt, Germany 
Triton-X Sigma; München, Germany 
Trypsin / EDTA (0.25% / 1 mM) Invitrogen/Gibco; Karlsruhe, Germany 
Tubes (0.5 / 1.5 / 2.0 mL) Eppendorf; Köln, Germany 
Tubes (0.5, 1.5, 2 mL) Eppendorf; Köln, Germany 
Tubes, flat bottom (60 mL) Sarstedt; Nümbrecht, Germany 
Tubes, sterile (15 mL) Sarstedt; Nümbrecht, Germany 
Tubes, sterile (50 mL) BD Biosciences; Heidelberg, Germany 
Xylene Cyanol FF Sigma; München, Germany 
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2.2. Participants and study design 
 
2.2.1. Association study population 
 
In the association study with an SNP map of about 20 Mb including the peri-MHC region 
three groups of participants were involved. One group consisted of a large German family 
sample of IBD patients (affected sibling pairs, ASPs) and their healthy parents (multiplex 
families). This included 178 families with a total of 386 affected individuals, 254 with CD 
and 132 with UC. The second group contained 461 monoplex families with only one affected 
individual and both healthy parents sampled. In this group there were 306 CD and 155 UC 
affected individuals. In both cohorts the affected individuals and both healthy parents were 
sampled whenever possible although some few families remained incomplete with only one 
parent. Thirdly a group of 550 blood donors was collected as unrelated control individuals. 
For each affected individual the diagnosis of either CD or UC was confirmed by standard 
diagnostic criteria (57, 119). 
 
 
 
 
 
 
 
Ascertainment criteria had to be determined prior to the initiation of patient collection. This 
included that clinical, radiological and endoscopic (type and distribution of lesions) 
examinations confirmed the diagnosis of CD or UC. Histology results needed to be consistent 
with the diagnosis. Other diseases, especially irritable bowel syndrome and infectious colitis, 
needed to be excluded firmly. In cases of uncertainty the patient was excluded from the study 
(30, 93, 120, 121). Patients and their family members were recruited at the 1st Department of 
General Internal Medicine at the University Clinic Schleswig-Holstein, Campus Kiel (Kiel, 
Germany), the Charité University Hospital (Berlin, Germany) and other collection centres in 
Germany as outlined in the appendix 8.3. The blood donors were collected through the 
Department of Transfusion Medicine at the University Clinic Schleswig-Holstein, Campus 
Kiel (Kiel, Germany). The detailed sample population overview is given in Table 2.2. The 
Study population IBD cases CD cases UC cases 
unaffected 
family 
members 
number of 
families 
unrelated 
healthy 
controls 
monoplex families 461 306 155 812 461 
multiplex families 386 254 132 274 178 
548 
total 847 560 287 1086 639 548 
Table 2.2: Population sample for the association study and the analysis of the candidate genes. 
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same population was employed as well for the genotyping analysis of SNPs defined through 
sequencing in the candidate genes. 
 
2.2.2. The population for HLA-DPA1 analysis 
 
The European population included into this analysis was part of the original chromosome 6p 
linkage study. The German families coincided with the multiplex family population used for 
the association study. Additionally multiplex families from the UK (48% of the total 
population) and the Netherlands (6%) were included. The families from the UK were sampled 
through the King's College School of Medicine, Guy's Hospital, and the ST. Mark's Hospital 
London (UK) and the Samples from the Netherlands through the Academic Medical Center, 
Amsterdam (The Netherlands). A total of 249 families were included with 527 IBD affected 
individuals (292 with CD and 235 with UC). As unrelated healthy European controls 174 
blood donors from the control group described above were comprised (Table 2.3). In the 
South-African population, families with one affected individual with the diagnosis CD or UC 
and one or more unaffected first-degree family member were sampled. These were either 
healthy parents or in some cases healthy siblings. A total of 50 families with 30 CD and 20 
UC affected individuals and 82 related healthy controls participated. Twice only the patient 
was included. The families from South Africa were from a variable ethnical background, with 
17 of white and 31 of mixed coloured origin. Collection of samples and ascertainment of the 
diagnosis according to the above mentioned criteria was performed at Groote Schuur 
Hospital, University of Cape Town, Department of Internal Medicine (Cape Town, South-
Africa). 
 
 
Study population CD cases UC cases IBD cases Related healthy controls 
number of 
families 
unrelated 
healthy controls 
European 292 235 527 380 249 174 
South-African 30 20 50 82 48* - 
South-Korean 23 61 84 - no families 71 
* from two families only the patient 
 
A population of 84 unrelated individuals diagnosed with CD (23) or UC (61) according to the 
inclusion criteria were recruited from referral patients at Yonsei University, College of 
Medicine (Seoul, South-Korea). Seventy-one unrelated healthy blood donors from the South 
Korean population were recruited through the same institution. 
Table 2.3: Population sample for the HLA-DPA1 analysis. 
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2.2.3. Sequencing samples 
 
For the sequencing of genomic DNA, the DNA was extracted from peripheral blood 
lymphocytes as described in the DNA isolation section and arrayed into a 96 well plate 
format. The amount of DNA was 5 ng either liquid or dried to the well. The samples were 
unrelated German individuals affected with IBD from the population sample for association 
studies. A standard population sample for sequencing consisted of 30 unrelated German 
individuals affected with IBD (15 with CD and15 with UC) characterised through the criteria 
mentioned above. They were sampled thrice onto a 96 well plate each time with two empty 
control wells. A second IBD population sample for sequencing was somewhat larger with 47 
unrelated German individuals (24 with CD, 23 with UC) and one empty control. They were 
applied to a 96 well plate twice. Initially the first cohort was used for sequencing of candidate 
genes. In situations of uncertainty caused by a bad sequencing result or only one individual 
showing a new polymorphism the second cohort was sequenced for confirmation of the 
results seen. Later the larger cohort became the standard sequencing sample. cDNA from 27 
IBD cell lines from peripheral blood was obtained from the Department for Molecular 
Genetics, Max-Delbrück-Center for Molecular Medicine, Berlin. From this cDNA 5 ng were 
used liquid for sequencing. 
 
2.2.4. Population samples for the analysis of LD structure 
 
This study employs populations from 5 different ethnical backgrounds, all unrelated and not 
affected by IBD. The initial screening was carried out in a sample of 45 white US Americans 
who described themselves as being of European ancestry. These individuals were obtained 
from the Coriell Institute for Medical Research (Camden, NJ, USA) where they had been 
recruited as part of the Human Variation Panels. The subsequent in-depth analysis was 
performed in the 550 unrelated healthy German individuals employed as controls in the 
association study. Additional populations included (i) 93 unrelated Norwegian blood donors 
recruited at the Rikshospitalet Oslo, Norway, (ii) 78 unrelated white British individuals from 
the European Collection of Animal Cell Cultures, ECACC, Wiltshire, and (iii) 45 self-
described US African-Americans also provided by the Coriell Institute.  
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2.3. Handling of samples 
 
Patient recruitment and sample/data handling was in accordance with approved procedures by 
the local ethics committees at participating institutions. IBD ascertainment criteria were 
determined prior to the initiation of patient collection according to standard diagnostic criteria 
(57, 119). In cases of uncertainty of the diagnosis the patient was withdrawn from the study. 
Patient contact was initiated through the general practitioner or a medical centre and informed 
written consent was obtained from all participants. Besides two 9 ml EDTA blood vials a 
questionnaire inquiring disease circumstances, other diseases, and environmental factors was 
received from every patient and their family members (appendix 8.4). The blood was taken by 
the general practitioner and the questionnaire completed either by the participant or with the 
aid of the general practitioner. All material was sent back by the postal way (30, 93). The 
blood was immediately frozen to –80°C and stored at this temperature until the preparation of 
the DNA. Samples that were collected by collaborators were either sent as frozen EDTA 
blood as extracted DNA. Informed written consent was obtained as well from the non IBD 
sample populations. 
 
2.3.1. DNA isolation 
 
DNA isolation from EDTA-full blood by guanidine-detergent lysis with DNAzol® was 
performed either from fresh or from frozen samples, stored at -80°C (122). The original 
protocol was slightly adapted to optimise the yield of DNA from the samples used. About 9 
ml blood was used. Frozen samples were thawed at room temperature immediately before 
preparation by gently inverting the blood vial occasionally. All following procedures were 
conducted on ice if not indicated otherwise. After the transfer to labelled sterile 50 ml tubes 
18 ml (double volume) of MRC buffer (Molecular Research Center; 320 mM saccharose, 5 
mM MgCl2, 1 % Triton-X, 1 mM Tris at pH 7.5) was admixed and incubated for 10 minutes. 
During this step the red blood cells were destroyed and protein particles were separated from 
intact leukocytes. MRC buffer was made on a weekly basis according to the needs. The 
samples were centrifuged for 10 min at 10000 xg and 4°C. The supernatant was discarded and 
the pellet rinsed with 5 ml MRC buffer, which was discarded directly afterwards. After 
resuspension of the pellet in 9 ml MRC buffer the volume was refilled to 18 ml with MRC 
buffer. Incubation and centrifugation were repeated as described. This procedure was repeated 
until the pellet was white, containing only leukocytes. The pellet was resuspended in 5 ml of 
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DNAzol® and incubated at room temperature (r.t.) for 15 min (up to 30 min) until the solution 
was transparent. In this step the leukocytes were destroyed and the DNA was set free from the 
nuclei. Where this was problematic, proteinase K (stable for 4 weeks at -20°C) was added 
(100 µg/ml final concentration) with incubation at r.t. for up to 12 h for enzymatic digestion 
of proteins. 2.5 ml ice cold absolute ethanol (0.5 vol. per 1 vol. DNAzol®) was added and 
gently mixed by inverting the tube. A small thread of DNA precipitate floating in the liquid 
was transferred into a labelled DNAse free 1.5 ml tube. For low amounts and degraded DNA 
the sample was centrifuged for 5 to10 min at 5000 xg at r.t., the supernatant discarded and the 
pellet transferred. The precipitate was then washed with 96% ethanol p.a., the liquid was 
discarded followed by a brief wash with 70% ethanol p.a., discarding the liquid again 
immediately. The precipitate containing the DNA was then dried at r.t. for several hours 
(overnight) and then dissolved in 500 – 1000 µl Tris EDTA buffer (TE), depended on the 
approximate amount of DNA gained for 1 day at r.t. and afterwards at 4°C. 
 
With a higher degree of throughput and automation of the DNA isolation process the protocol 
for the standard volume of 9 ml EDTA full blood was changed to the Invisorb Blood Giga 
Kit, which contains all chemicals used (Invitek, Berlin, Germany), following the protocol 
provided with the Kit. Frozen blood samples were thawed in cold water, the lid not touching 
the water, while gently inverting the blood vial occasionally. Thawed blood samples were 
transferred to labelled sterile 50 ml tubes previously filled with 30 ml of "Buffer 1" (4°C), 
shaken and incubated for 10 min at r.t.. During this step the red blood cells were destroyed 
while the leukocytes stayed intact. The samples were centrifuged for 3 min at 6000 xg and the 
supernatant discarded. Another 20 ml of "Buffer 1" one was added and the vial stirred until 
the pellet was dissolved followed by a second centrifugation as above. This step was repeated 
until the pellet was white, then the pellet was resuspended in 3 ml "Buffer 2" and 50 µl 
protein-kinase K followed by 2 h incubation at 60°C while rocking at 95 turns/min. The 
transparent solution with then free DNA (if not, the incubation was extended for another 1/2 
h) was transferred to labelled 15 ml tubes, 1.8 ml "Buffer 3" were added and after stirring it 
was incubated for 5 min on ice, followed by centrifugation for 15 min at 10000 xg. The 
supernatant was transferred to a new, labelled 15 ml tube and the double volume (9.6 ml) of 
96% ethanol p.a. added. Inverting the tube resulted in precipitation of the DNA, if 
precipitation did not take place the tube was incubated for 2 h at -20°C. After centrifugation 
for 3 min at 10000 xg the supernatant was discarded, the pellet transferred to a labelled 2 ml 
tube previously filled with 1 ml 70% ethanol p.a., stirred and centrifuged for 2 min at 10000 
Materials and Methods 32 
xg. The supernatant was discarded, the pellet dried in the tube with open lid until the ethanol 
was completely evaporated. Finally 500 µl TE (1x) buffer was added to dissolve the DNA.  
 
For small volumes of blood DNA was extracted with the PEQLAB DNA isolation system 
(PEQLAB Biotechnology GmbH, Erlangen, Germany). All procedures were conducted 
according to the protocol provided with the chemicals and at room temperature if not 
indicated otherwise. About 1.5 ml EDTA full blood was transferred to a labelled 15 ml 
reaction tube. 150 µl OBTM protease and 1.5 ml "BL buffer" (all buffers and chemicals except 
for isopropanol and ethanol p.a. were part of the PEQLAB DNA isolation system) were added 
and stirred. During 10 min incubation at 70°C, the samples were stirred once. 1.56 ml 
isopropanol was added and again stirred. At this point all cell components were destroyed and 
the DNA was released. The complete liquid was divided to two HiBind_DNA columns placed 
in two 2 ml collection vials and centrifuged each time 750 µl for 1 min at 8000 xg. While the 
DNA binds to the silica-filter of the column, other cell particles were washed through. Flow 
through and collection vial were discarded and the columns transferred to new collection 
tubes. 750 µl wash buffer (completed with 1 1/2 the volume 100% ethanol p.a.) was added to 
each column, and then centrifuged 750 µl for 1 min at 8000 xg. The wash step was repeated, 
the flow through discarded but the collection tube was used again for 2 min centrifugation at 
8000 xg. During this procedure protein residues were removed from the filter of the column. 
Both columns were placed into freshly labelled 1.5 ml reaction tubes. 200 µl elution buffer 
(70°C) was added on each column matrix followed by incubation for 2 min at r.t. to elute the 
DNA from the silica-filter. The columns were centrifuged at 8000 xg for 1 min, the flow 
through recovered and transferred again to the column. After another incubation of 2 min the 
samples are centrifuged again at 8000 xg. for 2 min. The DNA then was ready to use. 
 
DNA samples were stored either at 4°C or at -20°C. The quality and the concentration of the 
DNA were measured when all DNA was dissolved. If there was still precipitate in the tube it 
was centrifuged for 1 min at 8000 xg (r.t.) and the supernatant transferred to a new, labelled 
tube and measured, while the original tube was refilled with 500 µl TE (1x) buffer. The 
genomic DNA was quantified using PicoGreen (Molecular Probes Europe BV, Leiden, The 
Netherlands). The automated concentration measurement was carried out on a TECAN 
SPECTRO FLUOR fluorescence microplate reader (Tecan Deutschland GmbH, Crailsheim, 
Germany). 
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2.3.3. Application to 96 and 384 well format 
 
Individual DNA samples were arrayed in 96 well microtiter plates. Each 96 well plate 
contained a maximum of 93 DNA samples. Two wells contained the same CEPH (Centre 
d'Etude du Polymorphisme Humain, Paris, France) cell line (as a control in the diallelic 
discrimination assays) positioned for each plate layout at the same position, and initially 1, 
later 4 wells with always the same position were no DNA containing empty controls. Four 96 
well plates were arranged to one 384 well plate. Wherever family samples were involved the 
plates were designed to keep the families on one plate. The plate-layout with individual 
identification through barcodes was entered to the database system before the plate was 
produced. Each plate received an identification number. Application to 96 and 384 deepwell 
plates (ABgene, Epsom, UK) and adjustment of the concentration was performed with the aid 
of a TECAN Genesis RSP 150 multipipetting robot (Tecan Deutschland GmbH, Crailsheim, 
Germany). An aliquot of DNA -TE solution containing 2 ng (for diallelic discrimination 
assays) or 5 ng (for sequencing) DNA was then distributed via 96- and 384-channel Robbins 
Scientific Hydra microdispensers (Dunn Labortechnik GmbH; Asbach, Germany) to the 96 or 
384 well microplates (Costar Corning Incorporated; Cambridge MA, USA, Greiner Bio-One 
GmbH, Frickenhausen; Germany) to be dried at 60°C, the plates then were heat sealed with a 
ABGENE ALPS 300 (ABgene, Epsom, UK) for storage. 
 
2.4. Diallelic genotyping 
 
2.4.1. The principle of diallelic genotyping 
 
For the analysis of allele status at a known SNP position in a large group of DNA samples the 
method of diallelic genotyping (5’ nuclease assays) was applied. The 5' nuclease PCR assay 
detects the accumulation of specific PCR product by hybridisation and cleavage of a double-
labelled fluorogenic oligonucleotide during the amplification reaction. The method is based 
on a PCR reaction including the SNP of interest. Besides the forward and reverse primer, 2 
oligonucleotides (called probes), one for each allele, are involved in the reaction. The probe 
has a reporter fluorescent dye attached at the 5' end and a quencher dye at the 3' end. The two 
probes have reporter dyes with fluorescent emission at different wave-length. During the PCR 
reaction the oligonucleotide with the correct nucleotide at the position of the SNP hybridises 
to the reverse DNA strand and is cleaved through the 5’ nuclease activity of Taq DNA 
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polymerase. An increase in reporter fluorescence intensity indicates which probe has 
hybridised to the target PCR product and has been cleaved (123). Through separation from 
the quencher the dye becomes fluorescent (Fig. 2.1). Visualisation takes place through laser 
scanning technology (ABI Prism® 7700 Sequence Detection System or ABI Prism 7900HT 
Sequence Detection System). Fluorescence increases in each cycle, proportional to the rate of 
probe cleavage. To induce fluorescence, laser light is distributed to the 96 or 384 sample 
wells via a multiplexed array of optical fibres. The resulting fluorescent emission returns via 
the fibres and is directed to a spectrograph with a charge-coupled device (CCD) camera. The 
fluorescent dyes employed for the analysis are TET (tetrachloro-6-carboxyfluorescein) and 
FAMTM (6-carboxyfluorescein) and VIC® (trade name by Applied Biosystems) and the 
quencher TAMRA (6-carboxytetramethylrhodamine). The systems employed (Applied 
Biosystems TaqMan® technology und TaqMan®-MGB technology) allow 96 well and 384 
well platforms. The integrated software depicts the fluorescent status for each well in a 
diagram and allows to assign an allele calling to each well. A general setting of the software is 
that the TET (VIC® for TaqMan®-MGB probes) allele is always called 1, FAMTM-allele 2. 
Each well of the 96 well or 384 well plate results in a dot on the diagram according to the 
fluorescent intensity of the reporter dyes. The distribution is a cloud of the dots for each 
homozygous allele 1/1 or 2/2 calling group, and the heterozygous 1/2 calling group. One 
homozygous cloud is usually large while the heterozygous cloud is of medium size and the 
other homozygous cloud is small. For SNPs with one allele at a low frequency the smallest 
cloud could be missing sometimes. In cases where the SNP is not polymorph in the 
individuals of the plate analysed, only one cloud is present in the diagram. 
 
In contrast to the TaqMan® probes the TaqMan®-MGB probes contain a minor groove binder 
(MGB) which attaches to the minor groove of duplex DNA and by this stabilises 
hybridisation products and allows shorter probes. Furthermore a non-fluorescent quencher 
replaced the TAMRATM quencher, reducing the background fluorescence and improving the 
spectral discrimination. 
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2.4.2. The method of diallelic genotyping 
 
Different levels of automation were employed in the diallelic genotyping. Many allelic 
genotyping assays were ordered in a ready to use status (Assay-on-Demand, Applied 
Biosystems Inc., Foster City, CA, USA), or were designed from a sequence by a company 
(Assay-by-Design Applied Biosystems Inc., Foster City, CA, USA) (both TaqMan®-MGB 
technology). Both need no further optimisation. Several of the assays employed were self-
designed using the TaqMan® technology. The oligonucleotides were manufactured and 
labelled with fluorescent dyes by a company (Eurogentec S.A., Seraing, Belgium) according 
to the defined sequence.  
 
For the design of oligonucleotides employed in the diallelic assay the program Primer Express 
1.0 or 2.0 (Applied Biosystems Inc., Foster City, CA, USA) was used. The guidelines 
proposed in the program description were applied (124-126). The primer concentration was 
set to 50 nM. In the TaqMan probe document the probe was selected manually. The 
polymorphism was in the middle or the last third of the probe (minimum 5 bases before the 
end of the probe). The probe was not allowed to start with a guanine (G) as the first base. The 
required melting temperature (Tm) for the probes was about 70°C, a range of 2°C up and 
down is possible). The difference in Tm between the probes was not larger than 0.5°C. The 
sequence of the probes belonging to one assay was allowed to vary in length, with a 
Fig. 2.1: The principle of diallelic 
genotyping. 
During the PCR the compatible 
probe anneals to the DNA and is 
removed through the Taq-
polymerase during the elongation 
of the primer. This activates the 
fluorescent dye and the emission 
from each sample can be 
measured and plotted in a 
diagram. 
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maximum length of 40 bases, the minimum was 17 bases. The primer Tm was about 10°C 
below the Tm of the probes, therefore the optimal Tm for primers was between 58 to 60°C. 
Primers were not selected from repeat masked regions or regions with other SNPs. The 
average amplicon length varied between 50 to 150 bp, where the SNP needed verification the 
amplicon was chosen close to 150 bp or even longer to allow a clean sequencing product 
around the SNP. The program proposed up to 200 primer pairs for the selected probe. The 
forward primer was chosen at least at a 10-20 bases distance from the probe. For primers used 
for sequence validation minimum 40 bases distance to the SNP was required, eventually the 
reverse primer was used for sequencing. The reverse primer was allowed to overlap with the 
probe, but not to reach the SNP. Primers with high variation in the bases at the 3’end, no T at 
the last position, no three same bases in a row in the last third of the oligonucleotide were 
allowed. If the program was not able to find primers, the Tm and the amplicon length were 
altered slightly or a new probe was selected. In the primer test document the primers were 
tested for self-annealing and loops. Not more than three self-annealing or loop-bonds in a row 
were accepted, primer-dimerisation for up to 4 bonds was allowed. TaqMan® probes were 
labelled with the fluorescent dyes FAMTM or TET and with the quencher TAMRATM. 
 
For TaqMan® probes an optimisation of the primer concentration was needed. The 
optimisation was adapted from the procedure proposed in the protocol for the TaqMan® 
allelic discrimination (Applied Biosystems Inc., Foster City, CA, USA)(125) to a high 
throughput level including several control mechanisms. Therefore primers and probes were 
diluted to 100 µM storage concentration with double distilled water (DDW), work dilutions 
were at 20 µM for the primer and 10 µM for the probes. By adjusting initial concentration the 
effective Tm of the primer shifted by –2°C up to +2°C from the midpoint. This test was 
usually performed with only the FAMTM labelled probe. The following reaction 
concentrations were tested for each primer: 50 nM, 300 nM 900 nM, the concentration 50/50 
was not tested in the optimisation (the reaction solution for each concentration is shown in 
Table 2.4). Each concentration combination was tested 3 times with 2 ng DNA (dried) and on 
3 blank controls. The final concentration for the FAMTM probe was 100 nM. The reaction 
volume for the optimisation was 25 µl, with 16.6 µl of the TaqMan® Universal PCR 
MasterMix (Applied Biosystems Inc., Foster City, CA, USA). The standard cycle conditions 
was 60°C with 45 cycles on a GeneAmp® PCR System 9700 (Applied Biosystems Inc., Foster 
City, CA, USA). 
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After the PCR reaction the fluorescence was detected with the ABI 7700 Sequence Detector 
(Applied Biosystems Inc., Foster City, CA, USA) and the DRn for DNA and blank controls 
was measured. While Rn is the emission of the normalised reporter dye, Rn+ is the 
fluorescent emission when a DNA template is present and Rn- is the emission measured 
without a template, the DRn is calculated from (Rn+) - (Rn-). The primer concentration with 
the greatest difference between no template control and the DNA template and a constant 
value over all three samples was chosen. The assay was then tested on a plate with different 
DNA samples at the annealing temperatures 58°C, 60°C and 62°C with the final reaction 
volume of 5 µl (for earlier assays the reaction volume was 10 µl). Where no sufficient 
differences were observed the reaction was repeated with additional 2.5 µl MgCl2 (25 µM). 
The standard protocol for the assays is shown in the Tables 2.5 and 2.6. 
 
For SNPs that needed sequence verification the assay was tested on the sequenced samples. 
Other quality criteria were clearly separated clouds of dots in the analysis program, a small 
number of not amplified samples, no cloud duplications (more than 3 clouds total), no well 
with empty control in one of three calling dot clouds (otherwise contamination had 
happened), and all CEPH control DNA samples needed to be in the same cloud of dots. 
Hardy-Weinberg Equilibrium (HWE) was calculated for the independent DNA samples. After 
all samples for one assay were genotyped and analysed, the data were imported to the internal 
database system where additional quality tests were performed. 
 
For a higher automation on the 384 well platform a TECAN Genesis RSP 150 multipipetting 
robot (Tecan Deutschland GmbH, Crailsheim, Germany) was used to apply the complete 
reaction solution to the 384 well plates with the dried DNA. The PCR reaction was done on 
forward/ 
reverse primer 
(nM final conc.) 
Mix 
(µL) 
FAMTM 
probe 
(10 µM) µl 
forward 
primer 
(20 µM) µl 
reverse 
primer 
(20 µM) µl 
DDW total 
volume 
µl 
50/300 16.6 0.33 0.083 0.5 15.75 33.3 
50/900 16.6 0.33 0.083 1.5 14.75 33.3 
300/50 16.6 0.33 0.5 0.083 15.75 33.3 
300/300 16.6 0.33 0.5 0.5 15.33 33.3 
300/900 16.6 0.33 0.5 1.5 14.33 33.3 
900/50 16.6 0.33 1.5 0.083 14.75 33.3 
900/300 16.6 0.33 1.5 0.5 14.33 33.3 
900/900 16.6 0.33 1.5 1.5 13.33 33.3 
Table 2.4: Reaction solution for the probe concentration optimisation.  
DDW = double distilled water 
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T1 Thermocycler with 384 well application (Whatman Biometra GmbH, Göttingen, 
Germany) or GeneAmp® PCR System 9700 with 384 well application (Applied Biosystems 
Inc., Foster City, CA, USA). Plate fluorescence was measured automatically with an ABI 
Prism 7900HT sequence detection system (Applied Biosystems Inc., Foster City, CA, USA). 
Allele calling for each plate was done manually to ensure data quality. All markers had to 
have a genotyping performance of over 95%. Markers with lower performance were not 
included into the analysis. 
 
 
 
 
 
 
 
 
 
 
 
2.4.3. SNP marker selection 
 
For the association mapping study of the 20 Mb large peri-MHC (microsatellite markers 
D6S461 to D6S271) region SNPs were selected from the NCBI dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/index.html) or from literature. The SNP markers were 
selected to achieve an average density of one marker every 50 kb. Selection criteria for SNPs 
from dbSNP included that the SNP was tested in 10 or more chromosomes and the description 
was in genomic sequence, the minimum required sequence length was 120 bp on each side of 
the SNP. Polymorphisms were preferentially selected from coding sequence causing a change 
in the amino acid sequence. To achieve a tolerable density of the SNP marker, polymorphisms 
were chosen as well from intronic, untranslated or even anonymous DNA sequence.  
For a 5 µl PCR reaction volume Volume (µl) for one 
reaction 
Final  
concentration (nM) 
TaqMan® Universal PCR MasterMix 2.5 --- 
FAMTM probe (10µM) 0.05 100 
TET probe (10µM) 0.05 100 
Forward primer (20µM) 0.0125/0.075/0.225 50/300/900 
Reverse primer (20µM) 0.0125/0.075/0.225 50/300/900 
Water  to 5 µl total volume --- 
Temperature Time process function 
50°C 2 min  hold optimal AmpErase UNG activity 
95°C 10 min  hold DNA polymerase activation 
95°C 15 sec  melting 
58/60/62°C 1 min 
cycle 
40X annealing and extension 
10°C ¥ hold  
Table 2.5: Reaction solution for the diallelic genotyping PCR. 
Table 2.6: Temperature cycling conditions for the diallelic genotyping. 
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Fig. 2.2: SNP marker map for 
association mapping on 
chromosome 6p21. 
SNP marker density was higher in 
the central part covering the MHC 
region than in the telomeric and 
centromeric end of the map. 
21.29 Mb 
28.85 Mb 35.42 Mb 
44.14 Mb 
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SNPs described by "The Sequencing Consortium" (http://snp.cshl.org/) were preferred as they 
were always described in genomic sequence, other SNPs in the direct environment were 
indicated and repeat masked sequence was identified. All SNPs from the dbSNP were 
sequence verified prior to genotyping, tested on the sequenced samples for correct calling and 
had to have a genotyping performance of over 95%. Further quality standards were no 
significant derivation from the HWE in the controls and a test for Mendelian inheritance 
errors. A total of 142 SNP markers (self designed, Assay-on Demand and Assay-by-Design, 
Applied Biosystems, Foster City, CA, USA) were included in the analysis after quality 
control. Physical positions of the SNPs were determined from the NCBI assembly (build 32). 
The density of the markers was not equally distributed. The average density was 161 kb with 
a median of 60 kb. The maximum distance between two markers was 1860 kb, the shortest 
distance 68 bp. While a central area from 29.4 Mb to 37.5 Mb including the MHC region had 
a higher density (average of 80 kb, median 36 kb), the outer areas from 21.3 Mb to 44.1 Mb 
were less densely covered with markers (Fig. 2.2). Genotyping was performed in the 550 
control individuals, in the 178 multiplex families and in the 461 monoplex families. 
 
In order to explore the structure of linkage disequilibrium existing in the region around the 
MHC diallelic genotyping (5’ nuclease) assays were selected for SNPs located in a 10 Mb 
region on human chromosome 6p (microsatellite markers D6S461 to D6S291) between 
position 25.3 Mb - 36.3 Mb (NCBI release 30). SNPs were chosen from the Celera Human 
RefSNP database (version 3.6) through a prioritisation scheme that stipulated evidence for an 
independent discovery of the minor allele (127). PCR primers and TaqMan®-MGB probes 
were designed using an algorithm that generates oligonucleotide sequences and subsequently 
screens them against a genome sequence database, to avoid potential genotyping artefacts. 
SNPs were selected by imposing a “picket-fence” with an average grid density of 10 kb upon 
the genomic sequence of interest (127). Only those 920 SNPs that were found to be 
polymorphic in 10 unrelated DNA samples were included in subsequent experiments (Assay-
on-DemandIM, Applied Biosystems, Foster City, CA, USA). The full 920 SNP markers were 
typed in the 45 white US American individuals from the Coriell sample. 
 
Consequently to the analysis of the large region a smaller region representing all 
characteristics of LD observed in the initial screening was selected from the initial area. Being 
as well of special interest in the context of disease gene detection, a 3.53 Mb region of 
chromosome 6p21.3 covering the MHC (NCBI release 30 position 29.4 Mb - 32.9 Mb) 
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representative in this sense, was chosen for a more detailed and comparative analysis of 
haplotype structure in five different populations. An additional 37 SNPs were obtained from 
the association study marker set and another 11 SNP markers from external sequencing 
(Institute of Immunology University Clinic Schleswig-Holstein, Kiel, Germany) were 
included in order to enhance marker spacing and distribution of the 272 SNPs located in this 
region from the first set. Physical positions of the total 320 SNPs were determined from the 
NCBI assembly (build 30). The final average marker density in the region was 12 kb (median 
5.5 kb), with a minimum of 14 bp and a maximum of 189 kb. These SNP markers were typed 
in the 550 German, 93 Norwegian, 73 UK and 45 US African-American individuals (Coriell). 
Genotyping of the Coriell samples was conducted at the Services Development and Delivery 
Laboratories of Applied Biosystems, Foster City, California, USA. 
 
2.4.4. Genotyping of HLA-DPA1 
 
The HLA-DPA1 was one of several possible candidate genes in the HLA class II region. It is 
expressed on intestinal epithelial cells of non-inflamed small and to a lesser extent large 
bowel (128). Expression is increased during intestinal inflammation in CD and UC (128, 
129). Increased expression on epithelia in UC appears associated with the number of 
infiltrating mononuclear cells (130). In moderate to high inflammatory activity HLA-DP 
antigens were expressed strongly in enterocytes, glial cells, and capillary and venular 
endothelium (131). Increased expression of HLA-DP could be induced ex vivo by interferon-
gamma (IFN-g) and tumour-necrosis factor alpha (TNF-a) in isolated enterocytes and colonic 
epithelial cells from jejunal mucosal biopsies (132-134).  
 
Instead of the assessment of all HLA-DPA1 allelic variants known, polymorphisms at the 
nucleotide positions 91-92, 111, 114 and 149 (of the coding sequence) in exon 2 were 
analysed through sequencing. Exon 2 is relevant in the formation of the binding cleft and an 
alteration could influence the antigen presenting function. Primers for PCR amplification of 
the second exon were designed on sequences obtained from the NCBI Database (Accession 
Number X03100, Human HLA-SB (DP) alpha gene). The forward primer 
(5’TCAGGATGCCCAGACTTTCAA) was chosen from intron 1, the reverse primer 
(5’CAGGGGGCACTTAGGCTTCC) from intron 3. The oligonucleotides used as internal 
primers for sequencing (forward: 5’GCGGACCATGTGTCAACTTAT, reverse: 
5’GCCTGAGTGTGGTTGGAAG) were adopted from the literature (135) while the 
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optimised PCR and sequencing conditions were developed on the basis of PCR standard 
protocols (124, 136). Amplification was performed in 35 cycles at 60°C annealing for 30 sec. 
and 1.30 min elongation at 72°C. (AmpliTaq Gold Standard chemistry) with a GeneAmp® 
PCR System 9700 (both Applied Biosystems Inc., Foster City, CA, USA). Enzymatic 
purification of PCR products and sequencing were performed according to the standard 
sequencing protocol (see section 2.5.3). Obtained sequences were compared with Sequencher 
(Gene Codes Corporation, Ann Arbor, MI, USA) to consensus sequence (accession number 
X03100.1) and allelic variants. The three polymorphic sites were handled like the SNP 
markers with 2 alleles for the position 91-92, three alleles at position 111-114 and two alleles 
at position 149 (see as well Table 3.6). Allele variant data were entered to the database and 
subjected to quality control and analysis alike the diallelic genotyping results. Analysis was 
performed in the German family and trio IBD sample population, the South African family 
sample population and independent IBD cases and control samples from South Korea. 
 
2.5. Mutation detection and verification of SNP markers 
 
2.5.1. PCR optimisation 
 
The strategy for the optimisation of PCR conditions for different primer-pairs was developed 
on the basis of standard PCR protocols (136, 137). Adaptations were made in order to render 
a high throughput possible and to maintain quality standards. After dilution of the 
oligonucleotide to a storage concentration of 100 pmol/µl with DDW, a working solution of 
20 pmol/µl was made. The reaction solution contained the following reagents: 2.5 µl Qiagen 
Buffer (10 x concentrated)  0.5 µl dNTP (10 mM), 0.2 µl primer forward; 20 pmol/µl, 0.2 µl 
primer reverse; 20 pmol/µl 1.0 µl MgCl2 (25 mM) 0.15 µl Taq polymerase (QIAGEN GmbH; 
Hilden, Germany) and DDW, to a final amount of 25.0 µl per reaction. Two ng DNA were 
used, either already dried in the plate or if liquid DNA was added the amount of water was 
reduced by the equivalent volume. Optionally there was the possibility to add Qiagen special 
buffer for problematic amplifications. Also the amount of MgCl2 could be changed according 
to the conditions needed. The reaction solution was set up for 12 reactions (of which 10 were 
used). The PCR reaction was set up in a T1 Gradient (Whatman Biometra GmbH, Göttingen, 
Germany) with the following cycle program: 96°C - 10 min, (96°C -  1 min; 64°C - 1 min {–
0.5 °C per step}; 72°C - 1 min) 16x, (96°C - 1 min; 56°C - 1 min; 72°C - 1 min) 15x, 72°C - 
10 min, 10°C  ¥. The gradient covered the temperatures up to 5°C higher and lower than the 
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annealing temperature given in the protocol. This way a range of temperatures can be tested at 
once (e.g. a range from 59°C to 69°C in the example above). If needed, the temperature was 
altered to find the optimum for a primer combination. Using a 96 well plate up to 8 primers 
were tested at once. Five µl PCR products together with 1 µl 6-times loading buffer (0.25% 
bromophenol blue, 0.25% Xylene Cyanol FF, 30% Glycerol in Water) were applied to a 1.5% 
agarose gel (300 ml Tris borate EDTA (TBE), 3 µl ethidium-bromide). A 100 bp ladder 
(Invitrogen GmbH, Karlsruhe, Germany) was applied next to the PCR products, 
electrophoresis conditions were 150 V for 50 min. A picture was taken under UV light and 
observed bands of PCR products were compared to expected product length. Quality criteria 
were one clear band at the correct length without smear, no double bands, and a low amount 
of primer-dimer. If the quality criteria were not met several factors were open for alteration 
(MgCl2 concentration, adding Qiagen special buffer, temperature change and alteration of 
primer concentration).  
 
2.5.2. Sequence analysis 
 
After primer optimisation a reaction solution was prepared according to the conditions 
optimised before. The solution was applied to a 96 well plate (depending on the sequencing 
population occupying 48 wells or 32 wells) with 5ng DNA either dried to the wells or liquid. 
The plate design allowed PCR amplification for 2 or 3 primer-pairs at the same time if they 
had the same amplification cycle conditions. Five µl PCR product were mixed with 1 µl 6-
times loading buffer and tested on a 1.5% agarose gel (in 300 ml TBE, 1% ethidiumbromide, 
150 V for 50 min). Unwanted primer-dimers, and free dNTPs in the PCR product were 
removed by digestion. For a highly concentrated PCR product a 1:5 with DDW dilution was 
necessary before the digest, which was decided from the appearance of the bands on the 
agarose gel under UV light. If the bands were bright, the PCR product was diluted, if they 
were weak the original concentration was used. The enzymatic digest was performed in a new 
plate with 8 µl PCR product (diluted) at the following conditions: 0.30 µl SAP (Shrimp 
Alkaline Phosphatase; 1 U/µl) 0.15 µl ExoI (Exonuclease I; 10 U/µl) 1.55 µl DDW adding up 
to 2.0 µl complete reaction mix, with following incubation conditions: 37°C - 15 min, 72°C - 
15 min, 4°C - ¥, adapted from "the Current Protocols in Human Genetics" (138). The 
digested PCR product was again analysed through electrophoresis to test for the cleanness of 
the sequencing template. The chemicals used for sequencing were from the BigDye 
Terminator Ready Reaction kit (Applied Biosystems Inc., Foster City, CA, USA) based on 
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fluorescent truncation dNTPs. Two µl of digested PCR product were used for the sequencing 
reaction, 1.0 µl primer (forward); 1.6 pmol/µl, 1.0 µl BigDye Ready Reaction Mix from the 
kit, and 6.0 µl DDW for a reaction volume of 8.0 µl. The same reaction was performed with 
the reverse primer. The primers used in the sequencing reaction were either the same as from 
the PCR reaction or nested primer. The following cycle protocol for the sequencing reaction 
was used: 95°C - 5 min; (95°C - 1 min; 50°C - 45 sec; 60°C - 4min) 25x; 60°C -.5 min; 10°C 
- ¥. Sample cleanup was performed with Sephadex spin columns. The Sephadex spin column 
plates (MAHVN 4550) were prepared by adding Sephadex powder (G50 Superfine) with the 
aid of a Multiscreen Column loader (all through Amersham Biosciences, Freiburg, Germany), 
300 µl DDW were added to each column. After incubation for 3 h at room temperature with 
closed lid, the spin column plate was centrifuged at 910 xg for 5 min to eliminate the overdue 
water. Again 150 µl DDW was added followed by immediate centrifugation at 910 xg for 5 
min. The sequencing product was replenished with DDW to 30 µl total volume and pipetted 
to the centre of the spin column, the plate was fitted to a MicroAmp® Optical 96-Well 
Reaction Plate (Applied Biosystems Inc., Foster City, CA, USA). After centrifugation at 910 
xg for 5 min, the flow through contained the purified sequencing product. The sequence 
detection was performed with an automated, high-throughput, 96-capillary fluorescence 
detection system ABI PRISM® 3700 DNA Analyzer (Applied Biosystems Inc., Foster City, 
CA, USA), for fluorescent labelled DNA fragments. For the sequence analysis 
chromatograms were aligned and compared to the consensus sequences using Sequencher 
Version 4.0.5 (Gene Codes Corporation, Ann Arbor, MI, USA). 
 
2.5.3. SNP verification 
 
SNPs from the NCBI Database dbSNP needed verification through sequencing in a set of 
patients. In this case only primers were designed and ordered. Temperature and amplification 
condition optimisation were carried out as described above. Sequence verification of SNPs 
was usually performed in 23 IBD samples (plus one no DNA control) and only on one strand. 
This allowed the verification of 4 SNPs at once where the PCR cycle conditions were 
compatible. The 96 well plate designed for this purpose contained 4 times the same set of 
samples. Otherwise the sequencing protocol was followed as described above. The 
sequencing data were compared to the sequence in the SNP description in dbSNP or, where 
available, the TSC database (http://snp.cshl.org/) using Sequencher Version 4.0.5 (Gene 
Codes Corporation, Ann Arbor, MI, USA). The allelic setting for each sample was noted. 
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Additional SNPs in the direct environment were identified as the design of probes was 
affected through them. For SNPs that are not polymorphic in this set of patients the SNP was 
either eliminated from the list or sequenced in a second set (Sequencing population 47 
samples). SNPs that were not polymorphic were excluded. After optimisation, the SNP-assay 
was tested on the same set of samples. Allele-calling needed to be identical to the sequencing 
results, if not the assay needed further optimisation until the allele-calling was identical, or the 
SNP was excluded from further analysis. 
 
2.5.4. Mutation detection in candidate genes  
 
Several genes qualified themselves as candidates for association with IBD through their 
function and their position within the linkage region and near to association peaks. These 
genes were sequenced for polymorphisms in the exons. For all genes an alignment of mRNA 
or cDNA sequence with genomic sequence was performed to determine the exact positioning 
of the exons and to identify the known splice variants. Primers were designed on intronic 
sequence and the analysis performed in genomic DNA. Where nested primers were employed 
for sequencing, they were designed at minimum 40 bases distant from the exon boundaries for 
all exons. Mutation detection was performed in 30 unrelated German individuals affected 
with IBD (15 CD and 15 UC) or 47 unrelated German individuals affected with IBD (24 
patients with CD, 23 patients with UC). PCR amplification and sequencing were done 
according to the protocol described. Experimental sequences were aligned with consensus 
sequence using Sequencher Version 4.0.5 (Gene Codes Corporation, Ann Arbor, MI, USA). 
In case of uncertainty sequencing was repeated in an additional group of individuals. For 
newly found exon polymorphisms diallelic genotyping assays were designed and tested in the 
full German association study sample population. Positioning of the genes is given in the 
NCBI assembly build 32. Primer oligonucleotides used for PCR amplification and sequencing 
reaction are listed in the appendix 8.2, Table 8.3. 
 
2.5.4.1 MAPK14 
Three splice variants are well described for the MAPK14 gene locus, identified by the names 
MAPK14 (or p38a), Mxi2 and CSBP1. An alignment of cDNA sequences of MAPK14/p38-a 
(accession number L35253), Mxi2 (accession number U19775) and CSBP1 (accession 
number L35263) with the PAC genomic clone 179N16 (accession number Z95152), 
generated from chromosome 6p21.1/21.33, revealed 13 exons and the complete intronic 
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region of the p38-a gene as described previously (139, 140). The complete coding sequence is 
positioned from 35990 kb to 36075 kb on chromosome 6p21. Exons herein are numbered 
according to this alignment resulting in an alternative splicing of exon 9 and 10 for MAPK 14 
and CSBP1 and an extended exon 11 for Mxi2 (Fig. 3.6). While the amino acid sequence is 
identical for position 1 to 280 (exons 1 to 8), alternative internal splicing of exon 9 and 10 
accounts for 14 amino acid exchanges between MAPK14 and CSBP1. Mxi2 lacks 80 COOH 
terminal amino acids (exons 12 and 13), which are replaced by 17 residues encoded by exon 
11' (contiguous to exon 11) (140, 141). The variants MAPK14 and CSBP1 are described to be 
expressed at different levels in most human tissues (142-144) while in mouse Mxi2 is 
expressed solely in kidney (140). The relevance in inflammatory processes and the position 
within the chromosome linkage region suggested the p38-a gene locus an interesting target 
for mutation detection and further analysis in IBD affected individuals. The protein encoded 
by this gene is a member of the MAP kinase family. MAP kinases act as an integration point 
for multiple biochemical signals in the cell signalling process. Various environmental stresses 
and proinflammatory cytokines cause activation to MAPK14. The activation requires 
phosphorylation by MAP kinase kinases (MKKs). It has an important part in stress related 
transcription and cell cycle regulation. All 13 exons were PCR amplified by distinct primer-
pairs, furthermore the potential promotor region covering about 1000 nucleotides upstream of 
the 5'end of exon 1 was sequenced. All primers were tested negatively for homologous 
binding in p38-b, -g and -d. Sequencing was originally done in the set of 30 individuals. 
Where the results were not clear the sequencing reaction was repeated in the additional set of 
47 IBD affected individuals. 
 
2.5.4.2 MAPK13 
For MAPK13 (or p38-d) no additional splice variants were described in the literature. Twelve 
exons were confirmed in alignment of the mRNA (accession number AF004709) with PAC 
genomic clone 179N16 (accession number Z95152). The gene is positioned at 36092 kb to 
36105.5 kb on chromosome 6p21 centromeric to MAPK14. It is closely related to MAPK14 
and involved in a wide variety of cellular processes such as proliferation, differentiation, 
transcription regulation and development. Activation is triggered through proinflammatory 
cytokines and cellular stress. All primers were tested negatively for homologous binding in 
p38-a, -b, and -g. Sequencing was done in the cohort of 47 individuals (Fig. 3.6). 
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2.5.4.3 TREM1 
The TREM1 gene locus encodes for a triggering receptor expressed on myeloid cells. The 
expression and functional properties of TREM1 suggests a role in acute inflammation (145). 
The gene is located at 41232 kb to 41251 kb on the chromosome 6p21. The mRNA (accession 
number AF196329) encodes for 4 exons when aligned with genomic DNA (accession number 
NT_007592). Primers for the exons and a potential promotor region (about 300 bp proximal 
of exon 1) were designed on genomic DNA and sequencing was performed in a cohort of 30 
individuals (Fig. 3.6). 
 
2.5.4.4 BRPF3 
The BRFP3 gene was only predicted at the time it was analysed. The predicted transcript 
Enst00000259697 (ensemble: http://www.ensembl.org/) was aligned with chromosome 6 
contig NT_007592.9, resulting in 12 pieces of mRNA matching the genomic DNA. The 
transcript has by now been confirmed. The gene function is still unknown, the encoded 
protein contains a bromodomain and PHD finger. It is positioned neighbouring centromeric to 
MAPK13. To confirm the existence of the transcript the amplification and sequencing was 
performed in cDNA from 27 cell lines derived from peripheral blood lymphocytes of IBD 
cases. 
 
2.6. Internal database 
 
2.6.1. Follow up of phenotype-genotype sample data  
 
The large numbers of individuals with DNA samples, phenotype description, family 
information and genotype information was handled through an internal database system (146), 
which is an SQL Server database. All samples received an identification number at their 
entrance into the laboratory. Information about the individual like phenotypic trait (affected or 
unaffected, specification to UC and CD), gender, age, family relationship (pedigree 
information) and population information were entered to the database and linked to each 
other. Additionally, sample information like quantity and concentration of DNA and plate 
information (which patient's DNA is in each well of a 96 or 384 well plate) was connected. 
The plates with the DNA samples were again identified through a barcode system. 
Information about diallelic genotyping assays like oligonucleotide sequences (not available 
for Assay-on-Demand assays), chromosomal position, and genetic variants was entered as 
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well in the database. When an assay was applied to a sample and the resulting genotypes were 
entered in the database, the information was automatically linked to the individual sample 
through the barcode of the plate. The database allows to export data of individuals, within an 
analysis population, with their pedigree information, phenotypic trait and genotype 
information from a set of self selected SNP markers. The export format is the appropriate 
format for a selection of analysis programs (LINKAGE PREFILE). Besides that, a variety of 
application tools allowed to see which assays were genotyped on which samples (or plates), 
construct individual maps of markers together with the chromosomal position, and several 
quality measures. Additional applications helped to enter and edit sample information, create 
plate templates, to control robots to make plates and to measure DNA concentration. 
 
2.6.2. Quality control 
 
Integrated to the database system was a test for Mendelian inheritance errors (147). This 
application was part of the SNP genotyping data import to the database. It was utilized for 
each SNP marker and all populations the marker has been genotyped for. All inheritance 
errors were shown in a list with all family members and their genotyping data for that assay. 
The positions of the family members in the fluorescence diagram of the plate containing the 
family were seen through the linked plate-view (146). If the positions of one or more family 
members were not clearly within one of the clouds defining the genotype, the allele calling 
was wrong. The genotype data of the corresponding family members were set to 0. In cases 
where the positioning was clear, one of the individuals assigned to the pedigree was not a real 
member of the family. This might have been caused through a mix up of the samples or 
through infidelity. A few families with Mendel errors were normal and acceptable. The 
genotyping data for these were set to "0" and therefore were not included into the analysis. 
For SNP markers with a high number of inheritance errors, the SNP marker was excluded 
from the analysis when the assay was evaluated as not reliable. For sample populations of 
single individuals genotyping results were subjected to assessment of HWE by a c2-test at the 
1% significance level. This test was applied as well to genotypes from families, however a 
slight unbalance could be expected in this situation. A quick view tool of the database 
showing the allele calling allowed to test if plates had been called inversely by accident. In 
such a situation the import had to be repeated with the correct calling.  
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2.7. Statistical analysis 
 
2.7.1. Association analysis 
 
Genetic analyses were performed using the diagnostic disease categories IBD, CD and UC as 
described. Allele and genotype frequencies for each SNP were calculated from all unrelated 
control individuals. For the calculation of the allele and genotype frequency in the cases only 
one affected individual per multiplex family was selected randomly, in order to avoid a bias 
through overrepresentation of a family genome. From the monoplex families each affected 
individual was included. This was done separately for each category IBD, CD and UC. On the 
basis the allele and genotype numbers received in this process case control statistics were 
performed for alleles and genotypes using contingency tables (43). Pearson's c2 was used as a 
measure of independence or association between the disease trait and the allelic variants of 
the SNPs tested or their genotypic prevalence in the case and the control samples. The 
significance at the 95% confidence interval is given as p-value, additionally a permutation test 
with 1000 repeats was performed to verify significance. Family based transmission distortion 
was analysed in the study population using the transmission disequilibrium test (TDT) from 
TRANSMIT version 2.5 (148). This test is based on a comparison of alleles transmitted from 
parents to affected offspring against the alleles that were expected to be transmitted from the 
population frequency in the parent generation according to HWE calculations. For each 
haplotype or allele, a test for excess transmission of that haplotype was performed. A 
bootstrap significance testing was carried out using 1000 bootstrap samples. The family based 
association was calculated as well using Genehunter (40). This program calculated the TDT 
according to the original description (42) by comparing alleles transmitted from parent to 
offspring with alleles untransmitted. Transmissions from homozygous parents were not 
informative in this analysis. In addition, the transmissions and non-transmissions in each 
family were stored for use by multi-locus analysis. A test for significance was provided with a 
permutation method creating a new data set with each pair of transmitted and untransmitted 
alleles, arbitrarily reversing the assignment of which was transmitted. The TDT was 
calculated for 10000 permutation repeats for single marker analysis and 1000 repeats for 2 
marker analysis, comparing each simulated data set to the actual results observed in the real 
data set. In the data output it is indicated how many of the permuted data sets had a higher 
maximum value and how many had more results above certain thresholds (0.01, 0.001) of 
significance. In each program association was calculated for up to three-marker haplotypes 
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passing a sliding window through the marker map. Peaks of association were subject to 
further investigation in the candidate gene approach. 
 
Beside the investigation of association in the SNP marker map, an analysis of linkage was 
performed using Genehunter, in order to delineate the non-parametric LOD score (NPL) in 
the marker set analysed (40). With this method a non-parametric trait like the disease 
affection status (affected or unaffected) can be analysed for linkage within a genomic region. 
The diallelic SNP markers were employed as genomic markers to which recombination was 
measured within the ASPs. To enlarge the number of ASPs in the analysis as well dependent 
ASPs were included. To avoid the bias the dependent sibpair was weighted less and added 
less linkage that the independent ASPs. Together with the linkage scan, the overall count of 
recombinants was calculated along with the value expected on the basis of the given physical 
distance between the SNP markers for the entire data set. If recombination was observed 
significantly more often than expected this could be an indication of a marker that was error-
prone over multiple pedigrees or of an error in the entered genetic map, either in order or 
distance.  
 
As a measure of inter-marker linkage disequilibrium (LD) the Lewontin's D' (149, 150) was 
calculated employing an analysis option of the HAPMAX program (http://www.uni-
kiel.de/medinfo/mitarbeiter/krawczak/download/hapmax.exe). The measure estimates the 
difference between the number of two marker haplotypes observed and the one expected 
under the assumption of independence in segregation of markers using the correlation 
coefficient. Thereby the influence of allele frequency is considered in the calculation. Markers 
with a frequency below 1% in the control cohort were excluded from this analysis. 
 
For the analysis of HLA-DPA1 the same statistical association methods were employed. 
Pearson's c2 statistics were calculated on contingency tables for alleles and genotypes as well 
as the frequencies for each polymorphic site and for shared epitopes over the three 
polymorphic sites (43). Randomly selected cases from the families were taken from the 
German and the South African family sample. From the South Korean population sample of 
unrelated individuals all cases available were included in the analysis. As control samples for 
the German population unrelated blood donors were used. Unrelated control samples were 
available as well from the South Korean population. In the South African population a 
randomly selected healthy family member was chosen as control sample from each family. 
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Transmission distortion was analysed in the German and South African family cohort using 
TRANSMIT (148) and the TDT using Genehunter (40). Inter-marker LD between the three 
polymorphic sites was calculated using EH (151), which is able to estimate LD between 
multiallelic markers. 
 
For the candidate genes with significant initial association signals the case control and the 
TDT association were recalculated with all markers from the gene including newly generated 
ones from the mutation detection for each disease category. Furthermore the odds ratio (OR) 
was calculated for these SNP markers as a measure of increased risk of affection with a 
certain SNP variant. Stratification was performed for the NOD2 +/- genotypes in the IBD 
category according to allele status at the NOD2 gene mutations (3020insC, R702W, L1007P) 
(63-65). The SNP markers from the candidate genes were as well analysed for association 
with the following severity factors of IBD: (i) development of fistulae, (ii) formation of 
stenosis and (iii) previous resection of parts of the bowel, as described by the affected 
individuals in the questionnaire (appendix 8.4). If not annotated differently p-values were not 
corrected for multiple testing. 
 
2.7.2. Analysis of linkage disequilibrium structure 
 
In order to estimate the genetic differences between the 5 populations included into this study 
the F-statistics of population subdivision (FST) were calculated with the Arlequin program 
(152). The FST value is a measure for the deficiency of heterozygotes in the total of all 
populations that could be explained by subdivision into the original populations (153). 
 
Pairwise LD between SNP marker was quantified using Lewontin’s standardized deviation 
coefficient D’ (149, 150) comparing estimated two marker haplotypes with expected 
haplotypes in each population with the HAPMAX program (http://www.uni-
kiel.de/medinfo/mitarbeiter/krawczak/download/hapmax.exe). This was done for the large 10 
Mb region in the US American whites sample as well as for the smaller region of 3.53 Mb 
with the higher marker density, and in all 5 populations. In these analyses, markers were 
ignored for populations in which the rare allele occurred at a frequency of less than 5%. For 
the German population as well an allele frequency cut-off of 20% was adopted in order to 
reduce the influence of more recently evolved SNPs upon the inferred haplotype patterns. 
Markers were clustered according to D’ values using a standard UPGMA (Unweighted Pair 
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Group Method with Arithmetic Mean) algorithm (154). In this procedure the D' value for all 
marker pairs was compared and the two markers with the highest D' value were connected 
through a dendrogram. Afterwards the arithmetic mean was calculated for this pair and for the 
further clustering process used as new D' value. Then the next highest D' value is identified 
and the markers clustered. Through this process sometimes markers were combined not 
neighbouring in the physical map. The marker order was kept as close as possible to the 
physical order by minimizing the number of non-sequentially clustered markers through 
rotation of branches in the emerging dendrogram. A clustering of D' values in this way has 
not been described before and allows the identification of linkage structures without previous 
assumptions. 
 
LD structures in the 3.53 Mb region were compared between the different populations, 
employing the German population as reference population. The method developed for this 
purpose was to calculate Pearson's correlation coefficients of pair-wise D’ values markers in a 
sliding 500 kb window. In order to control sample size effects, random subsamples of 45 
individuals (i.e. the minimum population size available for study) were drawn from the 
Norwegian, and the UK population and all individuals from the two US populations. From the 
German population the random sample of 45 individuals was drawn 1000 times and the 
correlation coefficients averaged over all 1000 subsamples. In addition, 95% confidence 
intervals were estimated for the German population sample from this procedure.  
 
Metric LD units 
This analysis was performed through Francisco De La Vega at Applied Biosystems, Foster 
City, California 94404 / USA. Due to reasons of consistency it is not separated from the 
study. 
 
Metric LD units (LDU) were calculated, using the LDMAP program available at 
http://cedar.genetics.soton.ac.uk/public_html. This method has been developed to measure 
LD in the context of physical position of recombination (155). The LDU are additive over the 
physical distance with an increase in LDU representing a site of recombination. One LDU 
corresponds to the so-called “swept-radius” which has been suggested as the maximum 
(physical or genetic) distance over which useful LD can be expected (156). It equals the 
inverse of the exponential LD decay constant e. LD map construction depends on obtaining an 
estimate for ei for the ith interval between adjacent pairs of SNPs, using the information in all 
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SNPs typically within 100 kb. Two-marker haplotype data from SNP analysis were directly 
used as input to the LDMAP program to fit the Malecot model (156) for the decline of 
association with distance with expected value. For visualization of the LD map, the 
cumulative sum ? i=1..neidi, measuring the distance of the n-th marker from the map origin in 
LDUs, was plotted against physical distance ? i=1..ndi. Here, di is the physical length (in kb) of 
the ith marker interval (155).  
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3. Results 
 
3.1. Association mapping results  
 
3.1.1. Case-control association 
 
In order to further confine the area previously defined through linkage analysis in which a 
gene causing IBD, CD or UC might be located, a map of SNP markers was established within 
a 22.8 Mb long region on the human chromosome 6p covering the MHC region. After the 
exclusion of markers not matching the quality criteria a total of 142 SNP markers were 
employed for the association mapping (Fig. 2.2). For the analysis of association in the case 
control study design, the population was classified into the diagnostic categories healthy and 
affected (IBD), and the affection categories CD and UC. Cases for each category were taken 
from the monoplex families plus one randomly selected case from each multiplex family. The 
SNP markers, their position according to NCBI built 32 and the allele and genotype 
frequencies for each category can be seen in Table 8.1 appendix 8.1.1. Pearson's c2 was 
calculated for allele and genotypes.  
 
 
 
Fig. 3.1: Allele association analysis. Pearson's c2 was calculated for each of the 142 SNP 
makers. Not all markers are listed on the x-axis and the distance is not representing the physical 
distance. Significance of a peak at the 95% confidence interval is reached at a c2 value of 3.9 with 
1 df. 
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The association for each marker in the allele and the genotype analysis is shown in Fig 3.1 
and Fig. 3.2. Different peak associations can be identified for each disease category and for 
allele and genotype association. There were 8 peaks of association with IBD in the allele 
association analysis that reached a significance level of p<0.05. Peaks were characterised by 
an increased c2 value in several markers rising from both sides to the highest observed value 
in that physical region. Several markers and resulting peaks were mostly carried through one 
of the two IBD categories (CD or UC). For some markers, both CD and UC affected 
individuals contributed equally to the association. For CD 10 markers showed peak significant 
results in allele association, for UC 9 peak association markers were observed. The peak 
association markers for all categories are shown in Table 3.1, together with significance 
levels. It could be observed that markers within the same gene were associated to a different 
degree with the three categories of disease. From the makers with the highest c2, value several 
had an overall allele frequency below 10% (MOG_E3_G550A, rs902196, rs1059234, 
rs1105024, rs9395). This needs to be considered for the power of the association, and as well 
for the degree of inter-marker linkage. From the SNP marker map three areas (HSP70_Hom 
to HLA-G, SLC26A8 to MAPK13, and around TREM1) with major association leads were 
observed, each composed of several peaks with variable association intensity for the three 
disease categories. Several smaller peaks are located between those areas. 
Fig. 3.2: Genotype association analysis. Pearson's c2 was calculated as described in Fig. 3.1. 
Significance of a peak at the 95% confidence interval is reached at a c2 value of 6.0 with 3 df. 
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Gene SNP marker name c2 p-value 
IBD peak allele association 
  rs209179 6.17 0.01307 
MOG MOG_E3_G550A 17.10 0.00010 
HLA-DMB HLA-DMB_E3_T590C 5.23 0.02218 
MAPK14 hCV2455926 10.33 0.00131 
MAPK13 rs763096 9.04 0.00267 
MAPK13 rs2071863 10.87 0.00098 
TREM1 rs1817538 11.05 0.00089 
SRF rs9395 9.14 0.00253 
CD peak allele association 
RFP rs929042 4.21 0.04025 
HCG-V HCG-V_3pu_T3056C 4.48 0.03439 
HSP70-HOM HSP70-HOM_G2763A 5.37 0.02049 
AGER rs1035798 7.78 0.00534 
  rs902196 6.34 0.01182 
SLC26A8 hCV3001847 5.10 0.02387 
MAPK14 hCV3001824 9.66 0.00190 
CDKN1A rs1059234 6.42 0.01132 
PPIL1 hCV2061156 5.25 0.02195 
PTK7 rs1105024 6.83 0.00901 
UC peak allele association 
  rs1362073 4.35 0.03700 
UBD rs362536 8.64 0.00333 
CDSN CDSN_E1_A66T 4.20 0.04052 
SC1 SC1_E2_G2712A 10.26 0.00136 
DDAH2 rs707916 5.68 0.01725 
BTNL-II BTNL-II_E3_A158G 4.57 0.03262 
TEAD3 hCV2489242 4.76 0.02913 
MAPK14 hCV2455932 11.25 0.00080 
CCND3 rs1410492 4.22 0.03999 
 
In the genotype association analysis, the peak associations were partly shifted, but the main 
leads were still observed. Eleven markers showing peak associations were identified in IBD. 
Some of the SNPs with association to only one disease category in the allele association 
showed the highest c2 values for the combined category IBD in the genotype association. 
Eight peak association markers were observed for CD and 7 in UC (Table 3.2). Again low 
frequency was present in some SNPs. Frequencies of 10% or lower for the heterozygous state 
were observed for the following markers with peak association: rs902196, rs1105024 and 
rs9395. Overall Pearson's c2 values were higher than in the allele association analysis. 
Significance was not increased as in the analysis of genotypes a higher degree of freedom has 
to be taken into account (now 3 df instead of 1 df in the allele association). Even though the 
SNP markers with peak significance had shifted partially the areas in which association was 
highest were similar to the results from the allelic association. 
 
Table 3.1: SNP markers 
indicating association peaks in 
the allele association. 
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Gene SNP marker name c2 p-value 
IBD peak genotype association 
  rs209179 6.29 0.04315 
MOG MOG_E3_G550A 17.12 0.00019 
  rs2005423 9.92 0.00701 
BTNL-II BTNL-II_E3_A158G 9.65 0.00804 
HLA-DMB HLA-DMB_E3_T590C 8.14 0.01712 
TEAD3 hCV2489242 9.48 0.00874 
MAPK14 hCV2455932 10.94 0.00422 
MAPK13 rs763096 11.06 0.00397 
MAPK13 rs2071863 14.64 0.00066 
TREM1 rs1817538 13.54 0.00115 
SRF rs9395 9.28 0.00966 
CD peak genotype association 
HCG-V HCG-V_3pu_T3056C 8.94 0.01143 
  rs1265109 8.47 0.01446 
AGER rs1035798 9.98 0.00679 
  rs902196 9.68 0.00790 
MAPK14 hCV3001824 9.91 0.00704 
CDKN1A rs1059234 6.55 0.03776 
PPIL1 hCV2061156 6.06 0.04831 
PTK7 rs1105024 7.38 0.02500 
UC peak genotype association 
  rs932494 8.99 0.01114 
UBD rs362536 10.11 0.00639 
SC1 SC1_E2_G2712A 10.50 0.00526 
HLA-DQA1 HLA-DQA1_E3_C389T 6.36 0.04152 
  hCV2476745 9.47 0.00877 
STK38 hCV791696 6.55 0.03787 
CCND3 rs1410492 6.68 0.03536 
 
 
3.1.2. TDT association 
 
Besides the case control study design the association to disease in the predefined linkage 
region was tested using family based transmission distortion. Two TDT algorithms were 
applied to assess association. In the Transmit program a comparison of the number of alleles 
transmitted from healthy parents to affected offspring with the number of alleles transmitted 
according to HWE was employed (148). In the Genehunter program the number of alleles 
transmitted from parent to offspring was compared to the number of alleles untransmitted 
(40). The significance of the association was calculated using c2 and the p-value at the 95% 
confidence interval. The association was calculated for up to three-marker haplotypes in a 
sliding window. For the single point association with Transmit the results are shown in Fig 
3.3. Several association peaks were observed, again for the combined disease category IBD 
Table 3.2: SNP markers indicating 
association peaks in the genotype 
association. 
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and as well for the separated categories CD and UC. For IBD 7 peaks were identified, for CD 
another 7 markers show peak significant associations and for UC 4 markers were identified 
indicating the association peaks. The relevant markers for each disease category together with 
the number of alleles transmitted and the expected transmission are shown in Table 3.3.  
 
 
 
 
 
As a measure for significance testing a bootstrap with 1000 repeats was performed. The p-
values from the bootstrap analysis are shown in the Table 3.3. The bootstrap p-value should 
be reflecting the significance more appropriately when transmission is not uncertain. 
Significance of the bootstrap p-value was lower and some association peaks became 
insignificant: hCV2455932 and rs929042, or borderline significant: rs362536, rs126007. The 
most prominent lead was partly overlapping with the association described in the case control 
study (HSP70-Hom to C2). Several smaller association peaks near the two other main 
association leads from the case control analysis were observed but had little or no overlap. 
 
Fig. 3.3: Single point TDT (Transmit) association analysis. The c2 was calculated on the basis of 
the alleles observed to be transmitted compared to the number of alleles expected from the 
distribution in the parents according to HWE. Significance of a peak at the 95% confidence interval is 
reached at a c2 value of 3.9 with 1 df. Not all markers are shown and marker distance is not 
according to the physical distance. 
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Gene SNP marker name c2 p-value 
Bootstrap p-
value 
Transmission ratio 
(observed/expected) 
IBD TDT Transmit single marker association 
UBD rs362536 4.31 0.03794 0.046 836/808.69 
MOG MOG_E3_G550A 8.36 0.00384 0.008 1405/1428.2 
C2 C2_E7_G954C 7.56 0.00596 0.009 1567/1552 
AGER rs1035798 16.69 0.00004 0.001 1166/1118.5 
FKBP5 rs992105 7.35 0.00669 0.021 1336/1362.6 
MAPK14 hCV2455932 3.94 0.04721 0.055 1640/1623.5 
CDKNA1 hCV2969521 5.32 0.02105 0.019 988/1020.2 
CD TDT Transmit single marker association 
  rs126007 4.48 0.03439 0.046 808/827.24 
RFP rs929042 4.07 0.04359 0.051 842/823.73 
  rs1265109 10.11 0.00147 0.001 900/868.48 
DDAH2 rs707916 5.80 0.01601 0.031 638/663.52 
HSP70-HOM HSP70-HOM_G2763A 7.29 0.00693 0.006 754/726.54 
HSPA1B rs539689 6.08 0.01370 0.016 567/540.48 
  rs914815 5.02 0.02511 0.032 577/602.01 
UC TDT Transmit single marker association 
  rs1325016 8.77 0.00306 < 0.001 499/479.75 
RXRB rs926424 4.09 0.04308 0.022 354/368.5 
MTCH1 hCV2703063 6.15 0.01315 0.017 314/335.29 
FLJ20337 rs2055272 4.95 0.02615 0.029 345/361.31 
 
In the two-marker analysis short haplotypes were estimated from the alleles of 2 neighbouring 
SNP markers. While the pattern of the plotted two point TDT c2 (Fig 8.1 appendix 8.1.2) 
exhibited a similar pattern as in the single marker analysis, the peak significant association 
marker-haplotypes were sometimes slightly shifted. The results were similar for the 3-marker 
haplotype analysis. The association peaks were overlapping with the two-marker peaks (Table 
3.4). The frequency of several 3 marker haplotypes were very small, therefore the differences 
between expected and observed transmission was overestimated causing a spuriously 
significant result.  
 
 
Table 3.3: SNP markers indicating association peaks in the single point TDT 
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Gene 
SNP marker name c2 p-value 
Bootstrap p-
value 
Transmission ratio* 
(observed/expected) Frequency*  
IBD TDT Transmit 2 marker association 
RFP rs929042 9.20 0.02675 0.037 301.72/325.1 0.18 
MOG MOG_E3_G550A 10.65 0.01377 0.008 200.24/175.86 0.08 
C2 C2_E7_G954C 26.62 0.00001 0.000 1174.7/1116.3 0.65 
RXRB rs926424 9.06 0.02851 0.019 899.83/929.11 0.56 
FKBP5 rs755658 9.72 0.02107 0.031 283.4/254.31 0.16 
MAPK13 rs2007683 11.25 0.01045 0.004 2.7878/6.1433 0.07 
CDKNA1 hCV2969521 12.89 0.00487 0.007 776.9/819.49 0.39 
CD TDT Transmit 2 marker association 
GABABR1 GABABR1_E7_G141esA 14.53 0.00227 0.005 125.71/107.47 0.11 
CDSN CDSN_E1_A66T 10.92 0.01214 0.012 259.71/289.9 0.20 
VARS2 rs707926 8.82 0.03172 0.030 309.23/339.48 0.29 
  rs914815 10.24 0.01665 0.018 474.96/444.87 0.38 
TREM1 rs1351835 9.02 0.02904 0.012 0.52107/2.0837 0.13 
UC TDT Transmit 2 marker association 
  rs1928083 10.26 0.01647 0.012 41.66/52.038 0.09 
  rs1325016 11.74 0.00833 0.012 47.53/63.705 0.13 
  rs302976 8.40 0.03843 0.029 101.73/91.25 0.14 
SRPK1 rs1326752 8.62 0.03485 0.000 0.77853/3.1301 0.13 
*of the significant haplotype      
 
The plotted TDT association had a similar picture for the single marker association in 
Genehunter (Fig 3.4) than in the Transmit analysis event though the peaks were more 
prominent in the Transmit analysis. The TDT single marker analysis with Genehunter 
identified fewer significant association leads than the Transmit analysis (Table 3.5). The 
association peaks that were observed were overlapping with those from the Transmit analysis. 
Differences were only seen for the SNP in the gene AGER that was associated with IBD in 
the Transmit analysis and with CD in the Genehunter analysis, and for the SNP in HLA-C, 
that did not reach significance in the Transmit analysis. In the Genehunter program a 
permutation test to determine TDT significance was performed. For the single marker analysis 
of IBD 2308 out of 10000 permutations tested had a larger maximum value than the real best 
(9.72). For CD 1821 of 10000 had a larger maximum value than the real best (10.20) and for 
UC the highest value observed was 11.92 which was exceeded in 639 of 10000 permutation 
tests. 
 
 
Table 3.4: SNP markers indicating association peaks in the two point TDT analysis. 
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Gene SNP marker name c2 p-value 
Times 
transmitted 
Times 
untransmitted 
IBD TDT Genehunter single marker association 
UBD rs362536 4.39 0.03616 334 282 
FKBP5 rs992105 4.63 0.03145 137 175 
CDKNA1 hCV2969521 6.94 0.00842 367 299 
CD TDT Genehunter single marker association 
  rs1265109 8.52 0.00351 150 205 
AGER rs1035798 10.20 0.00141 170 116 
  rs914815 5.27 0.02167 186 233 
UC TDT Genehunter single marker association 
  rs1325016 11.92 0.00056 50 91 
HLA-C_ HLA-C_E2_G1019A 5.21 0.02245 88 121 
 
In the 2 marker analysis a number of significant association marker haplotypes for IBD were 
found as well in the Genehunter analysis: rs362536 - rs64036, CDSN_E1_A66T - rs1265109, 
HSP70-HOM_G2763A - rs539689, hCV2969521 - hCV1022631. The highest association 
was observed for C2_E7_G954C - rs1035798 (16.64, p-value 0.000045). The rate of 
transmitted/untransmitted was 227/148 for the haplotype carrying the greatest significance in 
the C2_E7_G954C - rs1035798 marker combination. Significant results that were caused by 
very low numbers of haplotypes transmitted and untransmitted are not listed here. The 
Fig. 3.4: Single point TDT (Genehunter) association analysis. The c2 was calculated on the basis 
of the alleles transmitted from parent to affected offspring compared to the not transmitted alleles. 
Significance of a peak at the 95% confidence interval is reached at a c2 value of 3.9 with 1 df. Not all 
markers are shown and the positioning is not according to the physical distance. 
Table 3.5: SNP markers indicating association peaks in the Genehunter single point analysis. 
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permutation analysis identified 25 out of 1000 permutations tested with a higher maximum 
value then the real best. A similarly high value was not observed in the CD category and the 
permutation analysis identified 70 of 1000 testes with a larger maximum value than the real 
best (14.44 C2_E7_G954C - rs1035798, p-value 0.000144). For the UC category the highest 
association observed was 11.44 (HLA-C_E2_G1019A - HLA-B_E5_G582, p-value 
0.000721), the permutation showed 296 of 1000 tests with a larger maximum value than the 
real best. The situation for the 3 marker analysis was similar with peak associations in the 
same regions. For the disease categories CD and UC no better association results were 
observed. 
 
3.1.3. Additional analyses 
 
A non-parametric linkage (NPL) analysis was performed to verify the presence of linkage in 
the region analysed and to evaluate the intensity of linkage to the disease trait. The 142 SNP 
markers from the association study were analysed using their physical position as determined 
from NCBI build 32. The NPL for IBD is shown in Fig 3.5, the plots for CD and UC are in 
the Appendix 8.1.3. (Figs 8.2, 8.3) The analysis was performed using Genehunter. 
Nonparametric linkage is present in the region on chromosome 6p analysed for IBD, for CD 
alone the NPL score is decreased, and for UC alone the NPL score was very low over the 
complete region. For the disease category IBD the NPL score reached values of 3.47 at two 
positions and was above 3 over a large region. To the centromeric side the NPL score 
decreases to 0.5 in the last position clearly marking the centromeric end of the linkage region. 
This decrease was not observed on the telomeric side of the region. Maximal values for CD 
were at 2.6 and for UC all values were below 1. The curve for CD is similar to the IBD NPL 
score but on a lower level, while the UC analysis is not comparable. The NPL is calculated 
from affected sibling pairs and strongly dependent on the population size. In the category IBD 
181 ASPs were analysed. For CD the number of ASPs in the analysis was 105 and for UC 
only 43 ASPs were available for the analysis. This could explain some of the difference in the 
NPL score. In the detailed analysis of the linkage region on chromosome 6p 428 ASPs were 
involved 
 
Recombination was calculated as part of the linkage analysis and compared to the expected 
recombination value (theta) between each marker. The only recombination values observed to 
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be higher than expected were between the marker rs747694 and hCV2489242, however not 
significantly.  
 
 
 
 
 
 
In order to reveal the LD between SNP markers Lewontin's standardized deviation coefficient 
D' was calculated (149, 150). Certain areas with a high internal D' value (< 0.7) could be 
observed in the SNP map. Mostly these included SNP marker from one gene or physically 
close positioned genes, but some markers exhibited a high LD over long distances. Blocks 
with high LD were formed by the markers covering SLC26A8 to MAPK13, TEL2, TREM1 
and FKBP5. Regions with a generally high D' value but less clear boundaries were observed 
in the region around TNF-a and UBD and the telomeric side of the SNP map. One of the 
UBD marker exhibited long range LD as did rs64036, the MOG marker, rs902196 and 
Fig. 3.5: Non-parametric LOD score for IBD. The NPL was calculated on the basis of 208 ASPs 
(181 independent ASPs) using the weighed pairs option of Genehunter. The NPL score is indicated 
as Z-all on the y-axis. The x-axis shows all markers involved and their physical position as short 
black lines. Marker names could not be indicated completely All NPL values were highly significant 
(p < 0.001) 
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rs763017. Some of these markers showed significant association with IBD CD or UC in the 
case control or the TDT analysis.  
 
3.2. Candidate genes  
 
3.2.1. HLA-DPA  
 
Three polymorphic sites in the HLA-DPA1 gene at nucleotide positions 91/92, 111/ 114 and 
149 in exon two were genotyped in a German, a South African and a South Korean 
population. The polymorphic structure of the region on exon 2 of HLA-PDA1 with the 
resulting amino-acid exchanges and the corresponding HLA-DPA1 alleles are shown in Table 
3.6. 
 
 
 
Corresponding  Shared 
epitope 
Nucleotide 
91,92 AA 31 Nucleotide 111, 114 AA 37-38 
Nucleotide 
149 AA 50 Allele DPA1* 
1 GAGATGTTC Q CTGGACAAGAAG D-K GCCAAGCC Q 0103; 0104; 0105; 0301; 0302 
2 GAGCAGTTC M CTGGATAAAAAG D-K GCCGAGCC R 02011; 02012 
3 GAGCAGTTC M CTGGACAAGAAG D-K GCCGAGCC R 02013; 02022 
4 GAGATGTTC Q CTGGACAAGAAG D-K GCCGAGCC R 0203; 0401 
5 GAGCAGTTC M CTGGATAAAAAG D-K GCCAAGCC Q 106 
6 GAGCAGTTC M CTGGATAAGAAG D-K GCCGAGCC R 2021 
 
Allele and genotype frequencies in the German and the South-Korean cohorts of UC, CD and 
IBD cases did not differ significantly from the frequency in healthy controls of the same 
ethnic background. An overview of the allele and genotype frequencies is given in Table 3.7 
and Table 3.8. Only the analysis of the South African population indicated a trend towards a 
higher allele and genotype frequency of the sequence GATAAA at the position 111/114 in 
UC patients in comparison with controls (allele frequencies: c2 = 8.66, p = .0131, 2 df; 
genotype frequencies: c2 = 12.7, p = 0.0127, 5 df). However, the South African population 
comprised 20 affected individuals in the UC category (Table 2.3) and a similar result was not 
observed in any of the other populations.  
 
Suggestive evidence for TDT association in the German population sample was observed for 
CD and the HLA-DPA1*02021 / *02016 allele, corresponding to shared epitope type 6 (Table 
Table 3.6: HLA-DPA1 shared epitopes, nucleotide exchanges and corresponding amino 
acids (AA) and alleles. 
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3.6). The corresponding TDT-c2 for linkage at this position was 4.5 with a nominal p-value of 
0.043. No further association was seen in the German or the South African family sample and 
the South Korean case control sample (all nominal p-values >0.1). 
 
 
European family population South African family population South Korean population 
Cases Controls Cases Controls Cases Controls 
Nucleotide 
position 
IBD CD UC unrelated IBD CD UC family IBD CD UC unrelated 
C-A 0.16 0.18 0.14 0.18 0.32 0.28 0.45 0.36 0.55 0.52 0.58 0.52 91, 92 
A-T 0.84 0.82 0.86 0.82 0.68 0.72 0.55 0.64 0.45 0.48 0.42 0.48 
C..G 0.86 0.84 0.87 0.83 0.78 0.84 0.50 0.80 0.84 0.89 0.82 0.89 
T..A 0.13 0.14 0.12 0.15 0.21 0.14 0.50 0.18 0.16 0.11 0.18 0.08 111, 114 
T..G 0.01 0.02 0.00 0.02 0.01 0.02 0.00 0.02 0.00 0.00 0.00 0.02 
A 0.85 0.83 0.87 0.82 0.66 0.69 0.50 0.67 0.42 0.41 0.40 0.46 149 
G 0.15 0.17 0.13 0.18 0.34 0.31 0.50 0.33 0.58 0.59 0.60 0.54 
 
 
European family population 
South African family 
population South Korean population 
Cases Controls Cases Controls Cases Controls 
Nucleotide position 
IBD CD UC unrelated IBD CD UC family IBD CD UC unrelated 
C-A/A-T 0.26 0.28 0.23 0.33 0.43 0.28 0.70 0.49 0.37 0.43 0.34 0.45 
C-A/C-A 0.03 0.04 0.02 0.02 0.11 0.14 0.10 0.11 0.37 0.30 0.41 0.30 91, 92 
A-T/A-T 0.71 0.68 0.75 0.65 0.47 0.59 0.20 0.40 0.26 0.26 0.25 0.25 
C..G/T..A 0.21 0.22 0.20 0.26 0.36 0.24 0.80 0.33 0.23 0.13 0.26 0.14 
C..G/T..G 0.02 0.04 0.01 0.03 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.04 
C..G/C..G 0.74 0.71 0.77 0.68 0.60 0.72 0.10 0.62 0.72 0.83 0.69 0.80 
T..A/T..A 0.02 0.03 0.02 0.02 0.02 0.00 0.10 0.00 0.05 0.04 0.05 0.01 
111, 114 
T..A/T..G 0.00 0.01 0.00 0.00 0.02 0.03 0.00 0.02 0.00 0.00 0.00 0.00 
A/G 0.25 0.25 0.22 0.33 0.47 0.34 0.80 0.49 0.40 0.48 0.38 0.42 
A/A 0.72 0.71 0.76 0.66 0.43 0.52 0.10 0.42 0.22 0.17 0.21 0.25 149 
G/G 0.03 0.04 0.02 0.02 0.11 0.14 0.10 0.09 0.38 0.35 0.41 0.32 
 
Linkage between the three polymorphic sites has been estimated using EH. They were in 
strong LD (pairwise c2 > 800.00, p < 0.001, 2 df), and the haplotypes of the six shared 
epitopes described in Table 3.6 were highly significant (c2 = 1947.51, p < 0.0001, df = 11). 
Analysis of the three most relevant shared epitopes showed a trend towards a higher 
frequency of the shared epitope type 2 containing the sequence GATAAA at position 111, 
114 (c2 = 5.66, p = 0.058, df = 3) in the South African population (HLA-
DPA1*02011/02012/02014) (Table 3.9). 
 
Table 3.7: HLA-DPA1 exon 2 polymorphism allele frequencies in three different populations. 
Table 3.8: HLA-DPA1 exon 2 polymorphism genotype frequencies in three different populations. 
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No differences were seen in the German and South Korean populations. Frequency 
distribution of the shared epitopes compared to the allele frequency in the three populations 
showed, that they were within the range for the ethnicity (157). 
 
 
Shared  German family population 
South African family 
population South Korean population 
epitope Cases Controls Cases Controls Cases Controls 
  IBD CD UC   IBD CD UC   IBD CD UC   
1 0.83 0.82 0.85 0.81 0.69 0.76 0.57 0.70 0.43 0.43 0.40 0.46 
2 0.13 0.13 0.13 0.14 0.22 0.12 0.36 0.18 0.16 0.11 0.18 0.08 
3 0.02 0.02 0.02 0.02 0.08 0.12 0.04 0.11 0.39 0.41 0.40 0.42 
4 0.00 0.01 0.00 0.01 0.01 0.00 0.04 0.01 0.02 0.04 0.02 0.01 
5 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 
6 0.01 0.02 0.01 0.02 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.02 
 
3.2.2. Other candidate genes 
 
The complete cDNA of the three splice variants of the MAPK14 (p38-a, CSBP1 and Mxi2) 
includes 13 exons. All exons and about 1000 nucleotides in the 5 prime regions were 
sequenced in 30 individuals, some exons have been sequenced in an additional 47 IBD 
samples. No polymorphisms in the exons or in the potential promotor region were found.  
 
This is in contrast to data reported at the NCBI locus link SNP information for MAPK14 
LocusID: 1432 (http://www.ncbi.nlm.nih.gov/LocusLink/), where several polymorphisms 
were reported for exon 9. Alignment of the three splice variants identified the exons 9 and 10 
to be of identical length with a high degree of similarity. The presence of both transcripts in 
an analysis of cDNA or mRNA could be causing the annotation of SNPs. Mutation detection 
in MAPK13 and BRPF3 did not identify any SNPs in the exons, predicted exons of BRPF3 or 
potential promotor region of MAPK13. The sequence analysis of TREM1 exons revealed 
SNPs in the exon 2 and one in the 3' untranslated region (3'UTR). These SNPs in the 
meantime received an entry in the dbSNP with the identification numbers rs2234237 (A to T, 
A=1, T=2) and rs2234246 (A to G, A=1, G=2) (Fig.3.6). The exon 2 polymorphism results in 
an exchange of amino acids from T to S at the AA position 25. One more SNP (a G to A 
exchange, G=1, A=2) in the potential promotor region 217 bp before the start codon has not 
been described yet. The frequency of these three new SNPs is shown in Table 3.10. The 
genotype frequencies differ between the control individuals and the IBD cases by 7% in the 
homozygous 2-2 (G-G) variant for the rs2234246. For both other SNPs the greatest difference 
Table 3.9: HLA-DPA1 exon 2 shared epitope frequencies in three different populations. 
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was seen between the frequency in controls and UC cases, while in the IBD and UC category 
the frequency was more similar to the control individuals. 
 
 
 
 
TREM1   Allele frequency Genotype frequency 
Population 1 2  1-1  1-2  2-2 
controls 0.50 0.50 0.27 0.46 0.27 
IBD 0.45 0.55 0.21 0.49 0.30 
CD 0.45 0.55 0.21 0.48 0.32 
rs2234246 
UC 0.46 0.54 0.19 0.53 0.27 
controls 0.90 0.10 0.82 0.17 0.01 
IBD 0.91 0.09 0.83 0.16 0.01 
CD 0.90 0.10 0.82 0.18 0.01 
rs2234237 
UC 0.94 0.06 0.88 0.12 0.00 
controls 0.93 0.07 0.87 0.13 0.00 
IBD 0.90 0.10 0.82 0.16 0.02 
CD 0.90 0.10 0.82 0.16 0.02 
prom-G217A 
UC 0.91 0.09 0.83 0.15 0.01 
 
Association for the new markers in the case control study design was weak but present for the 
IBD and CD disease category. The Pearson's c2 and corresponding p-values for all new SNPs 
Fig. 3.6: Schematic description of the candidate genes MAPK14, MAPK13 and TREM1.
Alternative splice versions are indicated as far as considered in this study. The candidate gene 
BRPF3 is not depicted as no polymorphisms were described for the gene and none could be 
identified during mutation detection. 
 
Table 3.10: Allele and genotype frequencies in the new polymorphisms of TREM1. 
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are shown in Table 3.11. Significance at the 95% confidence interval was reached only for the 
prom-G217A polymorphism in the allele and genotype analysis of the IBD category and in 
the allele association analysis of the same SNP in the CD category. The odds ratio (OR) was 
calculated for all SNP markers in the candidate genes. Generally the OR for the homozygous 
state was higher than for the heterozygous state.  
 
 
 
 
 
 
 
 
 
 
For IBD the marker rs2234237 from TREM1 had the highest odds ratio with 1.96 however 
this marker had a 95% confidence interval of 0.59 - 7.30. From MAPK14 hCV2455919 was 
the marker with the highest OR (95% confidence interval 1.03 - 3.10). All values for CD were 
below that. For UC the marker rs2234237 exhibits an OR of 3.15 (95% confidence interval 
0.65 - 4.95). The OR is affected through a low frequency of a marker, which shows in the 
large confidence intervals. The transmission distortion association for all three new markers 
did not show any significant results for the IBD disease category in the Transmit and the 
Genehunter analysis. For the subcategories CD and UC the results were similar, without 
significant results. 
 
Stratification was performed for all markers from the candidate genes MAPK14, MAPK13 
and TREM1 for the IBD category according to allele status at the NOD2 gene mutations 
(3020insC, R702W, L1007P) (63-65). After stratification for carriers of one of the three 
NOD2 mutations 72 control and 340 case individuals were analysed using the case control 
association. The stratification against the NOD2 mutations includes 332 controls and 482 
cases. Mostly the association with IBD is reduced for both, the NOD2 carrier and the non-
NOD2 carrier, which could be due to a reduced sample size. For the MAPK13 marker 
rs2071863 and the TREM1 marker rs1817538, rs1351835, and rs1817537 the association seen 
in the unstratified analysis seems to be carried mostly through the non-NOD2 carriers (Table 
TREM1 Allele association Genotype association 
SNP marker name c2 p-value c2 p-value 
rs2234246 4.25 0.03923 5.82 0.05447 
rs2234237 0.76 0.38791 1.24 0.53844 IBD 
prom-G217A 5.92 0.01501 6.82 0.03302 
rs2234246 4.17 0.04115 4.48 0.10617 
rs2234237 0.03 0.87017 0.28 0.86858 CD 
prom-G217A 4.37 0.03672 5.98 0.05022 
rs2234246 2.26 0.13489 5.67 0.05878 
rs2234237 3.51 0.06116 3.42 0.18058 UC 
prom-G217A 2.77 0.09631 4.28 0.11723 
Table 3.11: Allele and genotype association in the new polymorphisms of TREM1. 
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3.12). For all other SNPs the association seems to be contributed equally from both NOD2 
mutation carriers and non-carriers.  
 
 
 
The analysis of the TDT in the stratified samples showed only minor differences to the 
unstratified data. Significant association was not reached in any of the markers neither in the 
stratification for nor against NOD2 carriers. The data are only shown for the Transmit results 
in Table 3.13. In the TDT analysis using the Genehunter program produced similar or even 
weaker association. 
NOD2+ NOD2- SNP marker 
name Allele association Genotype association Allele association Genotype association 
MAPK14  c2 p-value c2 p-value c2 p-value c2 p-value 
hCV3001824 6.10 0.01356 9.73 0.00771 2.59 0.10801 4.51 0.10485 
hCV8852251 0.18 0.67581 0.45 0.79961 0.24 0.63148 3.96 0.13788 
hCV2455932 2.10 0.15093 4.30 0.11607 3.07 0.08036 7.21 0.02721 
hCV2455926 5.17 0.02294 7.33 0.02564 3.29 0.07016 5.04 0.08030 
hCV2455924 5.15 0.02317 7.76 0.02068 2.64 0.10513 4.09 0.12902 
hCV2455922 1.05 0.30534 1.15 0.56311 4.37 0.03655 4.94 0.08440 
hCV2455919 0.00 0.95487 0.11 0.94476 1.13 0.28761 2.63 0.26925 
MAPK13                 
rs763096 4.65 0.03106 5.35 0.06880 1.29 0.25866 3.88 0.14342 
rs2007683 0.01 0.94533 0.11 0.94732 0.08 0.79992 1.24 0.53847 
rs2815812 3.04 0.08154 4.06 0.13131 2.55 0.11117 3.70 0.15735 
rs2071863 2.27 0.13452 2.34 0.31026 6.82 0.00906 11.76 0.00280 
TREM1                 
rs2234246 0.42 0.51962 0.48 0.78633 3.90 0.04819 7.34 0.02547 
rs1817538 1.44 0.23418 1.46 0.48384 8.56 0.00349 12.89 0.00159 
rs1351835 0.31 0.59138 0.30 0.86061 7.68 0.00566 12.65 0.00179 
rs1817537 0.30 0.59733 0.30 0.86124 7.25 0.00716 10.82 0.00447 
rs2234237 0.13 0.72622 0.89 0.64105 0.60 0.44361 1.21 0.54716 
prom-G217A 0.00 0.96292 1.19 0.55221 3.80 0.05132 3.84 0.14635 
Table 3.12: Allele and genotype association after stratification +/- NOD2. 
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SNP marker 
name 
c2 p-value 
Bootstrap 
p-value 
Transmission 
ratio* 
(observed / 
expected) Freq.* c2 p-value 
Bootstrap 
p-value 
Transmission 
ratio* 
(observed / 
expected) Freq.* 
MAPK14  stratified for CARD15 carrier stratified for non-CARD15 carrier 
hCV3001824 0.04 0.8475 0.847 438/436.16 0.54 0.16 0.6922 0.716 598/593.63 0.54 
hCV8852251 2.92 0.0873 0.092 681/692.84 0.83 0.87 0.3498 0.327 942/949.43 0.83 
hCV2455932 2.63 0.1047 0.089 743/734 0.88 1.50 0.2213 0.243 1014/1006 0.88 
hCV2455926 0.06 0.8126 0.823 426/423.74 0.53 0.28 0.5965 0.626 590/584.11 0.53 
hCV2455924 0.00 0.9977 0.997 434/433.97 0.53 0.02 0.8853 0.882 592/590.4 0.53 
hCV2455922 0.16 0.6849 0.647 581/577.4 0.67 3.02 0.0824 0.091 747/764.92 0.67 
hCV2455919 1.22 0.2701 0.313 669/677.24 0.81 0.58 0.4479 0.467 928/921.6 0.81 
MAPK13     
rs763096 0.76 0.3826 0.377 427/435.04 0.60 0.15 0.7024 0.695 613/609.1 0.60 
rs2007683 0.47 0.4928 0.483 472/466.55 0.65 1.45 0.2288 0.231 621/632.68 0.65 
rs2815812 0.41 0.5245 0.509 582/576.66 0.72 2.01 0.1559 0.149 807/792.72 0.72 
rs2071863 0.44 0.5056 0.500 676/671.09 0.81 1.89 0.1691 0.155 930/918.09 0.81 
TREM1     
rs2234246 0.82 0.3661 0.387 401/392.77 0.54 0.69 0.4045 0.432 542/550.67 0.54 
rs1817538 1.37 0.2420 0.269 405/394.22 0.54 0.07 0.7912 0.813 534/536.75 0.54 
rs1351835 0.67 0.4135 0.412 395/387.66 0.53 0.31 0.5786 0.646 534/539.75 0.53 
rs1817537 0.44 0.5050 0.528 401/394.85 0.54 0.21 0.6435 0.691 541/545.87 0.54 
rs2234237 1.63 0.2024 0.196 678/684.37 0.89 0.48 0.4877 0.494 920/924.13 0.89 
prom-G217A 0.16 0.6870 0.734 679/676.8 0.88 0.04 0.8395 0.839 913/911.7 0.88 
*of the significant haplotype 
Association of the markers in the candidate genes was analysed as well for three aspects 
considered to be markers of severity in the progression of IBD. The information was obtained 
from the questionnaire filled by the participants of the family based study (appendix 8.4). 
These aspects were (i) the development of fistulae, (ii) the formation of stenosis and (iii) a 
previous resection of parts of the bowel. Some affected individuals had two or all three 
aspects in their disease history, and therefore were included in all three analyses. For the 
association analysis of fistulizing disease 266 affected individuals were included into the 
calculation of Pearson's case control c2. Despite the reduced population sample several 
markers from MAPK14 showed slightly increased association with the fistulizing disease, 
while the association for the MAPK13 markers did not change and in the SNPs of the TREM1 
gene no significant association was observed in contrast to the association with the disease 
category IBD (Table 3.14). The significant association in the MAPK14 markers 
(hCV3001824, hCV2455926, hCV2455924) was mostly caused by an increase in the 
frequency of homozygous state (by about 10%) while the heterozygous frequency was 
reduced compared to the control sample. These three markers had very similar frequencies 
and were in high LD (Table 3.15), possibly representing the same haplotype. Only the 
Table 3.13: TDT association (Transmit) after stratification +/- NOD2. 
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frequency of the marker hCV2455922 was reduced for the homozygous wild type state by 
about 10%, possibly representing a different haplotype.  
 
 
fistulizing disease association bowel resection association stenosis formation association 
SNP marker Allele Genotype Allele Genotype Allele Genotype 
MAPK14  c2 p-value c2 p-value c2 p-value c2 p-value c2 p-value c2 p-value 
hCV3001824 10.98 0.00092 12.00 0.00248 5.64 0.01759 6.10 0.04743 5.42 0.01998 5.86 0.05344 
hCV8852251 1.35 0.24876 1.51 0.47146 1.04 0.30668 0.97 0.61576 0.03 0.87652 2.63 0.26916 
hCV2455932 1.64 0.20432 1.82 0.40314 3.13 0.07721 3.50 0.17375 3.24 0.07237 4.31 0.11580 
hCV2455926 12.86 0.00034 13.50 0.00118 6.97 0.00835 7.37 0.02510 7.25 0.00715 7.39 0.02484 
hCV2455924 11.42 0.00073 12.19 0.00226 5.38 0.02045 5.89 0.05243 6.51 0.01077 6.76 0.03410 
hCV2455922 9.52 0.00206 9.52 0.00857 6.67 0.00983 6.76 0.03404 9.47 0.00212 9.42 0.00899 
hCV2455919 4.43 0.03545 4.26 0.11887 3.22 0.07292 4.08 0.13009 1.42 0.23713 1.71 0.42684 
MAPK13                         
rs763096 5.02 0.02498 5.08 0.07855 6.59 0.01029 6.61 0.03670 4.11 0.04262 4.06 0.13111 
rs2007683 0.02 0.89209 0.02 0.98869 0.24 0.63718 0.31 0.85718 0.09 0.78048 0.12 0.94135 
rs2815812 3.83 0.05029 4.99 0.08239 3.97 0.04625 4.69 0.09572 4.21 0.04028 4.22 0.12109 
rs2071863 10.63 0.00112 13.69 0.00107 8.98 0.00276 9.96 0.00687 12.98 0.00032 13.91 0.00095 
TREM1                         
rs2234246 0.01 0.93773 1.52 0.46852 2.03 0.15788 1.92 0.38395 2.30 0.13119 2.53 0.28292 
rs1817538 2.01 0.16008 4.20 0.12216 8.47 0.00367 8.06 0.01775 5.14 0.02335 5.59 0.06104 
rs1351835 0.80 0.37758 3.51 0.17309 5.62 0.01779 5.54 0.06252 4.72 0.02982 5.59 0.06110 
rs1817537 0.90 0.34479 3.14 0.20802 4.88 0.02722 4.80 0.09063 4.63 0.03135 5.64 0.05949 
rs2234237 0.00 0.96161 0.00 1.00000 0.11 0.75234 0.19 0.90705 0.15 0.69704 0.31 0.85752 
prom-G217A 1.16 0.28280 1.69 0.43041 1.41 0.23928 1.99 0.36972 0.18 0.67686 0.87 0.64650 
 
In the analysis of association with stenosis forming disease 303 affected individuals were 
included. The association was reduced compared to the full population. Only one marker from 
MAPK13 (rs2071863) showed a similar high association, than in the full population with a 
slight increase for the genotypic association (Table 3.14). The frequency in the affected 
sample population was increased by over 10% towards the frequent homozygous state. For 
the disease severity category of partial resection of the bowel 263 cases were included in the 
case control analysis. Similar to the analysis of the formation of stenosis, the association in 
the case control analysis in this category was weaker compared to the IBD or CD cohort 
probably due to the reduced sample size (Table 3.14). The TDT association to all three 
categories of disease severity did not reveal major differences to the association to IBD, CD 
or UC in the Transmit single marker analysis. One SNP marker from MAPK13 (rs2815812) 
had a higher significant association for all three severity categories (fistulae: 4.15, p-value: 
0.0415, stenosis: 6.50, p-value: 0.0107, resection: 5.00, p-value: 0.0253). In the Genehunter 
single marker analysis no significant association was observed for all severity categories, even 
Table 3.14: Allele and genotype association for severe disease phenotypes. 
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though the rs2815812 reached a close to significant level (3.34, p-value: 0.067522 for 
resection).  
 
Lewontin's D' values as a measure of inter-marker LD were high within the SNPs of each 
candidate gene indicating strong or even complete linkage of the markers. High inter-marker 
LD was as well observed between markers from MAPK14 an MAPK13 indicating their 
physical and genetic proximity. (Table 3.15 and 3.16). However some SNPs showed low D' 
values indicating that different levels of linkage between markers of the two genes was 
possible. This could be an indicator for different haplotypes represented by the SNPs or 
otherwise for differences in the ages of the SNPs. 
 
pairwise LD: D' in MAPK14-MAPK13  
hCV3001824 MAPK14       
hCV8852251 1           
hCV2455932 1 1          
hCV2455926 1 1 1          
hCV2455924 0.98 1 1 1        
hCV2455922 0.99 0.95 0.91 0.97 0.99       
hCV2455919 0.99 0.98 1 0.99 0.98 1  MAPK13 
rs763096 0.11 0.33 0.95 0.12 0.11 0.47 0.18     
rs2007683 0.39 0.06 0.81 0.38 0.37 0.57 0.02 0.99    
rs2815812 0.72 0.96 0.86 0.72 0.70 0.70 0.52 1 1   
rs2071863 0.93 1 0.87 0.96 0.93 0.98 0.41 0.99 1 1   
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pairwise LD: D' in TREM1  
rs2234246        
rs1817538 1       
rs1351835 1 1     
rs1817537 1 1 1    
rs2234237 0.98 0.98 0.98 0.98   
prom-G217A 1 1 1 1 1  
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Table 3.15: Inter-marker LD in MAPK14 and MAPK13. 
Table 3.16: Inter-marker LD in TREM1. 
Results 73 
3.3. Analysis of linkage disequilibrium structure 
 
With the intention to reveal structures of linkage between genes and SNP marker that could 
obscure association to disease or distort the true location of association an initial region of 10 
Mb that was part of the association map and covered the central MHC region was analysed 
for LD in 920 SNP markers in a small US American White population. Subsequently a 3.53 
Mb part of that region was analysed in more detail in 5 populations, three from Europe 
(Germany, Norway, UK) the original population of US American whites and a US African 
American population.  
 
In order to quantify the pair-wise genetic differences between the populations analysed, F-
statistics of population subdivision (FST) were calculated using all SNPs available for analysis 
with the Arlequin program. An FST value of 1 signifies a complete isolation of the populations 
analysed while a value of 0 denotes a complete admixture. Except for comparisons involving 
the English population, all differences were significant at the 95% level (FST-values between 
0.00392 - 0.07180). The English population was found to be significantly different only from 
the US African-American population, to all other populations with European origin the 
difference was not significant. 
 
After calculation of pairwise D' values for the genotypes of 920 SNPs in the US American 
White population with 45 individuals a cluster analysis of LD was performed using an 
unweighted pair group method employing the arithmetic mean (154). All markers employed 
for this analysis had a frequency of greater than 5%. Fig. 3.7 depicts UPGMA clustering from 
the 10 Mb region covering the MHC on human chromosome 6p (NCBI sequence coordinates 
25.3 - 36.3 Mb).  
 
On the vertical axis the markers are not in the physical correct order but rearranged according 
to the clustering. It was tried to be as close as possible to the physical order through the 
turning of the branches in the dendrogram, but in the clustering process sometimes markers 
were clustered that were not physically neighbouring. The vertical axis details the cluster 
dendrogram with a scale of D’ levels shown at the bottom. The scale indicate the arithmetic 
mean of all D' values of markers within that branch of the cluster tree. Levels of pairwise D’ 
are colour-coded from dark grey indicating high LD to light grey indicating low LD (in the 
top left corner). 
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The degree of linkage structuring in this region was found to vary greatly, from highly 
organized parts with blocks of strong internal pairwise LD to sections of very low LD. Large 
blocks with high LD of more than 100 kb were apparent at positions 26 Mb, 27.5 Mb, 28 Mb, 
32 Mb and 35 Mb; blocks of smaller size were found in the middle and in the most 
centromeric part of the region (e. g. positions 31.2-31.4 Mb and 36 Mb), but as well areas 
with high LD that can not be described as clear blocks and markers exhibiting high LD over 
Fig. 3.7: Cluster heat-map of pairwise D’ on human chromosome 6p21.A total of 920 SNPs (all 
with allele frequency of 5% minimum) located within 10 Mb (from D6S461 to D6S291) were 
genotyped in 45 white US American individuals. The graph relates the physical map of the region 
(horizontal axis, with every 5th SNP marked) to the order derived from UPGMA clustering of D’ 
values (vertical axis). The vertical axis details the cluster dendogram with a scale of D’ levels shown 
at the bottom. Levels of pairwise D’ are colour-coded from dark grey to light grey as indicated (top 
left corner). 
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long distances could be observed. Generally the LD observed was higher in the telomeric half 
but no fixed size of blocks with high LD was observed. What was regarded as a block 
depends on the level of D' chosen as cut-off. In the cluster heat map presented here it was 
observed that at some instances there is a steep decrease of D' between one marker pair to the 
next marker pair, as seen in the block at 27 Mb or 36 Mb where the D' value decreased from 1 
to below 0.25 within two SNPs. In other regions the change from high LD to low LD was in 
smaller steps as can be seen in the large high LD region at 28 Mb. This was reflected as well 
in the cluster dendrogram. The thick lines of the dendrogram show the D' clusters with a mean 
D' value of over 0.95. From the 10 Mb region described here a smaller region was selected for 
a more detailed analysis with more even distribution of the markers that was analysed in a 
larger population. The region chosen from the 10 Mb the contained all features described for 
the larger region, if so in a smaller scale. The MHC region is of special interest in respect to 
autoimmune and chronic inflammatory diseases and the 3.53 Mb from NCBI sequence 
coordinates 29.4 - 32.9 Mb showed to be representative in the terms described. The original 
markers where supplemented with 37 additional SNPs to minimize areas with low marker 
density and the total of 320 markers where genotyped in a 550 individuals large German 
population in order to increase the resolution of the analysis. Of the 320 SNPs located in this 
region, some 278 had a minor allele frequency above 5% in 550 German individuals. 
 
For these markers, large and clearly apparent blocks with high LD were observed in the 
telomeric subregion (Fig. 3.8). The centromeric subregion showed areas of high pairwise LD, 
some regions of less well defined blocks, and areas with no clear LD pattern. Some marker 
pairs were found to exhibit high LD over long physical distances. These patterns were as well 
observed in the 10 Mb region. General size of the blocks with high internal LD was smaller in 
this region but different kinds of blocks could be observed as well: steep decreases of LD 
from one marker to the next, a slow reduction of LD from a centre of high D' and blocks of 
high D' values that were interrupted by makers with low D' values. The differences in the 
appearance were mainly caused by an alternative turning of the branches, which reflects the 
physical order of the SNPs better but not exactly. This could be due to the higher number of 
individuals. The clustering was similar to the initial analysis with the difference of the 
additional markers. The genes that are included in this region can as well be seen in the 
Fig.3.10a, which shows exactly the same region. An obvious correlation of the classical HLA 
genes with a region of high or low D' values was not observed. 
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Cluster analysis adopting a 20% allele frequency cut-off (199 markers) resulted in a 
substantial reduction of long distance LD, but gave a similar quality and distribution of 
haplotype blocks (Fig. 3.9). The major characteristics of haplotype structure were found to be 
similar in all population samples (Figs 8.4 - 8.6, appendix 8.1.4). The degree of haplotype 
structure was not related to marker density (Fig.3.7, Fig. 3.10a).  
 
Fig. 3.8: Cluster heat-map of pairwise D’ in a representative 3.53 Mb region including the 
human MHC. A total of 320 SNP markers were genotyped in 550 German individuals. 278 SNPs with 
minor allele frequencies >5% were analysed. For details: see legend to Fig. 3.7. 
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An analysis of the density of the markers was performed by plotting the amount of markers 
within a 500 kb sliding window along the physical map (Fig. 3.10a). This 500 kb sliding 
window was used in the correlation analysis again and by this way the results became directly 
comparable. On top of the figure a selection of genes is placed according to their position on 
the physical map. Pearson correlation coefficients between D’ values in the sliding 500 kb 
window in 45 randomly drawn individuals from the different populations were calculated 
using the German individuals as reference population. Within the German population a 
random sample of 45 individuals was drawn 1000 times and the correlation coefficient was 
each time calculated with the remaining 505 individuals as reference. The average of the 1000 
was taken and the 95% confidence interval plotted. The analysis reflected the results from the 
cluster heat-map showing a high correlation where the high LD block structure was observed 
in the cluster analysis of the whole German sample (Fig. 3.10b). 
 
Fig. 3.9: 20% cut-off cluster heat-map of pairwise D’ in the 3.53 Mb region. 199 marker  
had a frequency of above 20%. For details: see legend to Fig. 3.7. 
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Fig. 3.10: Analysis of LD in a 3.53 Mb region covering the human MHC (NCBI sequence 
coordinates 29.4 - 32.9 Mb). 
Panel A: Density and map of SNPs genotyped. The total number of SNPs in a 500 kb sliding 
window (vertical axis) was plotted against the location of the centre of the window on the physical map 
(horizontal axis). Panel B: Correlation of D' between populations. D’ values were calculated 
between pairs of SNPs with allele frequency above 5% in 45 randomly drawn individuals from each 
population (UK White, 270 SNPs – green, Norwegian White, 267 SNPs – yellow, US American White, 
221 SNPs – red, US African-American, 209 SNPs – blue) and compared to D’ values obtained in the 
German White population (278 SNPs) in a 500 kb sliding window (vertical axis) 95% confidence 
intervals (dotted black lines). Panel C: Analysis of LD units. (by Francisco De La Vega at Applied 
Biosystems, Foster City, California 94404 / USA) Metric LD units (vertical axis) are obtained from a 
correlation between the distance of SNPs on a LD map and distances on a physical map (horizontal 
axis). Regions of strong LD result in sections of the curve where LD increases slower than physical 
distance (i.e. the curve flattens), while regions of high recombination activity are characterized by a 
disproportional increase of LD units over physical distances. Identification of populations by colour-
coding is described in Panel B.  
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A high degree of correlation, indicative of larger high-linkage blocks, was consistently seen in 
the telomeric subregion (29.4 - 30.6 Mb) whereas correlation coefficients declined toward the 
less structured, centromeric end (31.2 - 32.2 Mb). Correlation coefficients between the 
German and the other populations followed a similar trend: with few exceptions, all values 
from the Europeans and the white US sample fell within the 95% confidence interval defined 
in the German sample. These findings suggested a strong conservation of LD structure 
between populations. This notwithstanding, the coefficients from the US African-American 
sample fell outside the 95% confidence interval although a decrease was also seen to occur 
from telomere to centromere. This indicates the higher similarity between populations of 
European origin reflecting the common history. An influence of the marker density on the 
correlation could not be observed. 
 
Metric LD units 
This analysis was performed through Francisco De La Vega at Applied Biosystems, Foster 
City, California 94404 / USA. due to reasons of consistency it is not separated from the study. 
 
Linkage between markers is restricted through recombination. Therefore the analysis of 
recombination between markers over the region was also assessed in the form of metric LD 
units (LDU) (155) with the LDMAP program (Fig. 3.10c). This measure is based on the decay 
of LD calculated with the aid of the “swept-radius” which has been suggested as the 
maximum (physical or genetic) distance over which useful LD can be expected (155). In line 
with the cluster- and correlation-based analyses of D’, LD was found to be high in the interval 
29.4-30.78 Mb, resulting in a plateau in the LDU plots of all populations (Fig. 3.10c). In the 
centromeric subregion, a higher rate of recombination became evident in the form of steeper 
increments. Consequently, the number of LDUs per physical distance unit was higher in the 
3’ than in the 5’ half of the plot. After positions 29.4-30.78 Mb, the LDU plot of the white US 
American sample departed from the European samples, and differed particularly towards the 
centromeric end of the region. The total LDUs attained in the 3’ half of the region by the 
white US American sample was approximately 70% higher than for the European samples. 
The US African-American sample exhibited a substantially different LDU pattern in that it 
attained a 3.5 times higher total LDU for the whole region than the European samples, and an 
80% higher total LDU than the white US American sample. The overall pattern of steps and 
plateaus was the same in all samples, although the US African-Americans exhibited a 
prominent increase in cumulative LDU at distinct positions, particularly at 31.48 Mb. 
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4. Discussion  
 
The aim of this study was to further confine a previously identified linkage region for 
inflammatory bowel disease and the disease categories Cohn's disease and ulcerative colitis 
and from this to identify functional and positional candidate genes with the final aim to 
eventually identify one of the genes carrying a causative mutation for IBD. Due to the results 
from the association map and the experience with the genes analysed as positional and 
functional candidate genes it became necessary to refocus the work with the aim to reveal 
underlying structure of linkage disequilibrium between markers in the region of interest that 
could distort the true association locus or probably account false positive association results 
 
4.1. Association mapping  
 
Association mapping employing diallelic SNP markers was performed in the previously 
identified linkage region on chromosome 6p (bordering microsatellite markers: D6S461 to 
D6S271). Therefore a 22.8 Mb large region including the MHC was covered with 142 
diallelic SNP markers and genotyped in a large population sample of monoplex and multiplex 
families and unrelated controls. The SNP markers were tested for allele and genotype 
association with the disease phenotypes IBD, CD and UC in the case control study design and 
for TDT association in the single point and multipoint analysis for up to 3 markers. Several 
association leads were observed with each of the methods, however not entirely overlapping. 
Markers with the highest associations in the leads were mostly the same in the allele and 
genotype association in the case control study design, differences were observed for the 
disease specification for which the highest association was seen. While three major 
association leads in the regions of HSP70-HOM to HLA-G, SLC26A8 to MAPK13 and 
around TREM1 were identified in the case control association, the TDT analysis with 
Transmit had only one major association lead from HSP70-HOM to rs1035798 (AGER) and 4 
minor peaks. All peaks were observed as well in the Genehunter TDT analysis, pronounced to 
a different degree. One peak was only present in the UC population. The others were relevant 
for IBD with a greater weight for CD phenotype.  
 
While the overlap of some association results gives a good indication toward a potential 
location of a disease gene, the differences between the results achieved with the different 
methods of analysis need further enquiry. The use of diallelic SNPs as markers for association 
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fine mapping has been established by now as an adequate tool (158-160). Through the LD 
between physically close markers association to a disease causing mutation could be 
identified through an SNP that is located close if positioned on the same haplotype. Whether 
susceptibility genes can be detected is dependent on the degree of linkage disequilibrium 
(160). The presence of haplotype structures through LD between markers could as well give 
rise to association at a certain distance from the true stimulus. Therefore a thorough 
knowledge of the LD structure in the region of interest is needed.  
 
Problems intrinsic to the use of SNPs as markers for association mapping are the allele and 
genotype frequency of each marker (160), which could vary for ethnically different 
populations, and as well where undetected population stratification is present. If there is a 
large difference in allele frequency between the disease variant and the marker, the disease 
variant cannot be detected due to the different extent of LD and the difference in the 
haplotype (160). Additionally markers with a low allele frequency are of low information 
content as most of the genotypes analysed are identical be state (ibs) and not necessarily by 
descent (ibd). In the TDT analysis it has to be taken into account that only heterozygous 
parents are informative as only in this case it can be distinguished which allele was 
transmitted. In the situation of an SNP at HWE this means that at least 50% of the parental 
samples are not included in the analysis, which increases for rare alleles. This reduces the 
effective population size in the TDT analysis, which could either mean a substantial loss of 
power to detect association or the overestimation of association on the basis of small numbers 
of alleles actually transmitted or not transmitted. This effect might be a reason for the 
differences between the case control and the TDT association observed in this study. The 
phenomenon was more pronounces in the multimarker analysis where due to the larger 
number of possible haplotypes the frequency of some haplotypes is very low, even though the 
major two-marker haplotypes associated to one of the disease categories were not affected by 
this problematic. A similar situation is possible for the direct typing of classical HLA genes 
where a great number of alleles reduces the effective sample size for each allele resulting in 
overestimation of positive associations. 
 
The distribution of the SNP marker in the association map was not uniform. While a central 
region from the chromosomal position 29.4 Mb to 37.5 Mb has a marker density of 80 kb and 
a median distance between markers of 36 kb, the density outside this region was lower. This 
inconsistency and the variability in the distance between two markers were partly caused by 
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the selection criteria. Several SNPs were not confirmed during the sequencing verification, 
especially SNPs from dbSNP were to a high degree not detectable in the sequencing 
population used for verification. Additionally some assays were withdrawn from the analysis 
because of bad allelic discrimination, a high rate of unexpected null-alleles or a great number 
of Mendelian inheritance errors. The variability in the distance of the SNP markers entails 
problems with the association mapping. Association that peaks in the uncovered part of the 
map might not be detected and the centre of a detected association might not be defined 
precisely. The fidelity of the typing technology employed itself was high as was seen in a 
marker that was genotyped twice in the complete association cohort. The same alleles were 
assorted to the individuals involved in both tests. 
 
Crucial for the success of a mapping experiment is the correct positioning and distance of the 
markers in the genetic map. The region investigated had been subject to intensive sequencing 
(3). Still the exact positioning of the SNP markers and genes changes with every new release 
or between different sequence assemblies. The problem is more pronounced regarding the 
microsatellite markers employed for the initial screening of the chromosome 6. The different 
map constructs (e.g. Genethon, Marshfield, NCBI_RH etc) place the markers at different 
positions and distances to each other. For the selection of the region from which the markers 
were selected the NCBI sequencing positions were employed and SNPs between these were 
included into the analysis. As recombination within the SNP marker map was not 
significantly higher than expected from the physical distance, it can be assumed that the 
positioning of the SNPs to each other and the distance between the markers employed for the 
analysis did not alter considerably from their true location.  
 
An analysis of the linkage with disease in the SNP markers was performed and reached NPL 
score up to 3.47 in the IBD. Even though this reaches not the suggested standard of 3.6 (41) 
the value indicated strong linkage to IBD, taking into account, that the diallelic SNP markers 
are less informative than microsatellites, and the comparably small sample size of ASPs. The 
NPL score decreases only toward the centromeric region markedly below 3 while to the 
telomeric region it stays high to the end of the map. This might indicate that a greater linkage 
might be undetected telomeric of the region investigated. 
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Three regions with increased association were identified through the case control analysis and 
were partly confirmed in the TDT association. These association leads were used as indicator 
for an area where a disease relevant gene could be located. 
 
4.2. Candidate genes  
 
HLA-DPA1 is one of the genes that could be a candidate gene due to the association in the 
surrounding markers and the antigen presenting function as a HLA gene. Few studies have 
investigated HLA-DP. Most association studies involving the classical HLA genes focused on 
HLA-DR, or DQ. Some of these studies included the HLA-DPB1 and did not report 
significant results (103, 104, 113). In the one study analysing the DPA1 gene, a positive 
association was seen between CD and DPA1*0201 (114) in the Japanese population. A large 
European population of multiplex families with IBD affected children was sequence analysed 
at three polymorphic sites in exon 2 of the HLA class II gene DPA1. Results were compared 
to a South African family population and a South Korean case control population. Two of the 
polymorphisms are causing amino acid exchanges in the N-terminal domain of the HLA-DP 
antigen. The three loci form six shared epitopes according to the connected HLA-DPA1 
alleles (Table 3.6). No other polymorphism on the exon 2 was considered as these three loci 
represent the most common nucleotide exchanges (22). The positive association described for 
the HLA-DPA1*0201 allele in Japanese CD patients (114) was not replicated in this study. 
Although this might be due to the ethnic distance of the investigated population samples to 
the Japanese population (22) even in the Korean study population, which is similar in the 
HLA-haplotype distribution, no similar result was observed. 
 
Suggestive but weak evidence for association between the shared epitope representing the 
HLA-DPA1*02021 / *02016 alleles and CD was observed in the German family cohort. This 
was not seen in the smaller patient populations from South Korea or South Africa. This 
finding may point to a conserved haplotype existing in the German population that includes 
the allele DPA1*02021. A similar situation probably is present in the Japanese population 
explaining the positive results for the DPA1*0201 (114). In the South African population a 
marginally significant association for the non-coding polymorphism to ulcerative colitis was 
seen for the shared epitopes on exon 2. As this was not seen in any of the other populations, 
the mixed ethnic background and the comparatively small size of our South African ulcerative 
colitis study population could account for this result.  
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The incidence of CD and UC in the South African population, especially among persons of 
coloured ethnic background is low (161). In the Korean population, the situation is similar 
(95). Recruitment of affected individuals in these populations therefore was focused on 
unrelated patients to serve as a control for positive findings in the German population. The 
recruitment of multiplex families, which would be appropriate for a comparison to IBD 
affected families of the European population sample, was not feasible. 
 
The large size of the European study population and the possibility to compare to populations 
of highly different ethnicity made it possible to identify gene variations and shared epitopes 
even at a low impact level. The mainly negative findings are a strong indicator that the HLA-
DPA1 gene is not directly involved in the etiology of IBD. In order to exclude the HLA-
DPA1 from the candidate genes, a complete analysis of the DP antigen including the HLA-
DPB1 would be necessary, as common haplotypes are known (22) and the functional 
interaction as antigen is only given through the a-b heterodimer on the cell surface. While 
population size in most HLA-typing studies is a problem due to the large number of possible 
variants scaling down the effective sample size, this was not critical in this analysis. However 
the reduction to 3 polymorphic sites is not representative for the complexity of the MHC 
either. For further studies of classic HLA genes it might be necessary to include all known 
alleles in each of the HLA class II genes and the use of more clearly defined disease 
subgroups (113). 
 
Besides the sequence genotyping of the HLA-DPA1 4 other genes were of interest as 
positional and functional candidate genes. The three genes MAPK14, MAK13 and BRPF3 
were located within one of the association leads of the case-control association study. In the 
TDT analysis the association did not reach the significance level. The situation was similar 
for the TREM1, which was situated within a smaller association lead centromeric. 
 
MAPK14 is involved in a range of inflammatory processes. It has an important part in stress 
related transcription and cell cycle regulation Activation of the protein is triggered through 
environmental stresses and proinflammatory cytokines. While relevance of p38-a for 
inflammatory bowel disease has been shown, especially with regard to the TNF-a related 
pathophysiology (162, 163), the role of the kinase in the disease mechanism is yet not 
understood in detail. A significant rise in p38-a activity, but not expression levels, could be 
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observed (162) which would indicate an altered binding or phosphorylation site in the 
molecule itself. An alteration of phosphorylation sites or a modification of binding sites for 
reaction partners would require coding mutations in exons. 
 
In this study the exons and the potential promotor region of the gene locus of MAPK14 were 
sequenced in 60 chromosomes, some exons were reanalysed in another 94 chromosomes. No 
exon polymorphism was found and the polymorphisms described in the dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/) as exonic could not be confirmed in the individuals 
analysed. The alternate spliced exon 9 and 10 used in MAPK14 and CSPB1 have the same 
length of 81 basepairs and about 30% identity. The position of the alternate exon use is 
marked through a double sequence in cDNA analysis that could falsely be taken as SNPs 
(139). The absence of SNPs in the exons eliminates the possibility of an amino acid change in 
one of the active sites. The findings confirm that MAPK14 and its variants in human and 
other vertebrates are highly conserved (164). Cross species comparisons between chimpanzee 
and human revealed only three base exchanges in the translated region (139). This finding 
supports the pivotal importance of the enzyme in the cellular signalling pathway. The three 
known splice variants of the gene and the absence of SNPs in the coding sequence suggest 
that alteration of the gene through conventional mutational processes would have been 
deleterious in the evolution. Alternatively the use of splice forms could have evolved.  
 
The analysis of intronic and 3'UTR SNPs revealed association with IBD in the case control 
analysis. The support for this was very weak and not significant for the TDT analysis. Neither 
the stratification for nor against carriers of the three CARD15 mutations (3020insC, R702W, 
L1007P) (63-65) did alter the association results except for a reduction that could be expected 
due to reduced sample size and power. In the analysis of severity factors for IBD development 
of fistulae, the formation of stenosis and a previous resection of parts of the bowel as 
described through the affected individuals several markers from MAPK14 showed slightly 
increased association with the fistulizing disease despite the reduced population sample. This 
could be due to a more stringent phenotype but the effect was not observed in the TDT 
analysis. None of these SNPs could be identified as a classical splice site or splice enhancer. 
Otherwise the functionality of intronic SNPs is very limited and difficult to prove. The 
differences observed in the activity of the MAPK14 could be explained by a change in 
efficiency of an upstream signalling pathway component of MAPK14.  
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The MAPK13 kinase is closely related to MAPK14 with a similar function and activation and 
the results observed were similar. No exonic SNPs were identified in 94 chromosomes. The 
gene was located within the same association lead as the MAPK14 observed in the case 
control study design, and had no significant association in the TDT analysis. While the 
stratification results for NOD2 carrier showed no significant association, one marker of the 
MAPK13 (rs2071863) seemed to support the complete association observed in the full cohort. 
This result was still significant after the permutation analysis. The marker exhibited a shift 
toward the frequent homozygous genotype of about 10% reduction of the heterozygous state. 
Matching to this is the observation that most of the association of that marker was observed in 
the CD population as the NOD2 mutations account for part of the affection with CD. Still, in 
the TDT analysis the association was not significant. The same marker was observed with the 
highest associations in all three analyses for severity phenotypes, but the association was not 
carried fully. Again no direct function could be assigned to this SNP.  
 
For the TREM1 gene which is expressed in monocytes and neutrophil cells (145), and is 
involved in monocyte/macrophage- and neutrophil-mediated inflammatory responses. The 
sequence analysis identified three at that time novel SNPs, two of which are by no described 
as rs2234246 and rs2234237. While rs2234246 is in the 3'UTR only rs2234237 is an exon 
polymorphism with an amino acid exchange from T to S, this was the only marker not 
exhibiting any significant association in IBD, CD or UC. The third SNP detected through 
sequence analysis is in the potential promotor region. Association for all other markers was 
slightly stronger in the UC population regarding the case control design. In the TDT analysis 
none of the markers reached significant association. The case control association was 
completely carried by the NOD2 negative individuals, which agrees with the stronger 
association in UC, while none of the severity factors were observed to be of major 
association. 
 
One possible cause for the association signals would be linkage disequilibrium with a 
causative mutation with which the SNPs with positive associations share the same haplotype. 
Markers of both genes MAPK14 and MAPK13 were tightly linked within the gene but as well 
between the genes. Therefore they could represent the same haplotype associated with 
disease. Through the different allele frequencies the association might be altered to a certain 
degree. A less frequent allele usually indicates a younger SNP that displays LD in a higher 
degree to the surrounding marker and over a greater distance. An allele with the same 
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frequency as the disease causing mutation will represent the association more precisely. One 
gene that is close to the association lead seen in the SNPs of the MAPK14 and MAPK13 was 
the BRPF3. The positive association in the SNPs analysed could have been caused by LD 
with a potential causative mutation in BRPF3. However the sequence analysis of the BRPF3 
gene did not reveal any SNPs in the cDNA in the individuals analysed. 
 
Other possible explanations for the positive associations observed could be a variety of 
mechanisms. Even though the analysis of severity factors did not increase the association 
signals, the definition of the phenotype analysed surely is of critical importance. Several 
measures had been taken to make the disease definition of IBD as well as UC and CD 
consistent. Nonetheless, the spectrum of phenotypes in these definitions is large regarding the 
intensity of the diseases, the location of inflammation, the bandwidth of characteristics and 
the extra-intestinal manifestations (60, 61, 119). Especially in regard to the inflammatory 
diseases associated or linked to the MHC region which exhibit a considerable degree of 
overlap of certain manifestations like the inflammation of skin, joints or lungs (57), 
overlapping with the descriptions of psoriasis, rheumatic arthritis and sarcoidosis, there is a 
need to review the strategies adopted to identify causative mutations. Many of these diseases 
have more than one potential susceptibility gene. Certain characteristics present in different 
diseases could possibly be caused through the same gene in each of the diseases. In IBD about 
18 % of the genetic risk to develop CD could be attributed to the C-insertion mutation in the 
NOD2 gene on chromosome 16 (63-65). Further analysis revealed that the NOD2 mutations 
determine ileal disease only (165, 166). For the narrow disease description peripheral 
arthropathy of IBD it was demonstrated that a precise definition of phenotype could lead to a 
highly significant association with a gene (167). The collection of a cohort that complies with 
these conditions would need an in-depth definition of disease phenotypes and an intense 
screening of affected individuals, to achieve a population size that gives enough power for the 
analysis. Besides the other difficulties, the penetrance of the disease variant has to be 
considered (160). The intensity of penetration is difficult to estimate in a polygenic disease 
and no single model can be applied more significantly than others (91). 
 
Other important factors in the description of disease are the environmental influences. In twin 
studies it was observed, that even in monozygotic twins the concordance rate was 6.3% for 
ulcerative colitis and 58.3% for Crohn's disease (80). The role of the environment has been 
discussed, and especially the influence of modern industrialized life-stile seems of great 
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importance (66, 81). The presence of environmental factors triggering the development and 
possibly the phenotype of the disease add another variable to the analysis. 
 
Further evaluation in the candidate genes analysed herein would include the examination of 
splice variants and their distribution in the different disease categories compared to unaffected 
individuals and the probably the identification of additional splice variants. This would as 
well include mutation detection in the full sequence including the introns, which for example 
for MAPK14 stretch over several kb. Furthermore other genes within the association leads 
could be as well functional candidates and need further investigation. 
 
4.3. Linkage disequilibrium structure  
 
An organization of the human genome into conserved haplotype blocks, interrupted by 
historical recombination “hot-spots” or (less active) “warm-spots”, has been proposed 
repeatedly (25, 48, 56). At the same time, a number of methodological approaches to identify 
haplotype structure and to delineate recombination hot-spots have been expounded (51, 53, 
56). A ubiquitous presence of conserved blocks would allow the construction of LD maps of 
the human genome, facilitating characterization of genetic diversity between and among 
populations. Since previous results on MHC diversity and its presumed evolutionary history 
appeared to be incompatible with a strict organization into haplotype blocks, this region was 
investigated in more detail in different European and US-American populations.  
 
The construction of UPGMA trees based upon pair-wise D’ values and their comparison to 
physical marker maps allow the assessment of haplotype structure without any a priori 
hypothesis about the nature of such structure. The analysis of a 10 Mb region on chromosome 
6p, including the MHC, demonstrated the coexistence of different LD patterns in closely 
linked genomic regions. Although recombination hot-spots and haplotype blocks emerged in 
all population samples analysed, a universal and uniform haplotype structure was neither 
observed in the 10 Mb region nor in a 3.53Mb peri-MHC region analysed in more detail. 
Furthermore, recombination events were not confined to “hot-spots” even though the latter 
could be inferred easily in areas of conserved haplotype structure. The distance, up to which 
useful LD was still detectable within haplotype blocks, if present, was approximately 100 kb 
and corresponded to the typical block size suggested before (55). 
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Correlation in D’ between populations can be expected to be low in areas of high haplotype 
diversity. In this sense, the white European populations exhibited a qualitatively similar 
distribution of haplotype structure throughout the genomic region. Substantial differences 
were only observed in the comparison to the US-African American sample whereas the white 
US-Americans were relatively close to the Europeans for most of the analysed region. This 
finding is likely to reflect the known historical relationship between the populations and their 
migration histories. 
 
Similarities between populations were generally greater in regions with high LD, indicating 
the presence of a limited number of haplotypes generated by a small number of historic 
recombination events. This supposition was confirmed by the analysis of LDU as the 
correlation in D’ was found to parallel changes in LDU. Where historic recombination rates 
must have been high, correlation coefficients were low. The genomic position at which the 
LDU plot of the white US Americans diverted from the Europeans coincided with a sharp 
decrease in D’ correlation coefficient, placing the Americans outside the 95% confidence 
interval of the German intra-population comparison. One explanation could be recent 
admixture of the white US-American population with other European or non-European 
populations that broke up “old” European haplotype blocks. An even more pronounced trend 
towards wide-spread and frequent historic recombination events was seen in the US-African 
American sample, a finding that corroborates previous studies (53, 168).  
 
The density, allele frequency and age of SNPs all have an influence on the nature of the 
haplotype structure that can be detected. For the present analysis, therefore a 5% frequency 
cut-off was adopted (leading to the exclusion of 6% of markers) to reduce the number of 
evolutionary young markers that led to long-range LD. A high number of comparatively 
young SNPs with long distance LD and allele frequencies above 5% may be expected to exist 
in the MHC region due to its propensity to frequent recombination events and the selective 
pressure towards higher variability. A reanalysis adopting an allele frequency cut-off of 20% 
(32% of markers excluded) led to a further marked reduction in long distance LD, without 
changing the principal findings. For the density of the markers there could no direct 
dependence to the correlation or the LDU be observed. However even the 500 kb window 
with the lowest marker content had 18 markers. A lower density than this could still influence 
the level of LD detectable especially as with a decrease of density the risk of very large gaps 
rises. 
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Sample size also has an impact on the statistical ability to describe haplotype structure. The 
results suggest that a sample of 45 individuals would be sufficient to delineate major 
haplotype structure in areas of low recombination, but that larger samples and higher densities 
of SNPs might be required to resolve short haplotype structure in areas of high recombination 
activity. Therefore, every SNP available may have to be included in the genotyping and 
analysis strategy in those areas in which haplotype structure was not detected by the present 
study. 
 
The physical and biological explanation of the local variation and the interregional differences 
in LD structure is unclear. A link between recombination rate and occurrence of mutations 
has been suggested by some studies (54, 169). This should be found, when high variability 
and a fast turnover of new variants are of biological advantage in a given genomic region as it 
has been suggested for the MHC region. However, the classical HLA genes characterized by 
high levels of variability were not linked to areas of particularly high or low LD in our study. 
A higher degree of sequence conservation is usually observed for the introns rather than the 
exons of these genes, and the evolutionary mechanism underlying this phenomenon probably 
reflects the need for repeated recombination (170, 171). Similar patterns of LD distribution 
were also found outside the MHC, in the 10 Mb region analysed here and probably also exist 
in other chromosomal regions (172). Primary DNA structures as well as DNA topology have 
been discussed as potential factors promoting recombination (52, 173-175).  
 
The results on LD distribution may prove useful in the efficient assembly of SNP panels for 
future association mapping of chromosome 6p-linked complex diseases. In contrast to 
previous assumptions, substantial parts of the human genome cannot be parsed into uniform 
haplotype blocks and recombination hot-spots. Differences in recombination and LD pattern 
have to be taken into account for the study of variability between populations, even when 
block modelling of the more conserved regions is undertaken. The sample sizes and SNP 
density needed has to be adapted to the expected level of structuring by haplotype blocks. 
Thus, regions with well-defined block structure could be represented by fewer SNP markers 
or on the basis of smaller population samples than regions without such structure. 
 
In regions without haplotype block structure a high number of SNPs may be needed to detect 
association. The presence of long-range LD may result in significant problems in the 
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positional localization of the primary disease associated genetic variant. Genome wide 
haplotype mapping efforts will therefore result in a critical resource for the future of genetic 
mapping in phenotype diversity studies. 
 
4.4. Conclusion  
 
Association mapping with diallelic SNP markers is a useful tool to refine a previously 
identified chromosomal linkage region. Increased association could be detected with this 
method at 3 locations in the case control study design and 4 association leads were observed 
in the TDT analysis in families. Association detected through these methods is calculated on 
the basis of different assumptions. While association within a case control study design is 
based on identity by state of the disease allele and the marker used for analysis in the group of 
independent cases, the analysis of family based association identifies the transmission of 
alleles from parents to offspring. Both methods have difficulties and advantages. While a case 
control population is easier to assemble, the analysis of healthy parents minimises the 
influence of artificial differences. Due to the different kinds of analysis the resulting intensity 
and location of association might as well differ but still map the same signal, as the methods 
are influenced to a different degree by LD in the region of interest, the allele and genotype 
frequency and environmental factors. Limitations of using SNP marker and association as 
measure to determine the location of a potential susceptibility gene are the marker density and 
the structure of LD in the region analysed, but as well the frequency of the disease causing 
mutation. A certain marker density is necessary to map a region for association. The 
necessary minimal density was probably only achieved in the internal more densely covered 
central region of the map used in this study, so that association on the margins might not be 
represented well enough. The signals in the central part of the map were clear and useful for 
further analysis and the fact that none of the SNPs analysed in the candidate genes is the 
causative mutation does not reduce the possibility to find a disease locus within the 
associations detected. Several other functionally interesting genes are located in the area. 
Important for the interpretation of the data from the association is the knowledge about 
underlying LD structures in the region analysed. Where LD is strong the association signal 
might be carried over a long distance and the representativeness of the association depend as 
well on the frequency of the marker. Taking these aspects into consideration, the association 
mapping could be a useful tool in further disease gene identification. 
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On the basis of the association leads some functionally interesting genes were analysed in 
more detail. As a classic HLA gene the HLA-DPA1 was analysed on three polymorphic sites 
in the second exon. The data presented in this study suggest, that the HLA-DPA1 locus itself 
is not a major genetic risk determinant for IBD in any of the three populations described here. 
The not significant population-specific association signals might point to population-specific 
conserved haplotypes that may carry true susceptibility mutations. 
 
In four other genes from the association leads mutation detection on the exons and the 
potential promotor regions were performed. Only in the TREM1 gene a polymorphism was 
found in the second exon. None of the polymorphisms analysed in MAPK14. MAPK13 and 
TREM1 could be identified as disease causing. In the BRPF3 gene no polymorphism was 
discovered in the analysis of cDNA and no intron SNPs were known. The high conservation 
of the MAPK genes, which might be entailed through their relevance in the cell signalling and 
the presence of several splice variants might make it necessary to investigate other factors 
influencing the known increased activation of MAPK14. This could be additional splice 
variants with splice signals affected through intronic SNPs or binding sites for enhancer 
proteins. The observed association points to a variant causing disease in linkage 
disequilibrium with the SNPs analysed.  
 
With the results from the association mapping experiment and the analysis of candidate genes 
it became obvious that the previously existing descriptions of haplotype structures in the 
MHC were not representative and do not sufficiently explain the observed results. Therefore 
the region was analysed for LD structures in 5 different populations. In the 10 Mb region and 
the internal 3.53 Mb region investigated a great variety of linkage disequilibrium structures 
were observed. High LD levels and clear haplotype block structures were found to 
intermingle with areas of low or medium LD, both inside and outside the MHC. The pattern 
and characteristics of LD were similar in all European populations and the US American 
white population. The African-Americans, despite exhibiting a similar distribution of LD over 
the region, are nevertheless characterized by a higher degree of haplotype diversity. These 
findings are likely to have a strong impact upon the future design of systematic association 
studies of chromosome 6p-linked human diseases. In regions without haplotype block 
structure a high number of SNPs may be needed to detect association. The presence of long-
range LD may result in significant problems in the positional localization of the primary 
disease associated genetic variant. Therefore, even studies of functional candidate genes will 
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benefit from a map detailing the regional distribution of haplotype block structure. Genome 
wide haplotype mapping efforts will therefore result in a critical resource for the future of 
genetic mapping in phenotype diversity studies. 
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5.  Summary: Development of an SNP map in the peri-MHC Region 
on the human chromosome 6 as a tool to identify candidate 
genes for inflammatory bowel disease 
 
The human MHC region is located at the chromosome 6p21 and encodes for a great number 
of genes that express proteins with high relevance in the immune response and regulation. 
This includes the classical HLA genes, which are important in the recognition and 
presentation of antigens foreign to the body, but as well members of the cytokine signalling 
network, like tumor necrosis factor (TNF-a) or mitogen activated kinases (MAPK14). This 
makes the region an interesting target for the identification of susceptibility genes for 
autoimmune or chronic inflammatory diseases. Linkage to chromosome 6p21 and the MHC 
region has been established for several inflammatory and autoimmune diseases as for example 
for inflammatory bowel diseases (IBD). Inflammatory bowel disease, which can be divided in 
two phenotypes Crohn's disease (CD) and ulcerative colitis (UC), is a relapsing chronic 
inflammatory disorder of the gastrointestinal tract influenced by complex genetic, 
immunological and environmental factors.  
The first aim of this study was to develop a single nucleotide polymorphism (SNP) based map 
in the linkage region of IBD in order to further confine the region where a potential disease 
susceptibility gene could be located. With 142 SNPs about 20 Mb on the p-arm of 
chromosome 6 including the MHC were analysed for association within a population of 847 
IBD affected individuals and their healthy parents and a group of 550 unrelated blood donors 
as a control group. Association was tested with a case control and a family based transmission 
distortion technique (TDT). While three major association leads in the regions of HSP70-
HOM to HLA-G, SLC26A8 to MAPK13 and around TREM1 were identified in the case 
control association, the TDT analysis with Transmit had only one major association lead from 
HSP70-HOM to rs1035798 (AGER) and 4 minor peaks partly overlapping with the case 
control results. Based on this, five functional candidate genes were analysed in more detail: 
HLA-DPA1, MAPK14, MAKP13, BRPF3 and TREM1. In HLA-DPA1 exon 2 
polymorphisms at amino acid positions 31, 37-38, and 50 were typed by direct sequencing in 
affected individuals and if possible healthy family members from Europe and South Africa, 
and South Korea and unrelated healthy controls from Germany and South Korea. Weak 
association was only found for CD in the European family population for HLA-
DPA1*02021/*02016. Mutation detection in the coding sequence of MAPK14, MAPK13 and 
TREM1 identified only one exon polymorphism in exon 2 (T25S) of TREM1 and two more 
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intronic or in the 3' untranslated region. The case control analysis showed positive 
associations for intronic SNPs in all three genes but not for T25S. From these data neither of 
these genes is a major determinant of IBD risk. Further analysis of the neighbouring gene 
BRPF3 did not identify any exonic polymorphisms. Several other functional candidate genes 
made it plausible that the observed associations were caused through linkage disequilibrium 
(LD). Extent and structure of LD in the region was unclear. The human genome has been 
suggested to be organized into haplotype blocks, characterized by high internal levels of LD 
between SNPs, separated by recombination hot-spots. The distribution of linkage was 
investigated in a 10 Mb region using 920 SNPs in a population of 45 US-Americans of 
European ancestry, followed by a more detailed investigation of 3.53 Mb covering the MHC, 
using 320 SNPs in 550 German, 78 British, 93 Norwegian, and 45 individuals US-Americans 
of African ancestry. Clustering of Lewontin's D' and correlation between LD in different 
populations and physical distance between SNPs were implemented. The data show that LD 
between SNPs can have a variety of characteristics, and the knowledge about this is important 
for the interpretation of association results. High LD levels and clear haplotype block 
structures were found to intermingle with areas of low or medium LD, both inside and outside 
the MHC. All populations with European ancestry show a similar pattern and characteristics 
of LD structure, while the US-African American populations differs at several areas. These 
data provide a basis for the analysis and set-up of further association studies in the peri-MHC 
region, and show the importance of a thorough investigation of LD structures in a region of 
interest for disease gene detection with association methods.
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6.  Zusammenfassung: Entwicklung einer SNP-Karte in der 
erweiterten MHC Region auf Chromosom 6 des Menschen als 
Instrument zur Identifikation von Kandidatengenen für chronisch 
entzündliche Darmerkrankungen 
 
Die menschliche MHC Region (Haupt-Histokompatibilitätskomplex) auf Chromosom 6p21 
beinhaltet eine Vielzahl an Genen, deren Proteine in der Immunantwort und -regulation von 
großer Wichtigkeit sind. Dies beinhaltet einerseits die eigentlichen HLA (Humane 
Leukozytenantigene) Gene, welche für die Erkennung und Präsentation körperfremder 
Antigene wichtig sind, andererseits aber auch Faktoren der Zytokin-Signaltransduktion, wie 
zum Beispiel Tumornekrosefaktor-alpha (TNF-a) oder die Mitogen-aktivierten 
Proteinkinasen (MAPK14). Die Region ist damit ein interessantes Ziel für die Suche nach 
Genen, die eine Prädisposition für Autoimmunerkrankungen oder chronisch entzündliche 
Erkrankungen verursachen können. In Kopplungsstudien konnten für verschiedene 
entzündliche und Autoimmunerkrankungen, wie zum Beispiel chronisch entzündliche 
Darmerkrankungen (CED), Hinweise auf eine Verbindung mit dem MHC gezeigt werden. 
Chronisch entzündliche Darmerkrankungen können in zwei Ausprägungen unterteilt werden, 
Morbus Crohn (MC) und Colitis Ulcerosa (CU). Die Erkrankung ist gekennzeichnet durch 
wiederkehrende Entzündung des Magen-Darm-Traktes und wird durch ein komplexes 
Zusammenspiel von genetischen, immunologischen und Umwelt-Faktoren beeinflusst. 
 
Im Rahmen dieser Arbeit wurde zunächst eine auf Punktmutationen (SNPs) basierende Karte 
entwickelt, die den Bereich der positiven Kopplungsanalyse abdeckt, um ein mögliches Gen 
mit Prädisposition weiter einzugrenzen. Dazu wurden 142 SNP Marker in einer 20 Mb großen 
Region, inklusive dem MHC, auf Chromosom 6 in 847 erkrankten Personen sowie deren 
gesunde Eltern und einer Gruppe von 550 unverwandten Blutspendern als Kontrollgruppe auf 
Assoziation mit CED untersucht. Die Assoziation wurde in einem Fall-Kontroll-
Studienrahmen und mit Hilfe von familienbasiertem Transmissionsungleichgewicht (TDT) 
getestet. Mit der ersten Methode konnten drei Stellen größerer Assoziation festgestellt 
werden, HSP70-HOM bis HLA-G, SLC26A8 bis MAPK13 und rund umTREM1. Die zweite 
Methode hatte eine Hauptassoziation, HSP70-HOM bis rs1035798 (AGER), und mehrere 
kleinere, die teilweise mit den Ergebnissen aus der Fall-Kontrollstudie überlappten. Auf 
dieser Grundlage wurden die folgenden fünf funktionellen Kandidatengene ausgewählt und 
weiter untersucht: HLA-DPA1, MAPK14, MAKP13, BRPF3 und TREM1. In HLA-DPA1 
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wurden Basenaustausche an den Aminosäurepositionen 31, 37-38 und 50 in Exon 2 
untersucht. Beteiligt waren Erkrankte und, soweit vorhanden, gesunde Familienmitglieder aus 
Europa, Südafrika und Südkorea sowie unverwandte Kontrollpersonen aus Deutschland und 
Südkorea. Nur in der europäischen Familiengruppe wurde eine schwache Assoziation von 
MC mit HLA-DPA*02021/*02016 gefunden. Mutationssuche in der kodierenden Sequenz 
von MAPK14, MAKP13 und TREM1 führte nur zu einem SNP in Exon 2 von TREM1, der 
einen Aminosäureaustausch zur Folge hatte (T25S), sowie zwei weiteren SNPs im Intron und 
der 3' untranslatierten Region. Assoziation konnte nur für intronische SNPs der drei Gene in 
der Fall-Kontrollanalyse nachgewiesen werden. Aufgrund dieser Daten ist keines der oben 
genannten Gene ein wichtiger Risikofaktor für CED. Ein weiteres benachbartes Gen BRPF3 
zeigte ebenfalls keine exonischen SNPs. Die Vielzahl anderer funktioneller Kandidatengene 
in der Region legt nahe, dass die beobachteten Assoziationen aufgrund von 
Kopplungsungleichgewicht in der Region entstanden sind. Das Ausmaß, in dem 
Kopplungsungleichgewicht in der MHC Region vorliegt, ist nicht geklärt. Für das humane 
Genom wurde allerdings eine Organisation in Haplotypenblöcke mit hoher interner 
Kopplung, die durch Punkte häufiger Rekombination getrennt sind vorgeschlagen. Die 
Verteilung der Kopplung wurde zunächst in einer 10 Mb Region mit 920 SNPs in einer 
Gruppe von 45 US-Amerikanern mit europäischer Abstammung getestet. In der vertieften 
Analyse einer 3,53 Mb Region, welche den MHC beinhaltet, wurden 320 SNPs zusätzlich in 
550 Deutschen, 78 Briten, 93 Norwegern, und 45 US-Amerikanern mit afrikanischer 
Abstammung getestet. Dazu wurde eine Gruppierung der SNPs aufgrund von Lewontins D' 
Werten für Kopplung angewendet sowie eine Korrelationsanalyse der Kopplung in den 
verschiedenen Populationen im Vergleich zur physischen Distanz. Die Daten zeigen, dass 
Kopplung zwischen SNPs verschiedene Ausprägungen haben kann und dass die Kenntnis 
darüber wichtig ist für die Auswertung von Assoziationsergebnissen. Klare Haplotyp- 
Blockstrukturen wurden neben und vermischt mit Regionen mittlerer und geringer Kopplung 
gefunden, sowohl im MHC als auch außerhalb. Alle Populationen mit europäischer 
Abstammung zeigten eine ähnliche Struktur und Charakteristik, während die US-Amerikaner 
afrikanischer Abstammung an einigen Stellen deutliche Unterschiede zeigten. Diese 
Ergebnisse sind eine wichtige Grundlage für die Analyse und den Versuchsaufbau von 
Assoziationsstudien im erweiterten MHC Bereich und zeigen die Notwendigkeit gründlicher 
Kenntnisse der Kopplung in einer Region für die Suche von Krankheitsgenen. 
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8. Appendix 
 
8.1. Supplemental data 
 
8.1.1. Allele and genotype association analysis 
Table 8.1 part1: Allele and genotype frequencies in 142 SNP markers 
    Allele frequencies Genotype frequencies 
  Controls  IBD cases CD cases UC cases Controls  IBD cases CD cases UC cases 
SNP marker name 
Position 
(Mb) 1 2 1 2 1 2 1 2  1-1  1-2  2-2  1-1  1-2  2-2  1-1  1-2  2-2  1-1  1-2  2-2 
rs1563727 21.29 0.37 0.63 0.39 0.61 0.40 0.60 0.38 0.62 0.14 0.46 0.40 0.15 0.48 0.37 0.16 0.47 0.37 0.13 0.51 0.37 
rs1935005 22.25 0.78 0.22 0.80 0.20 0.79 0.21 0.81 0.19 0.61 0.34 0.05 0.63 0.33 0.04 0.62 0.33 0.04 0.65 0.32 0.03 
rs714591 22.42 0.56 0.44 0.56 0.44 0.55 0.45 0.58 0.42 0.32 0.49 0.19 0.32 0.48 0.20 0.32 0.46 0.21 0.32 0.51 0.17 
rs867543 22.58 0.57 0.43 0.55 0.45 0.55 0.45 0.55 0.45 0.33 0.49 0.18 0.30 0.49 0.21 0.29 0.50 0.20 0.32 0.46 0.22 
rs1997781 22.74 0.78 0.22 0.77 0.23 0.77 0.23 0.79 0.21 0.62 0.33 0.05 0.61 0.33 0.06 0.59 0.36 0.05 0.65 0.28 0.07 
rs1024216 22.77 0.58 0.42 0.55 0.45 0.55 0.45 0.55 0.45 0.34 0.49 0.17 0.30 0.51 0.19 0.28 0.54 0.18 0.31 0.48 0.21 
rs1928083 22.96 0.64 0.36 0.65 0.35 0.65 0.35 0.63 0.37 0.42 0.44 0.13 0.43 0.44 0.13 0.44 0.43 0.13 0.40 0.47 0.14 
rs1325016 23.81 0.20 0.80 0.20 0.80 0.21 0.79 0.17 0.83 0.03 0.33 0.64 0.03 0.32 0.64 0.04 0.33 0.63 0.02 0.29 0.68 
rs1402405 24.15 0.59 0.41 0.56 0.44 0.56 0.44 0.55 0.45 0.35 0.47 0.18 0.32 0.48 0.20 0.31 0.50 0.19 0.32 0.45 0.23 
rs932494 24.97 0.61 0.39 0.60 0.40 0.60 0.40 0.59 0.41 0.41 0.40 0.19 0.36 0.48 0.16 0.37 0.47 0.16 0.34 0.51 0.16 
rs302976 25.18 0.19 0.81 0.18 0.82 0.17 0.83 0.19 0.81 0.04 0.30 0.66 0.02 0.31 0.67 0.02 0.31 0.68 0.03 0.31 0.66 
rs1318016 25.82 0.77 0.23 0.73 0.27 0.74 0.26 0.72 0.28 0.59 0.35 0.06 0.54 0.40 0.07 0.53 0.41 0.06 0.53 0.38 0.09 
rs1141034 25.84 0.25 0.75 0.28 0.72 0.28 0.72 0.28 0.72 0.06 0.39 0.56 0.07 0.41 0.52 0.06 0.44 0.50 0.09 0.38 0.52 
rs1747522 25.88 0.50 0.50 0.49 0.51 0.49 0.51 0.48 0.52 0.24 0.52 0.25 0.24 0.50 0.27 0.24 0.50 0.26 0.23 0.49 0.28 
rs1540273 25.98 0.37 0.63 0.38 0.62 0.38 0.62 0.38 0.62 0.13 0.48 0.39 0.15 0.47 0.38 0.14 0.49 0.38 0.17 0.44 0.40 
rs1436310 26.03 0.60 0.40 0.58 0.42 0.58 0.42 0.58 0.42 0.37 0.46 0.18 0.33 0.49 0.18 0.33 0.50 0.17 0.34 0.48 0.18 
rs1535276 26.58 0.46 0.54 0.45 0.55 0.45 0.55 0.43 0.57 0.20 0.52 0.28 0.20 0.51 0.29 0.19 0.51 0.29 0.18 0.50 0.31 
rs126007 27.80 0.23 0.77 0.23 0.77 0.25 0.75 0.21 0.79 0.06 0.34 0.60 0.06 0.36 0.59 0.06 0.37 0.57 0.04 0.35 0.61 
rs126136 28.35 0.71 0.29 0.71 0.29 0.70 0.30 0.72 0.28 0.53 0.37 0.10 0.51 0.41 0.09 0.50 0.40 0.10 0.50 0.44 0.06 
rs209179 28.85 0.51 0.49 0.45 0.55 0.46 0.54 0.46 0.54 0.25 0.51 0.24 0.21 0.50 0.30 0.22 0.47 0.31 0.18 0.56 0.26 
rs929042 28.95 0.77 0.23 0.81 0.19 0.80 0.20 0.81 0.19 0.59 0.36 0.05 0.64 0.33 0.03 0.65 0.32 0.04 0.63 0.34 0.02 
rs1362073 29.44 0.30 0.70 0.34 0.66 0.33 0.67 0.36 0.64 0.09 0.42 0.49 0.12 0.44 0.44 0.11 0.44 0.45 0.14 0.43 0.42 
rs404240 29.58 0.97 0.03 0.97 0.03 0.97 0.03 0.97 0.03 0.93 0.07 0.00 0.95 0.05   0.94 0.05   0.95 0.05 0.00 
rs362536 29.58 0.45 0.55 0.52 0.48 0.50 0.50 0.54 0.46 0.20 0.51 0.29 0.26 0.52 0.22 0.23 0.55 0.22 0.30 0.46 0.23 
rs64036 29.58 0.97 0.03 0.97 0.03 0.98 0.02 0.97 0.03 0.94 0.06   0.95 0.05   0.95 0.05   0.95 0.05   
GABABR1_E7_G141esA 29.64 0.90 0.10 0.89 0.11 0.88 0.12 0.90 0.10 0.80 0.20   0.79 0.20 0.01 0.77 0.22 0.01 0.81 0.18 0.01 
MOG_E3_G550A 29.69 0.06 0.94 0.12 0.88 0.11 0.89 0.13 0.87   0.12 0.88 0.01 0.21 0.78 0.01 0.20 0.79 0.02 0.22 0.77 
rs1476572 29.73 0.78 0.22 0.71 0.29 0.72 0.28 0.70 0.30 0.62 0.31 0.07 0.51 0.40 0.08 0.52 0.40 0.08 0.50 0.40 0.10 
rs1569315 29.85 0.04 0.96 0.05 0.95 0.05 0.95 0.03 0.97   0.09 0.91   0.09 0.91   0.10 0.90  0.07 0.93 
HCG-V_3pu_T3056C 30.08 0.15 0.85 0.13 0.87 0.12 0.88 0.13 0.87 0.02 0.28 0.71 0.02 0.21 0.77 0.02 0.19 0.78 0.01 0.23 0.75 
HLA-E_E3_A1458G 30.51 0.44 0.56 0.47 0.53 0.47 0.53 0.47 0.53 0.17 0.54 0.29 0.22 0.49 0.29 0.22 0.50 0.28 0.24 0.47 0.29 
GTF2H4G-24T 30.93 0.20 0.80 0.20 0.80 0.20 0.80 0.19 0.81 0.05 0.30 0.66 0.04 0.32 0.65 0.04 0.32 0.64 0.04 0.31 0.65 
CDSN_E1_A66T 31.14 0.20 0.80 0.18 0.82 0.20 0.80 0.15 0.85 0.04 0.32 0.64 0.03 0.30 0.67 0.03 0.34 0.63 0.03 0.25 0.72 
rs1265109 31.18 0.25 0.75 0.23 0.77 0.23 0.77 0.21 0.79 0.09 0.33 0.58 0.05 0.35 0.60 0.05 0.38 0.58 0.06 0.31 0.63 
SC1_E2_G2712A 31.19 0.26 0.74 0.29 0.71 0.26 0.74 0.34 0.66 0.07 0.37 0.56 0.10 0.38 0.53 0.07 0.38 0.55 0.13 0.41 0.45 
HLA-C_E2_G1019A 31.29 0.39 0.61 0.37 0.63 0.38 0.62 0.35 0.65 0.14 0.49 0.37 0.13 0.48 0.39 0.13 0.49 0.38 0.12 0.47 0.41 
HLA-B_E5_G582A 31.38 0.36 0.64 0.35 0.65 0.35 0.65 0.35 0.65 0.12 0.48 0.41 0.13 0.45 0.43 0.13 0.43 0.44 0.11 0.47 0.41 
rs2005423 31.41 0.82 0.18 0.84 0.16 0.85 0.15 0.84 0.16 0.66 0.33 0.01 0.72 0.25 0.03 0.72 0.25 0.03 0.72 0.24 0.04 
MICA_E4_A8561G 31.43 0.58 0.42 0.57 0.43 0.56 0.44 0.58 0.42 0.32 0.52 0.16 0.33 0.49 0.18 0.32 0.48 0.20 0.33 0.51 0.16 
MICB_E3_C7991G 31.53 0.13 0.87 0.12 0.88 0.13 0.87 0.11 0.89 0.01 0.23 0.75 0.01 0.21 0.78 0.02 0.23 0.76 0.02 0.18 0.80 
TNFA_G308A_ 31.61 0.18 0.82 0.17 0.83 0.17 0.83 0.17 0.83 0.03 0.31 0.66 0.03 0.28 0.69 0.03 0.29 0.69 0.03 0.28 0.69 
rs707916 31.76 0.60 0.40 0.63 0.37 0.61 0.39 0.67 0.33 0.37 0.46 0.16 0.41 0.44 0.15 0.38 0.45 0.17 0.47 0.42 0.12 
rs707926 31.82 0.16 0.84 0.16 0.84 0.18 0.82 0.13 0.87 0.02 0.28 0.70 0.03 0.25 0.72 0.04 0.27 0.69 0.03 0.20 0.77 
HSP70-HOM_G2763A 31.85 0.34 0.66 0.31 0.69 0.29 0.71 0.34 0.66 0.13 0.42 0.45 0.10 0.43 0.47 0.09 0.40 0.51 0.10 0.48 0.42 
rs539689 31.87 0.48 0.52 0.46 0.54 0.45 0.55 0.45 0.55 0.22 0.53 0.25 0.22 0.48 0.30 0.23 0.45 0.32 0.18 0.54 0.28 
C2_E7_G954C 31.97 0.04 0.96 0.03 0.97 0.03 0.97 0.04 0.96   0.08 0.92   0.07 0.93   0.06 0.94  0.07 0.93 
rs1035798 32.18 0.70 0.30 0.74 0.26 0.76 0.24 0.71 0.29 0.49 0.42 0.09 0.56 0.35 0.08 0.60 0.33 0.08 0.52 0.39 0.09 
BTNL-II_E3_A158G 32.40 0.36 0.64 0.31 0.69 0.33 0.67 0.29 0.71 0.09 0.53 0.38 0.10 0.43 0.47 0.11 0.45 0.45 0.09 0.41 0.50 
HLA-DRA_E4_T724G 32.44 0.57 0.43 0.57 0.43 0.56 0.44 0.56 0.44 0.33 0.49 0.18 0.32 0.50 0.18 0.30 0.52 0.18 0.31 0.49 0.19 
HLA-DQA1_E3_C389T 32.63 0.29 0.71 0.25 0.75 0.25 0.75 0.26 0.74 0.08 0.42 0.51 0.08 0.36 0.57 0.06 0.38 0.56 0.10 0.31 0.58 
TAP2_E9_G1693A 32.79 0.07 0.93 0.06 0.94 0.07 0.93 0.06 0.94   0.13 0.86   0.12 0.88   0.12 0.87  0.11 0.89 
HLA-DMB_E3_T590C 32.90 0.16 0.84 0.20 0.80 0.18 0.82 0.21 0.79 0.04 0.23 0.73 0.04 0.31 0.65 0.03 0.30 0.67 0.04 0.32 0.63 
rs1063478 32.91 0.86 0.14 0.86 0.14 0.85 0.15 0.86 0.14 0.74 0.23 0.02 0.75 0.22 0.02 0.73 0.24 0.03 0.76 0.20 0.03 
rs206775 32.95 0.59 0.41 0.60 0.40 0.60 0.40 0.60 0.40 0.36 0.46 0.19 0.36 0.49 0.16 0.35 0.50 0.15 0.37 0.45 0.18 
RING3_E8_C6193T 32.96 0.04 0.96 0.03 0.97 0.04 0.96 0.03 0.97   0.08 0.92   0.07 0.93   0.08 0.92  0.05 0.95 
rs2581 32.98 0.45 0.55 0.43 0.57 0.43 0.57 0.42 0.58 0.20 0.50 0.31 0.18 0.49 0.33 0.17 0.50 0.32 0.18 0.48 0.34 
rs926424 33.15 0.29 0.71 0.30 0.70 0.29 0.71 0.34 0.66 0.09 0.40 0.51 0.09 0.43 0.48 0.09 0.40 0.51 0.10 0.47 0.43 
rs1547387 33.16 0.12 0.88 0.12 0.88 0.12 0.88 0.13 0.87 0.02 0.21 0.77 0.01 0.23 0.76 0.01 0.23 0.76  0.24 0.75 
rs466384 33.24 0.12 0.88 0.11 0.89 0.12 0.88 0.11 0.89 0.01 0.23 0.77 0.01 0.21 0.78 0.01 0.21 0.78 0.01 0.19 0.80 
TAPBP_E4_G325C 33.27 0.46 0.54 0.48 0.52 0.48 0.52 0.49 0.51 0.21 0.51 0.28 0.24 0.48 0.28 0.24 0.48 0.28 0.26 0.46 0.28 
rs999942 33.62 0.75 0.25 0.75 0.25 0.74 0.26 0.76 0.24 0.58 0.34 0.08 0.56 0.37 0.06 0.54 0.40 0.06 0.59 0.35 0.06 
rs10672 33.66 0.32 0.68 0.33 0.67 0.32 0.68 0.36 0.64 0.11 0.41 0.48 0.11 0.44 0.45 0.10 0.44 0.46 0.13 0.45 0.42 
rs747694 33.73 0.45 0.55 0.48 0.52 0.47 0.53 0.49 0.51 0.19 0.52 0.29 0.23 0.50 0.27 0.23 0.49 0.28 0.22 0.54 0.24 
rs943461 33.77 0.77 0.23 0.78 0.22 0.78 0.22 0.79 0.21 0.61 0.34 0.06 0.61 0.34 0.05 0.60 0.35 0.04 0.63 0.32 0.05 
rs902196 34.00 0.02 0.98 0.04 0.96 0.04 0.96 0.03 0.97   0.04 0.96   0.08 0.92   0.09 0.91  0.05 0.95 
rs914815 34.12 0.54 0.46 0.52 0.48 0.51 0.49 0.56 0.44 0.29 0.51 0.20 0.27 0.51 0.22 0.25 0.51 0.24 0.30 0.52 0.18 
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Table 8.1 part2: Allele and genotype frequencies 
    Allele frequencies Genotype frequencies 
  Controls  IBD cases CD cases UC cases Controls  IBD cases CD cases UC cases 
SNP marker name 
Position 
(Mb) 1 2 1 2 1 2 1 2  1-1  1-2  2-2  1-1  1-2  2-2  1-1  1-2  2-2  1-1  1-2  2-2 
rs1759627 34.19 0.17 0.83 0.17 0.83 0.16 0.84 0.17 0.83 0.04 0.27 0.69 0.02 0.29 0.69 0.02 0.28 0.70 0.02 0.30 0.68 
hCV2489254 35.42 0.30 0.70 0.33 0.67 0.32 0.68 0.34 0.66 0.08 0.43 0.49 0.13 0.40 0.46 0.13 0.40 0.48 0.14 0.41 0.45 
hCV2489242 35.44 0.62 0.38 0.58 0.42 0.59 0.41 0.57 0.43 0.38 0.49 0.13 0.36 0.44 0.20 0.37 0.44 0.19 0.36 0.43 0.22 
rs755658 35.55 0.90 0.10 0.92 0.08 0.92 0.08 0.91 0.09 0.81 0.18 0.01 0.84 0.15 0.01 0.84 0.14 0.01 0.83 0.16   
rs992105 35.55 0.83 0.17 0.83 0.17 0.83 0.17 0.82 0.18 0.68 0.30 0.02 0.68 0.29 0.03 0.69 0.29 0.03 0.67 0.30 0.03 
rs1320991 35.56 0.21 0.79 0.22 0.78 0.22 0.78 0.22 0.78 0.03 0.36 0.61 0.05 0.34 0.61 0.05 0.34 0.61 0.06 0.32 0.62 
hCV1256778 35.57 0.27 0.73 0.28 0.72 0.28 0.72 0.31 0.69 0.07 0.42 0.52 0.08 0.41 0.51 0.07 0.40 0.52 0.10 0.43 0.48 
rs1360780 35.60 0.68 0.32 0.69 0.31 0.69 0.31 0.69 0.31 0.46 0.45 0.09 0.47 0.43 0.09 0.48 0.42 0.10 0.46 0.46 0.08 
hCV15812414 35.70 0.83 0.17 0.82 0.18 0.82 0.18 0.83 0.17 0.68 0.30 0.02 0.67 0.30 0.03 0.66 0.31 0.03 0.68 0.28 0.03 
hCV1979181 35.73 0.40 0.60 0.39 0.61 0.40 0.60 0.37 0.63 0.14 0.51 0.35 0.16 0.46 0.38 0.15 0.49 0.36 0.17 0.41 0.42 
rs1326752 35.83 0.69 0.31 0.67 0.33 0.67 0.33 0.69 0.31 0.45 0.46 0.08 0.45 0.44 0.10 0.44 0.45 0.11 0.47 0.44 0.09 
hCV2472420 35.85 0.69 0.31 0.68 0.32 0.67 0.33 0.69 0.31 0.46 0.45 0.08 0.46 0.44 0.10 0.46 0.44 0.11 0.47 0.44 0.09 
hCV617976 35.88 0.69 0.31 0.68 0.32 0.67 0.33 0.69 0.31 0.46 0.46 0.08 0.46 0.44 0.10 0.45 0.44 0.11 0.47 0.44 0.09 
hCV617970 35.89 0.66 0.34 0.64 0.36 0.64 0.36 0.65 0.35 0.42 0.49 0.10 0.41 0.47 0.13 0.40 0.47 0.13 0.42 0.48 0.11 
hCV3001847 35.96 0.42 0.58 0.47 0.53 0.48 0.52 0.46 0.54 0.17 0.51 0.32 0.22 0.50 0.28 0.23 0.50 0.27 0.21 0.49 0.29 
hCV3001832 35.98 0.76 0.24 0.76 0.24 0.76 0.24 0.75 0.25 0.58 0.36 0.06 0.58 0.35 0.06 0.59 0.35 0.06 0.56 0.37 0.07 
hCV8852296 35.98 0.34 0.66 0.29 0.71 0.28 0.72 0.27 0.73 0.10 0.46 0.43 0.08 0.42 0.50 0.07 0.42 0.51 0.08 0.38 0.54 
hCV3001824 36.00 0.53 0.47 0.46 0.54 0.45 0.55 0.48 0.52 0.27 0.51 0.22 0.22 0.49 0.30 0.20 0.50 0.31 0.24 0.47 0.29 
hCV8852251 36.01 0.17 0.83 0.15 0.85 0.14 0.86 0.17 0.83 0.04 0.26 0.70 0.02 0.26 0.71 0.02 0.25 0.74 0.03 0.29 0.69 
hCV2455932 36.06 0.12 0.88 0.09 0.91 0.10 0.90 0.07 0.93   0.23 0.76 0.01 0.16 0.83 0.01 0.17 0.82 0.01 0.12 0.87 
hCV2455926 36.07 0.54 0.46 0.47 0.53 0.46 0.54 0.48 0.52 0.29 0.50 0.21 0.23 0.47 0.30 0.21 0.49 0.30 0.25 0.45 0.30 
hCV2455924 36.07 0.47 0.53 0.53 0.47 0.54 0.46 0.52 0.48 0.22 0.50 0.28 0.29 0.48 0.23 0.30 0.49 0.21 0.30 0.46 0.25 
hCV2455922 36.08 0.27 0.73 0.32 0.68 0.33 0.67 0.31 0.69 0.07 0.39 0.53 0.11 0.42 0.47 0.11 0.43 0.46 0.11 0.41 0.48 
hCV2455919 36.08 0.80 0.20 0.83 0.17 0.84 0.16 0.81 0.19 0.65 0.31 0.05 0.68 0.29 0.03 0.70 0.27 0.03 0.66 0.30 0.04 
rs763096 36.10 0.66 0.34 0.60 0.40 0.59 0.41 0.59 0.41 0.44 0.45 0.11 0.34 0.52 0.14 0.34 0.50 0.16 0.33 0.53 0.14 
rs2007683 36.10 0.36 0.64 0.34 0.66 0.33 0.67 0.33 0.67 0.13 0.46 0.41 0.10 0.47 0.43 0.11 0.45 0.44 0.09 0.48 0.43 
rs2815812 36.10 0.30 0.70 0.26 0.74 0.26 0.74 0.25 0.75 0.09 0.41 0.49 0.07 0.38 0.55 0.07 0.38 0.55 0.07 0.35 0.57 
rs2071863 36.10 0.22 0.78 0.17 0.83 0.17 0.83 0.16 0.84 0.04 0.38 0.59 0.03 0.27 0.70 0.03 0.27 0.70 0.04 0.25 0.71 
hCV2476692 36.24 0.71 0.29 0.68 0.32 0.66 0.34 0.73 0.27 0.51 0.40 0.09 0.46 0.43 0.10 0.44 0.44 0.12 0.53 0.39 0.08 
hCV2476745 36.27 0.71 0.29 0.71 0.29 0.70 0.30 0.71 0.29 0.53 0.37 0.10 0.50 0.41 0.09 0.51 0.39 0.10 0.47 0.47 0.06 
rs744848 36.33 0.19 0.81 0.18 0.82 0.17 0.83 0.19 0.81 0.04 0.30 0.66 0.03 0.30 0.68 0.03 0.29 0.69 0.04 0.31 0.65 
rs763017 36.33 0.01 0.99 0.01 0.99 0.01 0.99 0.02 0.98   0.02 0.98   0.03 0.97   0.03 0.97  0.03 0.97 
hCV3247999 36.34 0.86 0.14 0.85 0.15 0.86 0.14 0.82 0.18 0.75 0.23 0.02 0.71 0.27 0.02 0.74 0.25 0.02 0.66 0.31 0.02 
rs881648 36.35 0.12 0.88 0.14 0.86 0.14 0.86 0.14 0.86 0.01 0.22 0.77 0.02 0.24 0.74 0.02 0.24 0.74 0.03 0.23 0.75 
rs881647 36.35 0.40 0.60 0.41 0.59 0.41 0.59 0.41 0.59 0.15 0.49 0.36 0.17 0.47 0.36 0.18 0.46 0.36 0.16 0.49 0.34 
rs1885205 36.35 0.88 0.12 0.87 0.13 0.87 0.13 0.86 0.14 0.78 0.20 0.02 0.75 0.23 0.02 0.76 0.22 0.02 0.74 0.23 0.03 
hCV16175628 36.44 0.19 0.81 0.19 0.81 0.19 0.81 0.19 0.81 0.04 0.29 0.67 0.04 0.30 0.66 0.04 0.29 0.67 0.03 0.32 0.65 
hCV7516771 36.46 0.19 0.81 0.19 0.81 0.19 0.81 0.19 0.81 0.04 0.30 0.66 0.04 0.30 0.66 0.04 0.29 0.67 0.03 0.32 0.65 
hCV791696 36.47 0.70 0.30 0.70 0.30 0.71 0.29 0.68 0.32 0.52 0.36 0.12 0.50 0.42 0.09 0.52 0.38 0.10 0.45 0.46 0.09 
hCV3053930 36.49 0.27 0.73 0.27 0.73 0.26 0.74 0.28 0.72 0.09 0.37 0.54 0.07 0.39 0.54 0.08 0.36 0.56 0.07 0.44 0.50 
hCV2969554 36.56 0.80 0.20 0.79 0.21 0.79 0.21 0.77 0.23 0.64 0.31 0.05 0.62 0.34 0.04 0.63 0.33 0.04 0.59 0.37 0.04 
rs1059234 36.65 0.92 0.08 0.94 0.06 0.94 0.06 0.93 0.07 0.84 0.16   0.88 0.12   0.89 0.11   0.87 0.13   
hCV2969521 36.66 0.42 0.58 0.44 0.56 0.43 0.57 0.45 0.55 0.18 0.49 0.33 0.20 0.48 0.32 0.19 0.49 0.32 0.23 0.44 0.33 
hCV1022631 36.69 0.40 0.60 0.39 0.61 0.40 0.60 0.38 0.62 0.18 0.44 0.38 0.16 0.47 0.37 0.16 0.48 0.37 0.16 0.45 0.39 
hCV1022677 36.73 0.64 0.36 0.65 0.35 0.64 0.36 0.65 0.35 0.39 0.50 0.12 0.43 0.44 0.13 0.42 0.45 0.13 0.43 0.44 0.13 
hCV3211720 36.81 0.34 0.66 0.35 0.65 0.35 0.65 0.36 0.64 0.14 0.41 0.45 0.13 0.45 0.42 0.11 0.47 0.42 0.14 0.43 0.43 
hCV2061156 36.84 0.73 0.27 0.78 0.22 0.79 0.21 0.76 0.24 0.53 0.40 0.07 0.61 0.34 0.05 0.61 0.36 0.04 0.59 0.34 0.07 
hCV2061161 36.84 0.56 0.44 0.53 0.47 0.53 0.47 0.52 0.48 0.33 0.46 0.21 0.29 0.49 0.23 0.28 0.50 0.22 0.29 0.48 0.24 
hCV2703063 36.93 0.45 0.55 0.47 0.53 0.45 0.55 0.48 0.52 0.21 0.49 0.30 0.23 0.48 0.29 0.21 0.48 0.31 0.25 0.47 0.28 
hCV2317531 36.95 0.17 0.83 0.18 0.82 0.18 0.82 0.18 0.82 0.02 0.29 0.69 0.03 0.31 0.66 0.03 0.30 0.67 0.02 0.32 0.66 
hCV2729903 37.14 0.21 0.79 0.21 0.79 0.21 0.79 0.21 0.79 0.05 0.33 0.62 0.04 0.34 0.63 0.04 0.34 0.63 0.04 0.35 0.62 
rs2055272 37.29 0.36 0.64 0.36 0.64 0.36 0.64 0.36 0.64 0.11 0.50 0.39 0.13 0.46 0.41 0.14 0.45 0.41 0.12 0.48 0.40 
hCV685985 37.30 0.85 0.15 0.85 0.15 0.85 0.15 0.85 0.15 0.71 0.27 0.01 0.73 0.24 0.03 0.72 0.26 0.02 0.74 0.23 0.03 
hCV3025711 37.33 0.50 0.50 0.54 0.46 0.53 0.47 0.54 0.46 0.25 0.50 0.25 0.30 0.49 0.22 0.28 0.49 0.22 0.30 0.48 0.22 
hCV685941 37.35 0.65 0.35 0.67 0.33 0.66 0.34 0.68 0.32 0.41 0.46 0.12 0.45 0.43 0.12 0.44 0.45 0.12 0.47 0.42 0.11 
hCV3025667 37.43 0.68 0.32 0.71 0.29 0.71 0.29 0.71 0.29 0.49 0.39 0.12 0.51 0.39 0.09 0.51 0.40 0.09 0.53 0.37 0.10 
rs1757191 37.48 0.49 0.51 0.45 0.55 0.46 0.54 0.44 0.56 0.25 0.48 0.27 0.21 0.48 0.31 0.23 0.47 0.30 0.19 0.50 0.31 
rs1739629 38.58 0.37 0.63 0.37 0.63 0.37 0.63 0.37 0.63 0.15 0.43 0.42 0.15 0.45 0.41 0.15 0.45 0.40 0.16 0.42 0.42 
rs1332010 38.99 0.30 0.70 0.29 0.71 0.28 0.72 0.28 0.72 0.09 0.43 0.48 0.08 0.42 0.50 0.09 0.38 0.52 0.05 0.47 0.48 
rs1004279 39.02 0.74 0.26 0.77 0.23 0.76 0.24 0.79 0.21 0.55 0.38 0.07 0.58 0.38 0.05 0.57 0.38 0.05 0.61 0.35 0.04 
rs1541816 39.16 0.48 0.52 0.47 0.53 0.47 0.53 0.48 0.52 0.22 0.52 0.26 0.23 0.48 0.29 0.22 0.49 0.29 0.24 0.48 0.28 
rs1014737 41.02 0.11 0.89 0.12 0.88 0.12 0.88 0.11 0.89 0.01 0.20 0.78 0.01 0.22 0.77 0.01 0.23 0.76 0.01 0.19 0.80 
hCV2504280 41.05 0.86 0.14 0.85 0.15 0.84 0.16 0.88 0.12 0.74 0.25 0.01 0.72 0.26 0.02 0.71 0.27 0.02 0.76 0.23 0.01 
hCV2814735 41.16 0.36 0.64 0.34 0.66 0.34 0.66 0.34 0.66 0.14 0.43 0.43 0.12 0.44 0.43 0.12 0.43 0.44 0.12 0.44 0.44 
rs1817538 41.24 0.48 0.52 0.55 0.45 0.55 0.45 0.55 0.45 0.25 0.45 0.30 0.30 0.50 0.20 0.31 0.49 0.20 0.28 0.54 0.18 
rs1351835 41.24 0.48 0.52 0.55 0.45 0.55 0.45 0.54 0.46 0.26 0.44 0.30 0.30 0.50 0.21 0.31 0.49 0.20 0.27 0.54 0.19 
rs1817537 41.24 0.52 0.48 0.45 0.55 0.45 0.55 0.46 0.54 0.30 0.44 0.26 0.20 0.50 0.30 0.20 0.49 0.31 0.19 0.53 0.27 
hCV1620987 41.31 0.27 0.73 0.25 0.75 0.24 0.76 0.26 0.74 0.07 0.39 0.54 0.06 0.38 0.56 0.06 0.36 0.58 0.06 0.40 0.54 
hCV3042474 41.32 0.74 0.26 0.76 0.24 0.77 0.23 0.75 0.25 0.55 0.39 0.07 0.57 0.38 0.06 0.59 0.36 0.05 0.55 0.40 0.05 
rs742735 41.61 0.78 0.22 0.77 0.23 0.78 0.22 0.76 0.24 0.61 0.34 0.05 0.60 0.35 0.05 0.61 0.34 0.05 0.58 0.36 0.06 
rs1410492 41.90 0.75 0.25 0.73 0.27 0.74 0.26 0.69 0.31 0.54 0.41 0.05 0.53 0.40 0.07 0.55 0.39 0.06 0.49 0.41 0.10 
rs1160867 42.89 0.53 0.47 0.55 0.45 0.56 0.44 0.54 0.46 0.29 0.49 0.22 0.31 0.48 0.21 0.30 0.53 0.17 0.33 0.41 0.26 
rs1105024 43.08 0.05 0.95 0.08 0.92 0.08 0.92 0.07 0.93   0.10 0.90   0.16 0.84   0.17 0.83  0.13 0.87 
rs9395 43.15 0.03 0.97 0.06 0.94 0.06 0.94 0.05 0.95   0.06 0.94   0.11 0.89   0.11 0.88  0.09 0.91 
rs1111786 43.49 0.98 0.02 0.97 0.03 0.97 0.03 0.96 0.04 0.95 0.05   0.93 0.07   0.94 0.06   0.92 0.08   
rs1418488 44.14 0.34 0.66 0.35 0.65 0.35 0.65 0.35 0.65 0.10 0.46 0.43 0.12 0.47 0.41 0.12 0.47 0.41 0.12 0.46 0.42 
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For the examination of association of IBD with the SNPs in MHC region 142 SNP markers 
were genotyped using diallelic discrimination analysis. With this method the genotype of each 
sample is directly determined so that the genotype and allele frequency in a population can be 
directly derived. The complete allele and genotype frequencies for the control group, the 
group of IBD affected individuals and in both disease categories CD and UC are given in 
Table 8.1. Blanks in one of the genotype fields identify SNPs where only one homozygous 
and the heterozygous state were observed in the population investigated. In the case 
population only one affected individual per family was included for the calculation of the 
frequencies. 
 
8.1.2. Two-point TDT analysis  
 
 
 
 
 
 
From the multipoint TDT analyses only the two-point Transmit results are shown here. The 
tendency in the results from the Genehunter analysis was very similar. Used for the plot was 
the global c2, which is calculated from all haplotypes of the two marker unit. In the three-
marker analysis the situation is reflected, no new association leads could be observed. 
Fig. 8.1: Two point TDT (Transmit) association analysis. The c2 was calculated on the basis of 
the two marker haplotype alleles transmitted from parent to affected offspring compared to the 
alleles expected from HWE. Significance of a peak at the 95% confidence interval is reached at a 
c2 value of 6.6 with 3 df. Not all markers are shown and the positioning is not according to the 
physical distance. 
Appendix 112 
8.1.3. Additional linkage analysis results  
 
Linkage analysis using Genehunter was performed for all three disease categories. Here the 
NPL scores for CD and UC are shown (Fig 8.2 and 8.3). For the analysis of NPL in CD 105 
ASPs were available, in the UC analysis only 43. In relation to the number of ASPs in the 
analysis and that SNPs were the markers employed, which are less informative than 
microsatellites, an NPL score of 2.5 at the maximum is a good indicator of Linkage to CD in 
the region. Similar to the NPL in IBD there is a clear decrease towards the centromeric part of 
the region. To the telomeric side the decrease is less prominent but steeper than in the analysis 
of IBD. 
 
 
 
The NPL score in the UC category is below 1 over the complete region. This is too low to 
claim linkage to UC in the region. However with the additional 43 ASPs from UC in the IBD 
analysis the NPL score experienced another increase (compared to the CD results). This 
indicated the linkage is added though the UC ASPs and is present in UC as well.  
Fig. 8.2: Non-parametric LOD score for CD. The NPL was calculated on the basis of 105 
ASPs using the weighed pairs option of Genehunter. All NPL values were highly significant (p < 
0.001). Z-all identifies the NPL score while on the vertical axis the physically correct positions of 
the markers are indicated 
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Besides the calculation of the NPL scores the Genehunter program generated a comparison of 
recombination events expected (theta) from the physical distance and the observed 
recombinations. Given in the Table 8.2 is the marker and the interval (the marker and the next 
marker), and the theta expected besides the observed recombination. In most situations the 
observed recombination was below the expected. The maker intervals where the observed 
recombination was larger than the expected did not sum up to a significantly higher value. 
Therefore it can be assumed that the marker order is correct and the used physical distances 
between markers are close to the real distances. 
 
 
 
Fig. 8.3: Non-parametric LOD score for UC. The NPL was calculated on the basis of 43 
ASPs using the weighed pairs option of Genehunter. Significance was not achieved for the 
values. For details see Fig. 8.2. 
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Table 8.2 Analysis of recombination. 
SNP marker name interval theta observed  
SNP marker 
name interval theta observed 
rs1563727 01-02 0.0096 0.0048 (0.0194/4)  rs1320991 72-73 0.0001 0 (0.0000/4) 
rs1935005 02-03 0.0017 0 (0.0001/4)  hCV1256778 73-74 0.0003 0 (0.0000/4) 
rs714591 03-04 0.0016 0 (0.0001/4)  rs1360780 74-75 0.001 0 (0.0000/4) 
rs867543 04-05 0.0016 0 (0.0001/4)  hCV15812414 75-76 0.0003 0 (0.0000/4) 
rs1997781 05-06 0.0003 0 (0.0000/4)  hCV1979181 76-77 0.001 0 (0.0000/4) 
rs1024216 06-07 0.0019 0 (0.0001/4)  rs1326752 77-78 0.0003 0 (0.0000/4) 
rs1928083 07-08 0.0085 0.0001 (0.0004/4)  hCV2472420 78-79 0.0003 0 (0.0000/4) 
rs1325016 08-09 0.0034 0.0001 (0.0003/4)  hCV617976 79-80 0.0001 0 (0.0000/4) 
rs1402405 09-10 0.0082 0.0001 (0.0005/4)  hCV617970 80-81 0.0007 0 (0.0000/4) 
rs932494 10-11 0.0021 0 (0.0002/4)  hCV3001847 81-82 0.0002 0 (0.0000/4) 
rs302976 11-12 0.0065 0.0001 (0.0005/4)  hCV3001832 82-83 0.0001 0 (0.0000/4) 
rs1318016 12-13 0.0002 0 (0.0000/4)  hCV8852296 83-84 0.0001 0 (0.0000/4) 
rs1141034 13-14 0.0004 0 (0.0000/4)  hCV3001824 84-85 0.0001 0 (0.0000/4) 
rs1747522 14-15 0.001 0 (0.0001/4)  hCV8852251 85-86 0.0005 0 (0.0000/4) 
rs1540273 15-16 0.0005 0 (0.0000/4)  hCV2455932 86-87 0.0001 0 (0.0000/4) 
rs1436310 16-17 0.0055 0.0001 (0.0004/4)  hCV2455926 87-88 0.0001 0 (0.0000/4) 
rs1535276 17-18 0.0122 0.0005 (0.0021/4)  hCV2455924 88-89 0.0001 0 (0.0000/4) 
rs126007 18-19 0.0055 0.0003 (0.0011/4)  hCV2455922 89-90 0.0001 0 (0.0000/4) 
rs126136 19-20 0.005 0.0003 (0.0010/4)  hCV2455919 90-91 0.0001 0 (0.0000/4) 
rs209179 20-21 0.001 0 (0.0002/4)  rs763096 91-92 0.0001 0 (0.0000/4) 
rs929042 21-22 0.0049 0.0002 (0.0007/4)  rs2007683 92-93 0.0001 0 (0.0000/4) 
rs1362073 22-23 0.0014 0 (0.0002/4)  rs2815812 93-94 0.0001 0 (0.0000/4) 
rs404240 23-24 0.0001 0 (0.0000/4)  rs2071863 94-95 0.0014 0 (0.0000/4) 
rs362536 24-25 0.0001 0 (0.0000/4)  hCV2476692 95-96 0.0003 0 (0.0000/4) 
rs64036 25-26 0.0005 0 (0.0001/4)  hCV2476745 96-97 0.0006 0 (0.0000/4) 
GABABR1_E7_G141esA 26-27 0.0005 0 (0.0001/4)  rs744848 97-98 0.0001 0 (0.0000/4) 
MOG_E3_G550A 27-28 0.0004 0 (0.0001/4)  rs763017 98-99 0.0001 0 (0.0000/4) 
rs1476572 28-29 0.0012 0.0001 (0.0002/4)  hCV3247999 99-100 0.0001 0 (0.0000/4) 
rs1569315 29-30 0.0023 0.0001 (0.0004/4)  rs881648 100-101 0.0001 0 (0.0000/4) 
HCG-V_3pu_T3056C 30-31 0.0043 0.0002 (0.0007/4)  rs881647 101-102 0.0001 0 (0.0000/4) 
HLA-E_E3_A1458G 31-32 0.0042 0.0001 (0.0003/4)  rs1885205 102-103 0.001 0 (0.0000/4) 
GTF2H4G-24T 32-33 0.0021 0 (0.0001/4)  hCV16175628 103-104 0.0001 0 (0.0000/4) 
CDSN_E1_A66T 33-34 0.0003 0 (0.0000/4)  hCV7516771 104-105 0.0001 0 (0.0000/4) 
rs1265109 34-35 0.0001 0 (0.0000/4)  hCV791696 105-106 0.0002 0 (0.0000/4) 
SC1_E2_G2712A 35-36 0.0011 0 (0.0000/4)  hCV3053930 106-107 0.0007 0 (0.0000/4) 
HLA-C_E2_G1019A 36-37 0.0008 0 (0.0000/4)  hCV2969554 107-108 0.0009 0 (0.0000/4) 
HLA-B_E5_G582A 37-38 0.0004 0 (0.0000/4)  rs1059234 108-109 0.0001 0 (0.0000/4) 
rs2005423 38-39 0.0002 0 (0.0000/4)  hCV2969521 109-110 0.0004 0 (0.0000/4) 
MICA_E4_A8561G 39-40 0.0009 0 (0.0001/4)  hCV1022631 110-111 0.0004 0 (0.0000/4) 
MICB_E3_C7991G 40-41 0.0008 0 (0.0001/4)  hCV1022677 111-112 0.0008 0 (0.0000/4) 
TNFA_G308A_ 41-42 0.0015 0 (0.0002/4)  hCV3211720 112-113 0.0002 0 (0.0000/4) 
rs707916 42-43 0.0006 0 (0.0001/4)  hCV2061156 113-114 0.0001 0 (0.0000/4) 
rs707926 43-44 0.0003 0 (0.0000/4)  hCV2061161 114-115 0.0009 0 (0.0000/4) 
HSP70-HOM_G2763A 44-45 0.0002 0 (0.0000/4)  hCV2703063 115-116 0.0002 0 (0.0000/4) 
rs539689 45-46 0.001 0 (0.0001/4)  hCV2317531 116-117 0.0019 0 (0.0001/4) 
C2_E7_G954C 46-47 0.0021 0.0001 (0.0003/4)  hCV2729903 117-118 0.0015 0 (0.0000/4) 
rs1035798 47-48 0.0022 0.0001 (0.0003/4)  rs2055272 118-119 0.0001 0 (0.0000/4) 
BTNL-II_E3_A158G 48-49 0.0004 0 (0.0001/4)  hCV685985 119-120 0.0003 0 (0.0000/4) 
HLA-DRA_E4_T724G 49-50 0.0019 0.0001 (0.0003/4)  hCV3025711 120-121 0.0002 0 (0.0000/4) 
HLA-DQA1_E3_C389T 50-51 0.0017 0.0001 (0.0002/4)  hCV685941 121-122 0.0008 0 (0.0001/4) 
TAP2_E9_G1693A 51-52 0.0011 0 (0.0001/4)  hCV3025667 122-123 0.0006 0 (0.0000/4) 
HLA-DMB_E3_T590C 52-53 0.0001 0 (0.0000/4)  rs1757191 123-124 0.0109 0.0002 (0.0008/4) 
rs1063478 53-54 0.0004 0 (0.0000/4)  rs1739629 124-125 0.0041 0.0001 (0.0003/4) 
rs206775 54-55 0.0001 0 (0.0000/4)  rs1332010 125-126 0.0003 0 (0.0000/4) 
RING3_E8_C6193T 55-56 0.0002 0 (0.0000/4)  rs1004279 126-127 0.0014 0.0001 (0.0002/4) 
rs2581 56-57 0.0017 0 (0.0001/4)  rs1541816 127-128 0.0186 0.0006 (0.0024/4) 
rs926424 57-58 0.0001 0 (0.0000/4)  rs1014737 128-129 0.0004 0 (0.0001/4) 
rs1547387 58-59 0.0009 0 (0.0000/4)  hCV2504280 129-130 0.001 0.0001 (0.0002/4) 
rs466384 59-60 0.0003 0 (0.0000/4)  hCV2814735 130-131 0.0008 0 (0.0002/4) 
TAPBP_E4_G325C 60-61 0.0035 0 (0.0002/4)  rs1817538 131-132 0.0001 0 (0.0000/4) 
rs999942 61-62 0.0004 0 (0.0000/4)  rs1351835 132-133 0.0001 0 (0.0000/4) 
rs10672 62-63 0.0007 0 (0.0000/4)  rs1817537 133-134 0.0007 0 (0.0002/4) 
rs747694 63-64 0.0003 0.0045 (0.0181/4)  hCV1620987 134-135 0.0001 0 (0.0000/4) 
rs943461 64-65 0.0023 0.032 (0.1279/4)  hCV3042474 135-136 0.003 0.0002 (0.0006/4) 
rs902196 65-66 0.0012 0.0163 (0.0653/4)  rs742735 136-137 0.0029 0.0002 (0.0006/4) 
rs914815 66-67 0.0007 0.0103 (0.0411/4)  rs1410492 137-138 0.0099 0.0003 (0.0012/4) 
rs1759627 67-68 0.0123 0.1698 (0.6794/4)  rs1160867 138-139 0.0019 0.0001 (0.0002/4) 
hCV2489254 68-69 0.0002 0.0027 (0.0110/4)  rs1105024 139-140 0.0006 0.0003 (0.0014/4) 
hCV2489242 69-70 0.0011 0.0145 (0.0581/4)  rs9395 140-141 0.0035 0.0018 (0.0073/4) 
rs755658 70-71 0.0001 0 (0.0000/4)  rs1111786 141-142 0.0064 0.0034 (0.0135/4) 
rs992105 71-72 0.0001 0 (0.0000/4)  rs1418488         
      total recs = 1.06 real map = 23.14, observed map = 30.49,  
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8.1.4. Cluster heat-maps of other populations 
 
Here the results of the cluster analysis in the other three populations are shown. While 
regarded from the physical axis the regions of high LD are similar for all populations of 
European ancestry. The US-African Americans were less similar and the major high LD areas 
were smaller but still present. The fragmentation of areas with high LD is greater in this 
population, which mirrors the otherwise reported shorter haplotypes seen in populations with 
African ancestry. The differences between the populations from the aspect of clustering are 
mainly due to a different turning of the branches, while the cluster themselves stay similar. 
 
 
 
Fig. 8.4: Cluster heat-map of 
pairwise D’ in the UK 
population. 
 A total of 320 SNP markers 
were genotyped in 78 UK 
individuals. 270 SNPs with minor 
allele frequencies >5% were 
analysed. The graph relates the 
physical map of the region 
(horizontal axis, with every 5th
SNP marked) to the order 
derived from UPGMA clustering 
of D’ values (vertical axis). The 
vertical axis details the cluster 
dendogram with a scale of D’ 
levels shown at the bottom. 
Levels of pairwise D’ are colour-
coded from dark grey to light 
grey (top left corner). 
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Fig. 8.5: Cluster heat-map of 
pairwise D’ in the Norwegian 
population. 
 A total of 320 SNP markers 
were genotyped in 93 Norwegian 
individuals. 276 SNPs with minor 
allele frequencies >5% were 
analysed. The graph relates the 
physical map of the region 
(horizontal axis, with every 5th
SNP marked) to the order 
derived from UPGMA clustering 
of D’ values (vertical axis). The 
vertical axis details the cluster 
dendogram with a scale of D’ 
levels shown at the bottom. 
Levels of pairwise D’ are colour-
coded from dark grey to light 
grey (top left corner). 
 
Fig. 8.6: Cluster heat-map of 
pairwise D’ in the US African 
American population. 
 A total of 320 SNP markers 
were genotyped in 45 US African 
American individuals. 209 SNPs 
with minor allele frequencies 
>5% were analysed. The graph 
relates the physical map of the 
region (horizontal axis, with 
every 5th SNP marked) to the 
order derived from UPGMA 
clustering of D’ values (vertical 
axis). The vertical axis details the 
cluster dendogram with a scale 
of D’ levels shown at the bottom. 
Levels of pairwise D’ are colour-
coded from dark grey to light 
grey (top left corner). 
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8.2. Sequencing primer 
 
Table 8.3a: Primer for PCR amplification and sequencing in MAPK14 
primer forward oligonucleotide primer reverse oligonucleotide 
MAPK14       
p38_prom_A_F1 TGGTCAGGCTGGTCTCGAACTC p38_prom_A_R TCCCGTTCCAGCTGCTGC 
p38_prom_B_F1 TGGCTCTTGGAACCGCGA p38_prom_B_R GTAGAACGTGGGCCTCTCCTGAG 
p38_prom_A_F2 CCCGACCTCAGGTGATCCG    
p38_prom_B_F2 CGACCACTGGAGCCTTAGCG    
p38_prom_A_F3 CTGGGATTACAGGCGTGAGC p38_prom_A_R2 GCTAAGGCTCCAGTGGTCG 
p38_prom_A_F4 AGGCGTGTGCTGCCAGC p38_prom_A_R3 GCGAGAAGAGAACAATAACTGGAGAC 
p38_E1s_F GAGAGGGTGCGGGTGCAG p38_E1s_R CGCTGAGCAGTGGAGCAGG 
p38_E1s_F2 GGGCCCACAGGGCCAC    
p38_E1s_F3 GGCGACCAGCGCAAGGT    
p38_E2s_F AGACCCTTTAATTTGGAAATAGCC p38_E2s_R AACGTTTGATGCACTCCAGC 
p38_E2s_F2 AAATACCCCAAAATAATATTTAGAACAGC    
p38_E3s_F CCCGGCCTAGACCCTGACTC p38_E3s_R ACCCAAAAAGAGGTGCATGATAGG 
p38_E3s_F2 AGATTAAGACCTGATGGGTACTATACTGAG    
p38_E4s_F1 CAGCCTGGCAGTAGAGCGAG p38_E4s_R GAACATGGCAGTTTACTGTACTATATGACC 
p38_E4s_F2 CTGAAGATAAGAACTTTCTTAGGGGTTCTAG p38_E4s_R2 AAAGTTGTTTACTTGTTTGTTTAAGCC 
p38_E5s_F CTTACTGATTCATGAAAATGTGCAGC p38_E5s_R ATCTTCTTTCTTTAATCAGCTTAAACCTACAG 
p38_E5s_F2 TATATGTTATAAATATGACAATAGAAGGTTGG    
p38_E6s_F TGTAGGGGGAGAATTGATCATGC p38_E6s_R ATACGAATTTCAGATAGTCATGGCTCAC 
p38_E6s_F2 CATGCATCATAAAGTTGATCCTGTC    
p38_E7s_F GACCAGGAAATCTCTTTATGAAAGTGC p38_E7s_R CCCAAATGCATCCAACATGG 
p38_E7s_F2 CTCCTTTTTAATAAGGCAACAGAGG    
p38_E8s_F GAGTATGATTGTTGAGCCTCAGATGTC p38_E8s_R AAGCAAAATACTGAGAGTCTTCCCTAGAG 
p38_E8s_F2 TTGAATATTTCACCCCTAGTTACGG    
p38_E9s_F AGGGATTCACCGTGTTGGCTAG p38_E9s_R GATTGGTAGAAGGCAAGTGGCAG 
p38_E9s_F2 CATTTTTGTTCTCGGTTGTTCTG    
p38_E10s_F TGCAGCTGTGGGCTCTCG p38_E10s_R TTAAGAACTGTTGGTTATACGGTGGC 
p38_E10s_F2 TAGGGGGAATGGAGGGTAGG    
p38_E11s_F TTAACACTCGTTCCTTAGCAGGACC p38_E11s_R TCTCTCCTTTCTCCACTGTACCTGC 
p38_E11s_F2 CAAGATTCTTTCTTTGAGAGCAGTAAC    
p38_E12s_F GTCAAAACTATGTTTGCTCAATAAGGC p38_E12s_R ATTCATTCTGCATTAGAGACCTCATCTAC 
p38_E12s_R2 TAGCAAGTTGGTTATGACCATTCAG    
p38_E13s_F GAAGTCAGAGTGCTTGCCAGC p38_E13s_R GAAATCTCTGCAACAAGAGGCAC 
p38_E13s_F2 CAGCAAAGAGAATAGCCTAAACCTC     
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Table 8.3b: Primer for PCR amplification and sequencing in MAPK13 
primer forward oligonucleotide primer reverse oligonucleotide 
MAPK13       
MAPK13_e1_F1 CAGGTGGGAGCGTAGCAGC MAPK13_e1_R AGGTGGCGCTGGCGAG 
MAPK13_e1_F2 GAGGAGCGGGCGGC MAPK13_e1_R2 CTTGAGGTCCGCGGTCAAG 
MAPK13_e1_F3 GGAGCGCAGGGCTGGA    
MAPK13_e2_F1 CATATTCTAGGTGGTGGGCCTAGTC MAPK13_e2_R ACTGTCCCGAGCTCTCCATACCG 
MAPK13_e2_F2 AGCCCAGCTGCCCAGTG    
MAPK13_e3_F1 CTTCCAAGAAGGTTGGAGACATGC MAPK13_e3_R CACCCGGAATAGAAACCCTAGACC 
MAPK13_e3_F2 GGATGGCCCTGTGCATG    
MAPK13_e4_F1 ACACTGGAGGGTGTCTCTATGACC MAPK13_e4_R TGGCCGACCTGTAACAGTGC 
MAPK13_e4_F2 CCCTGTTCTGCCCTGAGGTC    
MAPK13_e5_F1 GGGACTTGGAGGCTGGCAG MAPK13_e5_R TTGAAGCCTGAAACACTCAGCTCA 
MAPK13_e5_F2 GGGACGCCTTGCTGTCTAGAC    
MAPK13_e6_F1 GGGCCCTGAGAGAACACCTAGTC MAPK13_e6_R CAAAATCCAGAATCTATGGCACAGG 
MAPK13_e6_F2 GGCCTGGCTGAGGTCACAC MAPK13_e6_R2 GGATAAATAGAAAAGGAACTTGCTGAG 
MAPK13_e7_F1 TGAGGACTGTGAACTGAAGGTGAGTG MAPK13_e7_R GAGGGAGAGTGTCACCTGGACTG 
MAPK13_e7_F2 CCCAGAGGCGGGATAGGC MAPK13_e7_R2 CACAGACCAGATGTCCACTGCAG 
MAPK13_e7_F3 GAGTGGGCTGCAGGCTCAG    
MAPK13_e8_F1 GTGATCCTCAGCTGGATGCACTAC MAPK13_e8_R TCTACAGGGAGTATGTATCACTCTCACA 
MAPK13_e8_F2 CAGACAGGTCAGTGGTCAATGC    
MAPK13_e9_F1 AGAGCAGGAGGTGGTTAGGCAG MAPK13_e9_R TGTGGGAAGGTGCTGGTGAG 
MAPK13_e9_F2 GGAGCCTGGATGATCAGTTGC MAPK13_e9_R2 GATTAAGACAAGAGTGCCTGCCAG 
MAPK13_e9_F3 TCAGCCTGGCACGTTGGA    
MAPK13_e10_F1 TTGTGGAAGAAGGCTCACCAGC MAPK13_e10_R AGCAGGTCCGCAGCTGCA 
MAPK13_e10_F2 GGCACTCTTGTCTTAATCTCACCG    
MAPK13_e11_F1 CCCCAGGGTGAGTCTCAGAGC MAPK13_e11_R TAGGGCTGGCAGAGGCCAG 
MAPK13_e11_F2 GCCTCTCAGCGTATCCCAGAG    
MAPK13_e12_F1 TTGAGCTGACTTCGCTCTCCATG MAPK13_e12_R1 GCAATCGCACCAGCTGCAG 
MAPK13_e12_F2 GCTCTCCATGCTGTCTCTGAAG MAPK13_e12_R2 ACAGAGCACAAGGCCTCAGC 
MAPK13_e12_F3 CCAGCCCTACCTGCCACCTC MAPK13_e12_R3 CGCAGTCTCCGAGCCTGC 
 
Appendix 119 
Table 8.3c: Primer for PCR amplification and sequencing in TREM1 and BRPF3 
primer forward oligonucleotide primer reverse oligonucleotide 
TREM1       
TREM1_prom_F1 TGTGGGCCTGACTCTCTTCACTAC TREM1_prom_R CTCATCCTTCTGTGCACCAGC 
TREM1_prom_F2 ACACTAAACTGGATGTGAATGGAG    
TREM1_e1_F1 GGCCTCATATCCTGTTGTGCA TREM1_e1_R CCTGTGCTCTGAAGCTTCAACAG 
TREM1_e1_F2 CAACTTTCCGAAGCCTCTAGGTC    
TREM1_e2_F1 TGGAGGCCTCAAGAACCTCATC TREM1_e2_R TGCTGATGCTACCACCACTGC 
TREM1_e2_F2 TGAAATATGGGTGGTTGGACAAG    
TREM1_e3_F1 CCTACCCGTCCATCAACTCATC TREM1_e3_R CCTCACTTTCACATCCTCTCAGC 
TREM1_e3_F2 TTTCATCCATACATCCATACATCCA    
TREM1_e4_F1 GGACAGGGACCTATACTCTCCACTG TREM1_e4_R GTGGAATGAAGGTCCAAGCATG 
TREM1_e4_F2 TTTTGGCAATGAGACAGACTGA    
BRPF3       
BRF3-e0F1 GGGAGAAGACCGCGCTCC BRF3-e1R1 TTCTGCCGGGACTTCCGAC 
BRF3-e1F1 GAGGAAGCCTCGTCGGAAGTC BRF3-e1R2 GTATCTGTGGGACAGCAAGCATG 
BRF3-e1F2 GAAGCATCAGTGAGACTGGCGAT BRF3-e2R1 GGGACTGCAGATGGGAGTGC 
BRF3-e2F1 ACAAGATCTGTAGTGGTCTCTCCTTTCAG BRF3-e3R1 TCTTCCGAATCAGCTCAATCAGC 
BRF3-e3F1 GAGAGCAGGATGAGAAGACAAGTGC BRF3-e4R1 CACTCAAGTTGACTGGTTCTGCGA 
BRF3-e4F1 AAGTCCAGCAGGCTGCCATG BRF3-e5R1 AAGTCTTCCAATTTGGGTGACTCG 
BRF3-e5F1 ATTACCTGGAATTCATATCCAAGCCA BRF3-e6R1 TGCTCCAGCACAGCTGCATC 
BRF3-e6F1 TTGTCCCCAGAGGTGCAGCT BRF3-e7R1 TCCCCTTCGCTCTCACTACAGC 
BRF3-e7F1 AACTGCCTCCTCCGCCAAC BRF3-e8R1 CTGCAAGCTTCAAATGCCAGTC 
BRF3-e8F1 CATGACCAACGGCTTTGGAA BRF3-e9R1 GAGCCATTGTAGTCAGAGTCTCCGT 
BRF3-e9F1 ACGCAGCCGTGGGAAGC BRF3-e10R1 CAAGGCAGGGTAGGAGGGGTAG 
BRF3-e10F1 CCTTTGAAGACCGCGGAGAC BRF3-e11R1 CCAGGTGCGCTTGTTGTCA 
BRF3-e11F1 GGGAGGGCCTCCTGCAC BRF3-e12R1 TCAGGTGGATCATCGCACG 
BRF3-e11F2 GCTTCCAAGGGACAAAGTCCTG BRF3-e12R2 CCTGCCAGGAGAACCATGC 
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8.3. Blood collection centres 
 
The following organisations, medical centres and local physicians participated in the 
contacting of affected individuals and their families and the unrelated control individuals and 
the collection of blood samples and questionnaires: 
The cooperation of the German Crohn’s and colitis foundation (DCCV e. V.); Prof. Raedler / 
Hamburg, Prof. Kruis, Köln; Dr. Theuer, Heilbronn; Dr. Meckler, Gedern; Prof. Lochs, Dr. 
Wedel, T. Herrmann, Berlin; Dr. Herchenbach, Recklinghausen; Prof. Scheurlen, Würzburg; 
Dr. Demharter, Augsburg; Dr. Simon, Munich; Dr. Purrmann, Moers; Dr. Jessen, Kiel; Dr. 
Zehnter, Dortmund; Dr. Lübke, Dr. Weismüller, Koblenz; Dr. Eiche, Denkendorf; Dr. 
Schönfelder, Aache; Prof. Fleig, Halle, all in Germany. 
Dr. Wewalka, Linz; Dr. Knofloch, Wels, both in Austria.  
Prof. Dr. Ulrich R. Fölsch, Prof. Dr. Stefan Schreiber, Dr. Susanna Nikolaus, Dr. Tanja 
Kühbacher, 1st Department of General Internal Medicine at the University Clinic Schleswig-
Holstein, Campus Kiel (Kiel, Germany); 
Dr. Peter Nürnberg, Charité University Hospital (Berlin, Germany);  
Prof. Dr. Neppert, Transfusion Medicine at the University Clinic Schleswig-Holstein, Campus 
Kiel (Kiel, Germany). 
Prof. Dr. Christopher Mathew, Dr. Alastair Forbes, King's College School of Medicine, Guy's 
Hospital, and the ST. Mark's Hospital London (UK). 
Prof. Dr. SJH van Deventer, Dr. Pieter CF StokkersAcademic Medical Center, Amsterdam 
(The Netherlands). 
Prof. Dr. Trevor Winter and Marc Kidd, Groote Schuur Hospital, University of Cape Town, 
Department of Internal Medicine (Cape Town, South-Africa). 
Prof. Dr. Won Ho Kim, Yonsei University, College of Medicine (Seoul, South-Korea). 
Prof. Dr. Morten Vatn; Rikshospitalet Oslo, Norway, 
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8.4. Questionnaire 
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This questionnaire was completed by all affected individuals from the European and the 
South African populations but as well by the unaffected family members, each adapted to the 
mother tongue. All information was entered into the database. The severity markers used in 
the analysis were taken from the information provided by the individual in the questionnaire  
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